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Niemann-Pick Disease Type C (NPC) is a rare, autosomal recessive genetic disorder 
featuring a loss of proteins responsible for unesterified cholesterol (UC) trafficking through the 
late endosomes/lysosomes (LE/LY) of every cell of the body. Disruption of this pathway leads to 
abnormal accumulation and storage of UC and other lipids.  A broad range of visceral and 
neurological symptoms result from this accumulation exhibiting a variable age of onset and a 
disease progression that is ultimately fatal. The disease has an incidence of approximately 1 in 
120,000 live births and has no known effective treatment.  
β-Cyclodextrin (β-CD) are natural small molecules macrocycles composed of glucose 
units with a hydrophobic inner cavity and hydrophilic outer rims. β-CD derivatives have recently 
been shown to be effective therapeutics for NPC in cellular and animal models. In the mouse 
model of the disease, β-CD therapy increases overall lifetime by as much as 50% and slows the 
progression of neurodegeneration. The progress has led to the initiation of a National Institutes of 
Health phase I clinical trial.  
A main drawback of β-CD administration is the poor pharmacokinetic profile 
characterized by rapid renal clearance of the drug through the urine. Libraries of β-CD derivative 
carrying high molecular weight polyrotaxane (PR) systems have been designed to prevent 
glomerular filtration of the injected β-CD dose. An initial family of unmodified β-CD PRs was 
synthesized, characterized, and their therapeutic efficacy was tested in NPC fibroblasts. This was 
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xxv 
followed by screening of PRs consisting of mixed β-CD derivative threading featuring charged 
sulfobutylether β-CD.  
Finally, we sought to define PR structure-property effects on in vivo pharmacokinetics, 
biodistribution, toxicity, immunogenicity, and protein hard corona composition. This was 
accomplished using a family of gadolinium carrying PRs composed of triblock Pluronic co-
polymers of varying molecular weights and hydrophilic/lipophilic ratios.  The effect of varying 
threaded β-CD derivative surface chemistry on PR mediated hemolysis and hard protein corona 
was also studied. Knowing if structure-property relationships exist in the in vivo performances of 
PR materials will help with building pre-clinical profile, selecting candidate materials for a given 















Niemann-Pick disease Type C (NPC) is just one of approximately 50 known lysosomal 
storage disorders involving the absence or dysfunction of one or more proteins within the lipid 
transport pathways of the cell.1 This autosomal recessive genetic disorder features a loss of 
proteins responsible for unesterified cholesterol (UC) trafficking through the late 
endosomes/lysosomes (LE/LY) of the cell. Disruption of this pathway leads to abnormal 
accumulation and storage of UC and other lipids.  A broad range of visceral and neurological 
symptoms result from this accumulation, exhibiting a variable age of onset and a disease 
progression that is ultimately fatal. Few potential treatments exist for NPC patients and those that 
do are inadequate. There is no effective treatment currently approved by the United States Food 
and Drug Administration (FDA) for clinical use.  
 The Niemann-Pick disease family is divided into four patient groups.2 Niemann-Pick 
Types A and B are distinct from NPC in that they are characterized by a deficiency of acidic 
sphingomyelinase (AS) and an abnormal accumulation of sphingomyelin.2-4 Type A is defined by 
presentation of both neurological and visceral disease, while Type B usually exhibits visceral 
disease only. Distinct from these genotypes are Niemann-Pick Types C and D. Both of these 
classes are characterized by disrupted production of one of either Niemann-Pick C1 or Niemann-
Pick C2 proteins. These defects lead to UC accumulation and involve both neurological and 
!!
2 
visceral symptoms. No AS deficiency as been reported in these phenotypes. Type D is distinct 
from Type C in that all of the patients have a common Acadian ancestry.2, 4, 5 
 
1.1.2. Natural History 
 Because of its genetic origin, UC sequestration in NPC patients occurs in every cell of the 
body. This means that symptoms are not localized and can affect the visceral organs of the chest 
and abdomen as well as the central nervous system (CNS). Visceral symptoms include 
organomegally usually involving, but not limited to, the spleen and liver. Progressive organ 
dysfunction occurs as accumulating UC does increasing damage. The severity of organ disease is 
proportional to the amount of UC present in the tissue.18,72-73 Neurological symptoms are more 
varied and numerous. Patients may display any combination of supranuclear gaze palsy, delayed 
motor development, ataxia, dystonia, dysphagia, dysarithria, seizures and dementia.6  While 
neurological symptoms are often the first to drive patients and their families to visit the clinic, the 
initial presentation of the disease can be visceral, neurologic, or psychiatric. 
 It is now understood that NPC is not a homogenous affliction, but instead has a widely 
varying potential age of onset (Figure 1.1). Although previously characterized by the onset of any 
NPC related symptom,7 are now grouped based on the onset of neurological symptoms.8 Because 
of low awareness, the age at which a diagnosis of NPC is definitively made can be even more 
variable.7  NPC disease is roughly grouped into four forms, perinatal disease, infantile disease, 
late infantile/juvenile disease, and adult onset disease. Perinatal disease presents at birth, usually 
with liver disease, and is often fatal by six months of age.9, 10 Infantile disease presents within 12-
18 months of birth and is usually characterized by delayed motor development and 
organomegally. Patients in this classification typically succumb to the disease by age five.  
The most commonly studied form of NPC, representing 60-70% of documented cases, is 
the late infantile/juvenile onset form.7 Altered gait and organomegally will often present within 
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the first 3-5 years of life. If presenting later, at 6-12 years of age, patients tend to exhibit poor 
academic performance as the initial symptom. Both situations have the potential for other 
neurological symptoms and nearly ubiquitous supranuclear gaze palsy. Patients experience an 
inevitable intellectual decline before death in their teenage years.7 The adult onset form of NPC 
follows a similar, truncated, course. This often includes the symptoms of dementia, psychosis, 
and movement disorders.11 The latest known diagnosis has been of a 66 year old patient with no 
discernable neurological symptoms.12 
 
 
Figure 1.1: Age of NPC Neurological Disease Onset Correlated With Lifespan (A).1 Breakdown 
of Onset Periods and the Most Likely Neurological and Systemic Symptoms (B).7 !!
 NPC is a rare disease. It has an estimated incidence of 1:120,000-1:150,000 live births.7 
This figure is likely under-representative of the actual extent of the patient population due to low 
public awareness and ineffective diagnosis. There are no routine genetic, blood, or urine tests 
capable of diagnosing NPC.7 Typically, when NPC is suspected, a biopsy is made and a culture is 
generated from the patient’s cells. These samples are screened for abnormal lysosomal UC 
accumulation by staining with a small molecule dye, Filipin, which fluoresces when it binds UC 
deposits. Specific Filipin localization is a sensitive probe of UC sequestration. This test is often 
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coupled with UC homeostasis assays measuring the rate of cholesterol ester (CE) formation.13 
Occasionally, structural studies of skin and liver biopsies can provide support for an NPC 
diagnosis, but these studies are prone to false negatives.10 
 
 
1.1.3. Normal Cholesterol Trafficking and Homeostasis 
 Cholesterol is a ubiquitous and essential metabolite of the human body. It helps 
strengthen cell membranes, modulate their behavior and maintain their structural integrity.  UC is 
a precursor compound to many steroid hormones, oxysterols, and vitamin D-- all of which are 
vital components within the body. Finally, UC and CE are involved in many regulatory pathways 
within the body such that misregulation or imbalance of UC and CE has wide ranging biological 
effects. In NPC, a breakdown in normal UC processing gives rise to the disease phenotype 
discussed above. 
The acquisition of cholesterol for use by the cell occurs through two independent 
mechanisms. Cholesterol can be exogenously acquired through diet by internalizing circulating 
lipoproteins; particularly low density lipoproteins (LDL), which contain large numbers of both 
UC and CE. LDL has the ability to undergo receptor-mediated uptake into clathrin-coated 
vesicles via the LDL receptor, but may additionally undergo bulk phase endocytosis.14 
Cholesterol taken up from circulation is typically used within the cell.15 Secondly, UC can by 
synthesized de novo from precursor compounds in the endoplasmic reticulum (ER) through a 
sequence of reactions involving multiple enzymes and intermediates.  This UC pool is typically 
utilized by the plasma membranes of the cell. The UC utilized by the CNS is almost exclusively 
synthesized within the body, as LDL particles are unable to cross the blood-brain barrier (BBB) 
that protect the brain from general circulation.16 
Because of the importance of cholesterol homeostasis for normal cell function, the 
synthesis, uptake, and export by the cell are tightly regulated. There are two main mechanisms by 
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which these factors are controlled. The first involves sterol regulatory element binding protein 2 
(SREBP2). This transcription factor regulates UC homeostasis by controlling the genes involved 
in cholesterol de novo synthesis and LDL receptor activity.17 In a situation where the internal UC 
pool is decreased, SREBP2 would be activated and trigger an increase in UC synthesis and LDL 
surface receptors. The second mechanism is known as the liver X receptors (LXR). These are a 
family of nuclear receptor transcription factors that control the genes involved in cholesterol 
efflux from the cell.18 In a time of decreased internal UC, cholesterol efflux would be down 
regulated by LXR to slow cholesterol loss from the cell. These mechanisms will work in tandem 
to maintain UC homeostasis and are greatly affected by the trafficking blockages that are 
characteristic of NPC. 
 
 
Figure 1.2: Normal Cholesterol Trafficking Through the Late Endosome/Lysosome Maintains 
Homeostasis. !
 
In a normally functioning cellular environment, endosomes carrying internalized 
cholesterol will fuse with acidic lysosomes.19 Here, CE borne by LDL particles will be 
hydrolyzed by the action of lysosomal acid lipase (LAL) to yield free UC.  From here it is 
thought that the tandem action of two proteins, NPC1 and NPC2, mediate the transport of UC out 
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of the LE/LY (Figure 1.2).20, 21 The exact process by which this occurs is unknown and is the 
subject of continued interest and research effort. In the end, this process leads to UC being 
transferred from the LE/LY to the metabolically active pool, the organelles, and the plasma 
membrane.22 Loss-of-function mutations in either NPC1 or NPC2 are the drivers of NPC disease 
presentation.  
 
1.2. Niemann-Pick Proteins  
 
1.2.1. Niemann-Pick C2 
NPC2, previously known as HE1, is a soluble luminal protein composed of 132 amino 
acids and weighing 14.5 kDa.20, 23 It has been shown to reside in multiple locations in the cell, 
including in endosomes, the trans-golgi network, and other organelles.24 NPC2 exhibits a 
hydrophobic binding pocket with a high affinity for UC as evidenced by site directed mutagenesis 
and confirmed by crystal structures with and without a UC ligand.25-27!In these structures, the 
isooctyl chain of UC faces into the binding pocket. Additionally, NPC2 has been shown to 
transfer UC between lipid membranes in vitro.28 NPC2 mutations are found in ~5% of all NPC 
cases and in nearly every case are nonsense or frameshift mutations.20 
 
1.2.2. Niemann-Pick C1 
NPC1 is a large integral membrane glycoprotein with a molecular weight of 170-190kDa. 
The protein is 1278 amino acids in length with 13 transmembrane domains and four hydrophilic 
loops, three of which are luminal and one cytoplasmic.29 NPC1 has been shown to localize in late 
endosomes and lysosomes and to interact with lysosomes and the trans-golgi network.30, 31 The 
protein structure exhibits three important domains including a sterol sensing domain (SSD), a 
cysteine rich loop, and a luminal domain, which are vital to its function in UC mobilization.32 
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Every function of the protein and the role of each domain have not yet been described 
completely.7 NPC1 is thought to regulate transport of multiple kinds of lysosomal cargo, 
including UC, glycolipids, and other fatty acids.31, 33-35!Approximately 95% of NPC disease cases 
involve mutations in the NPC1 protein.19 
At least, 133 NPC1 mutations have been reported to result in NPC disease (Figure 1.3).7 
These mutations are scattered throughout the protein, but have been shown to concentrate in a 
number of key areas. One-third of the disease causing mutations affect the cysteine-rich luminal 
loop.7 Additionally, those mutations that fall within the protein SSD have profound effects on 
protein function.32 Clinically, the most common mutations are I1061T, P1007A, and G992W 
mutations. The I1061T mutation accounts for 20% and 15% of NPC cases in the UK and the US, 
respectively.36, 37 P1007A mutations affect populations of European descent and the G992W 
mutation is overrepresented in Nova Scotian patients.7 Less common mutations include R518Q 
and P474L, which tend to affect Japanese and Italian patients, respectively.38, 39!In addition to 
reflecting ethnic origins, certain mutations also correlate with disease onset and severity. For 
instance, some mutations, including C63R, Q92R, C113R, and T137M, are over-represented in 
the severe infantile onset disease, and some, including I1061T, are present in all forms except the 





Figure 1.3: Known NPC1 Mutations7 !!
1.2.3. Cholesterol and the NPC Proteins  
The exact mechanism by which NPC1 and NPC2 work to move UC through the LE/LY 
system is not known. What is clear, however, is that the loss of either protein leads to an identical 
NPC disease state intracellularly. Based on this observation, it has been proposed that NPC2 and 
NPC1 work directly in sequence, with the former protein handing UC off directly to the latter 
through protein-protein interactions.20, 21!Further evidence for this exchange mechanism comes 
from the fact that NPC2 and the NPC1-N-terminal domain (NPC1-NTD) bind UC with opposite 
orientations; the former with the UC isooctyl chain buried within its binding pocket and the later 
with the UC hydroxyl group into the pocket.27, 42 Additionally, it has been shown that there are 
surfaces on the NPC1 second luminal domain with which NPC2 can interact.43 Finally, in in vitro 
assays, NPC2 has been shown to be able to transfer UC from model lipid membranes to NPC1-
NTD.44 The desired NPC1-NPC2 hand-off structure, however, has never been observed. So while 
it is possible that there is a direct transfer between the proteins, it has also been proposed that 
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NPC1 activity simply depends on NPC2’s ability to insert UC into the surrounding plasma 
membrane.45, 46 
Whatever the mechanism of action, loss of either NPC1 or NPC2 proteins leads to 
extensive lipid storage within the cell. This includes UC, bis (monoacylglycerol) phosphate 
(BMP), and other sphingolipids.47 The major component of visceral lipid storage is UC (Figure 
1.4). Storage of both intracellularly synthesized and LDL-derived UC occurs in these sites.48, 49!In 
the CNS, while UC storage is elevated, the main storage lipids are the gangliosides GM2 and 
GM3, culminating in demyelination of axons and extensive death of Purkinje cells.50 This 
accumulation has many deleterious effects on cellular function. A central outcome is the altering 
of protein and lipid trafficking. All cellular mechanisms modulated by UC downstream will be 
affected.47 In NPC deficient cells, NPC1 positive endosomal and lysosomal compartments move 
around the cell at much slower rates than similar compartments in wild type cells.51, 52 
Additionally, although large stores of UC exist within the cell, the metabolic pool of UC available 
to the cell is depleted and the cell perceives a lack of cholesterol downstream. This leads to 
activation of SREBP2, increasing LDL uptake, upregulated cholesterol synthesis, and a 
downregulation of LXR, thereby decreasing cholesterol efflux.53 In this way, the cholesterol 








Figure 1.4: Mutations in NPC1 or NPC2 Proteins Prevent Escape of Unesterified Cholesterol 
From the Late Endosome/Lysosome. !
1.3. Current and Potential NPC Treatments 
Initial treatments for NPC focused on attempting to reduce or slow the sequestration of 
UC. Attempts at utilizing low cholesterol diets, UC synthesis inhibitors such as statins, and drugs 
that prevent the absorption of UC from the intestines did not succeed in preventing 
neurodegeneration (ND) or extending lifetimes.54, 55 They did, however, result in a reduction of 
UC in the peripheral tissues.56 This result is likely because tissues of the CNS rely on 
endogenously synthesized UC. Additionally, attempted inhibition of LAL reduced UC 
accumulation while triggering an accumulation of CEs. A condition similar to that which arises 
from impaired production of LAL known as Wolman’s disease.57 
A treatment that has had some success clinically is Miglustat, an iminosugar that inhibits 
the first enzyme in glycosphingolipid synthesis.58 In a study following NPC patients through 4-8 
years of treatment, most showed stabilization in many neurological symptoms including the 
ability to swallow.59 Unfortunately, There was no control group in the study and the side effects 
included epistaxis, insomnia, tremors, weight loss, and diarrhea. Shorter-term studies have also 
shown improvement and/or stabilization of neurological symptoms.60, 61!In mice, Miglustat 
treatment increases animal longevity by 25% and delays onset of neurological dysfunction.62 The 
exact mechanism by which it mediates these beneficial effects is unknown, but a reduction in 
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glycosphingolipid accumulation may relieve congestion in the LE/LY and facilitate movement of 
UC from sites of storage. In 2009, the European Agency of Medicines approved Miglustat for 
treatment of NPC patients, but the long-tem efficacy of the treatment is still unknown.59 
 Histone Deacetylase Inhibitors (HDACis) are small molecule drugs that act to alter the 
acetylation patterns of histones in the nucleus. In this way, they affect gene expression by altering 
chromatin structure.63 HDACis have been extensively studied as treatments for a spectrum of 
conditions, leading to two FDA approved drugs, Vorinostat and Istodax, for the treatment of 
cutaneous T-cell lymphoma.64, 65 Upon incubation with NPC1 cells, a number of HDACis, 
including Vorinostat, were found to reduce cholesterol accumulation and increase the quantity of 
NPC1 produced.63  It is hypothesized that increased production of mutated, but still moderately 
functional, NPC1 protein is able to increase the efficacy of cholesterol mobilization in the cell. 
HDACis may also be increasing the levels of protein folding chaperones to produce a more 
functional form of the mutant NPC1 protein.63 Although there is a significant amount of clinical 
data available for Vorinostat in adult cancer patients, much less is known about its performance in 
juveniles, leading to concerns about off-target effects (e.g. widely changing the expression and 
regulation of proteins having no involvement in NPC). 
 The indication that NPC mice have dysfunctional production of neurosteroids led to the 
suggestion that allogregnanolone (ALLO) may serve as an effective NPC treatment. ALLO 
functions in the growth, survival, and differentiation of neurons. Cerebral concentrations of 
ALLO are diminished in NPC disease.66 When NPC mice were treated with ALLO, solubilized 
by 20% HP-β-CD, it resulted in marked delays in ND. Indeed lifespan of treated mice nearly 
doubled from 67 to 124 days.66 Upon further investigation, ALLO administered without the 
solubilizing excipient resulted in none of the beneficial effects previously shown.67 In fact, it was 
late discovered that the solubilizing HP-β-CD excipient was the active agent in effectively 
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treating the disease. Numerous studies since this discovery have shown that β-cyclodextrin (β-
CD) derivatives to be attractive potential treatments for NPC.67-69  
 
1.4. β-Cyclodextrin and Derivatives 
 
1.4.1. Introduction 
Cyclodextrins (CDs) are macrocycles composed of glucose units tethered by α (1-4) 
glucosidic linkages. They are naturally produced from the enzymatic degradation of starches and 
have come to be industrially prepared for a wide variety of purposes. The majority of their 
applications are based on their ability, as cage molecules, to include small hydrophobic 
compounds within their central nonpolar cavities. The most common CD variants, α-CD, β-CD, 
and γ-CD, are comprised of 6, 7, and 8 glucose units, respectively (Figure 1.5). These compounds 
have unique properties and a long history of scientific investigation and continuing interest in 
their great potential. 
 
1.4.2. Discovery and History 
 The first documented description of cyclodextrin came from Antoine Villiers (1854-
1932) in the late 1800s. As he studied the enzymatic degradation of starches upon treatment with 
a particular species of bacteria, he noted the appearance of a crystalline, insoluble side product.70, 
71  Franz Schardinger (1853-1920) later isolated the specific strain of bacteria responsible for the 
byproducts and crudely isolated two compounds which he called Dextrin A and Dextrin B.72 
Later, he was the first to describe their production, separation and purification, and was the first 
to propose a cyclic structure for the compounds.73 Hans Pringshelm (1876-1940) showed that 
CDs form complexes with small molecules, including hydrocarbons and halogens.74 He also 
!!
13 
made the first biological tests utilizing CD derivatives, injecting them into rabbits and pigs in an 
attempt to treat diabetes.75, 76  
 Karl Freudenberg (1886-1983) experimentally demonstrated that the cyclic structure of 
CDs were composed of glucose units.77 In the late 1930s, this was finally confirmed by X-ray 
structure analysis.78, 79 Friedrich Cramer (1923-2003) coined the term “inclusion complex” in 
1967 after some time studying complexes between CDs and amines, aliphatics, aromatics, and 
gases.80, 81  CDs began to be extensively studied for a range of applications. Between the 1950s 
and the 1980s, the first patents for CD based products appeared, the first company based on CD 
technology, Cyclolab, opened, and Jozsef Szejtli (1933-2004) initiated the first International 
Cyclodextrin Symposium. The first pharmaceutical product incorporating a CD, a prostaglandin 
E2 formulation with native β-CD, was approved in Japan in 1976.  
 
1.4.3. Cyclodextrin Properties and Uses 
 CDs are comprised of α-(1-4)-glucosidic bond linked glucose units with a hydrophobic 
inner cavity and hydrophilic outer rims. The structure is not a perfect hollow cylinder, but rather 
has a slight “V” shape. Alcohol moieties on the CD surface, 18-24 depending on the CD species 
under consideration, are arranged such that there is a narrow rim containing only primary 
hydroxyl groups and a broader rim containing only secondary hydroxyl groups. Free rotation of 
the primary hydroxyls allow for at least partial blockage of the CD cavity on one end. β-CD, the 
focus of NPC therapy, contains 21 hydroxyl groups and has an average core diameter of 0.78 nm 
(Figure 1.5). Through alcohol modification, a vast array CD derivatives have been synthesized 
and utilized.82, 83 Because of production costs and complicated syntheses, few CD derivatives are 
manufactured on a large scale. The main derivatives sold and used industrially are HP-β-CD, sold 





Figure 1.5: Cyclodextrin Dimensions71 !
 
The lipophilic environment of the CD core solubilizes hydrophobic molecules in aqueous 
media by minimizing mismatching hydrophobic-hydrophobic contacts. Interactions between host 
and guest occur largely through van der Waals interactions and, as such, a CD inclusion complex 
is subject to equilibrium conditions.86 Size matching of the guest molecule in relation to the CD 
internal diameter (i.e. the degree of van der waals contact), plays an important part in binding, as 
molecules that are too large in size will not be able to enter the CD cavity, and molecules too 
small in size will not have sufficient contact with the interior surfaces. This is largely governed 
by the narrowing that occurs due to the internal H-3 and H-5 hydrogens.87  
As CD research matured, it was understood that inclusion of hydrophobic guests had the 
potential to greatly affect their properties. In pharmaceuticals, this was seized upon as a natural 
way to increase the solubility of insoluble drugs, replacing the use of organic co-solvents and 
surfactants with known toxicological properties.88, 89 Drug formulation with CD derivatives was 
also found to affect drug stability, bioavailability, and pharmacokinetics in ways that improved 
their efficacy.71 After their introduction in Japan in 1976, a complex of Piroxican and β-CD 
became the first treatment available in the European market in 1988. Finally, the US FDA 
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approved an oral solution of itraconazole and HP-β-CD in 1997. To date, β-CD derivatives are 
contained in greater than 40 drug formulations internationally.71 
Outside of pharmaceuticals, CDs have found application in the food, cosmetic, and 
agricultural industries.71 A great deal of study has gone into studying CDs as effective chemical 
reaction catalysts.90 Applications have been shown using CDs in a wide range of chromatographic 
applications including use as stationary phases in chiral and achiral separations, in electrophoretic 
separations, and in gas chromatography.91-94!Finally, completing a non-exhaustive list, CDs have 
greatly impacted the fragrance, aroma and textile industries.95, 96   
 
1.5. Cyclodextrins and Niemann-Pick Type C !
1.5.1. Therapeutic Efficacy 
 After the serendipitous discovery of their efficacy, β-CD derivatives have been 
increasingly explored as potential NPC therapeutics due to their opportunity for rapid translation 
into a rare disease indication. In the mouse model of the disease, a one-time injection of 4,000 
mg/kg HP-β-CD at seven days of age increased overall lifetime by as much as 50%. 
Neurodegeneration, as evidenced by loss of Purkinje cells, was slowed but not completely 
prevented (Figure 1.6).97 A significant decrease in the total UC sequestered in the livers of treated 
mice was also observed, with a corresponding improvement in liver function as evidenced by 
levels of aspartate aminotransferase and alanine aminotransferase enzymes in serum. Whole body 
UC, while reduced from untreated NPC controls, was still elevated when compared to wild type 
mice. Serial injection starting at 7 days showed even greater benefit, normalizing UC in many 
organs, doubling lifespan and further slowing neurodegeneration.67-69 However, even with 
repeated injections of these large doses, neurodegeneration could not be prevented fully and no 
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response was seen in the lungs of treated mice.69, 97, 98 The cat model of the disease showed a 
similar response to treatment, with the exception of possible damage to animal hearing.99 
 
 
Figure1.6: HP-β-CD Treatment A) Extends the Average Lifetime of NPC Mice55 and B) Prevents 
Purkinje Cell Death That Can Lead to Neurodegeneration.100 !!!
 The observation that neurodegeneration could not be prevented may result from the 
inability of HP-β-CD to cross the BBB. The beneficial effects on the brain were decreased when 
treatment was commenced later than 7 days of age.101 When treatment started at 49 days of age, 
treatment was completely ineffective (Figure 1.6).100 In young mice, HP-β-CD is able to access 
the brain through a BBB that has not fully formed. This barrier closes as the mice age and more 
effectively excludes treatment. When bypassing the BBB with continuous infusion directly into 
the ventricles, death of Purkinje cells was prevented completely.102, 103 Thus, achieving access to 
the brain will be critical in order for β-CD derivatives to be a truly meaningful therapy. 
 
1.5.2. Mechanism of Action 
 Practically, treatment with β-CD mediates efflux of sequestered UC beyond trafficking 
blockades in the LE/LY and into the cytosol (Figure 1.7). In essence, β-CD replaces the lost 




pinocytosis where they exhibit their effects.104, 105 Intracellular evidence of UC mobilization by β-
CD derivatives comes from a decrease in SREBP2 and UC synthesis rates, an increase in CE 
formation, and the activation of LXR genes. The cell is no longer sensing a downstream lack of 
UC and, thus, cholesterol uptake and efflux return to normal rates. β-CD treatment, then, is 
bypassing a UC mobilization block and allowing movement beyond the LE/LY.  
 
 
Figure 1.7: HP-β-CD Treatment Overcomes the Transport Defect in NPC Through an Unknown 
Mechanism. !!!
The exact mechanism of action by which β-CD derivatives mediate beneficial changes in 
NPC is still a subject of debate. The assertion has been made that β-CD is simply extracting UC 
from exterior PMs and carrying it out through the urine, driving UC relocation from the LE/LY. 
However, no significant increase in UC was found in the urine of wild type mice after β-CD 
treatment.19  Additionally, depletion of UC from the exterior of cellular plasma membranes would 
be expected to have corresponding effects on SREBP2, CE, and LXR. The effects are not seen in 
normal mice, indicating that they only come about when large cholesterol stores are present 
within the animal.55, 100 Finally, SBE-β-CD is still able to overcome NPC transport defects despite 
Defect Bypass 



























































































































































being unable to remove UC from PMs because of its highly negative charge.106 Thus, it appears 
that β-CD derivatives are not mediating their therapeutic effects before internalization.  
There are two intracellular efflux mechanisms generally proposed for β-CD mediated UC 
release. The first involves vesicular transport of UC:β-CD complexes away from the site of 
accumulation. In this situation, β-CD would break up and solubilize UC aggregates or crystals 
before leaving the site together. A stoichiometric amount of β-CD would therefore be needed. 
Contrary to this potential mechanism, β-CD-Dextran polymers have been reported to co-localize 
with sites of UC accumulation and reduce storage. These polymer systems do this while 
remaining in the LE/LY, lending support to a second potential mechanism in which β-CD acts as 
a catalytic transfer agent.107 In this scenario, β-CD would shuttle UC from LAL or UC aggregates 
and into the limiting membrane. This mechanism would also bypass NPC1 and NPC2, wherein 
the UC could then flip from the inner to the outer membrane leaflet and be carried forward to 
downstream locations. Regardless of the mechanism, the beneficial effects of treatment are clear 
as shown in Figure 1.6. 
 
1.5.3. HP-β-CD Pharmacokinetics 
A main drawback of HP-β-CD treatment is the rapid clearance of the molecule from the 
body. In 49-day old mice, the half-life (T1/2) of subcutaneous injection is 1.6 h with 90% of the 
drug being cleared from the body by 6 h (Figure 1.8).100, 102!The vast majority of this dose was 
found unmetabolized in the urine after clearance from the blood stream by glomerular filtration in 
the kidneys.108 When administered directly into the brain, T1/2 rose to 6.5 h.102  This extension of 
residence time is likely because of the inability of HP-β-CD to effectively move across the BBB. 
In 7-day old mice, a much higher percentage of the dose, 40%, remained in the blood at 6 h, 
translating to a three-fold increase in plasma concentration when compared to the 49-day old 
group. This can be attributed to incomplete glomerular formation and, therefore, inadequate 
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filtration. Thus, these developmental features may account for some of the increased efficacy of 
early treatment.100 When considering administration of β-CD to human patients, however, this 
poor pharmacokinetic profile must be considered. Quick clearance of the injected dose from the 
blood is likely to limit its efficacy, thereby necessitating injections of large concentrations of drug 
at frequent intervals to counteract rapid loss from renal filtration. 
 
 
Figure 1.8: HP-β-CD Pharmacokinetics After Subcutaneous Injection.100 !
 
1.5.4. National Institutes of Health Trial 
The positive results in animal models of NPC led to a Phase I clinical trial for HP-β-CD 
at the National Institutes of Health (NIH). Because the most troubling effects of the disease are 
often the neurological symptoms, the main focus of the trial was delivery of β-CD to the brain. 
Enrolling two patients and beginning in January 2013, the trial utilized Ommaya reservoir 
administration. These devices are deposited under the scalp and a catheter is inserted through the 
brain into the cerebrospinal fluid. Drug can be infused regularly through this port without the 
discomfort of spinal taps. Unfortunately, the study had to be halted later that year due to 
infections secondary to device implantation. The study resumed in September 2013 with 12 
patients undergoing more invasive CD administration through lumbar puncture. The trial is 
!!
20 
currently ongoing, but planning of a phase II/III benefit trial to determine clinical benefit is in the 
planning stages. 
 
1.6. Cyclodextrin Polyrotaxanes 
 
1.6.1. Polyrotaxane Properties and Components 
 Polyrotaxanes (PRs) are a class of materials consisting of multiple macrocyclic host units 
“threaded” onto a high molecular weight polymer guest. These materials are then “capped” at the 
polymer termini by bulky blocking moieties that act to prevent macrocycle dethreading (Figure 
1.9). PRs isolated without endcaps are known as pseudopolyrotaxanes (PPRs). The field of PR 
chemistry was preceded by a long history of scientific investigation into physically interlocked 
molecules including rotaxanes, catenanes, and knots.109-111 Many hosts have been studied 
including, but not limited to, transition metal complexes, crown ethers, and cyclic amides.112-114 β-
CD as a PR host molecule has been extensively studied and is of great interest because of wide 




Figure 1.9: Cyclodextrin Polyrotaxane Structure and Synthesis  
 
 !
 The first report of a CD carrying PR was comprised of α-CD and poly (ethylene glycol) 














































































































well118-120. Polymer guests that have been internalized include poly(oxytrimethylene), 
poly(oxytetramethylene), poly(propylene oxide)(PPG), poly(perfluoroalkyl ethers), polyesters, 
polyamides, polycaprolactone and a wide variety of di- and tri-block copolymers.121-128 In 
addition to linear polymers, a variety of branched, star, and side-group polymers have been 
rotaxinated as well.120, 129-131!PR endcaps must be chosen depending on the CD derivative that is in 
use. Disubstituted benzene termini are large enough to prevent dethreading of α-CD, whereas 
larger entities must be used for β-CD and γ-CD, including polycyclic moieties, amino acid 
endcaps, or branched stoppers.115, 118, 132, 133!Terminal stoppering is the most common 
methodology, but stoppering of multiple pendant groups along a rotaxinated chain has also been 
reported.116   
  The same forces, in large part, which govern small molecule CD inclusion control the 
threading of the macrocycles onto a polymer backbone. Hydrophobic and van der Waals forces 
are the main interactions between the CD cavity and the guest.71, 134 A polymer that is a better fit 
for the specific CD cavity will show tighter binding. This is evident in the fact that PEG will form 
PR complexes with α-CD, but not β-CD, as the larger β-CD cavity does not allow for proper 
contact.134 In addition to this, CD PRs benefit from stabilization due to hydrogen bonding 
between adjacently threaded CD monomers.134 Maximization of energetically favorable hydrogen 
bonding leads to CD threading in either head-to-head or tail-to-tail orientations, as primary 
alcohols rims are more complimentary to another primary alcohol rim and secondary alcohol rims 
more complimentary to secondary. This H-bonding stabilization leads to substituted-CD PRs 
being less stable than native.134   
 
1.6.2. Cyclodextrin Polyrotaxane Applications  
 The unique physiochemical characteristics of PRs imbue them with great potential for 
future applications. They can be synthesized from biocompatible and biodegradable materials, 
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making them attractive for pharmaceutical and biological applications. Interesting and tunable 
gelation properties make them candidates for use as hydrogels and tissue engineering scaffolds. 
Flexibility, CD mobility, and facile functionalization give them potential as targeted drug carriers, 
biorecognition scaffolds and gene transfection agents. Finally, the potential to build 
biodegradability into endcap cleavage gives the promise of tunable release or breakdown through 
the molecularly engineered dethreading of CDs by reactions that can be programmed 
synthetically in advance.  
Tendency of PRs and PPRs to form stable, injectable gels made them attractive for slow 
release hydrogel applications.135, 136 Drugs, proteins, or DNA can be physically incorporated into 
these gels for extended release profiles that would likely improve bioavailability.137 Release rates 
have been shown to from days to months depending on the polymer properties and CD ratios 
used.138 CD PR and PPR hydrogels have been studied which incorporate PEG, copolymers, and 
polymer mixtures.135, 136, 139-141 An additional potential application has been reported in the 
application of degradable PR gels for bone and tissue cartilage regeneration.142 This continues as 
an active area of investigation.   
The ability to tune the cleavage of PR endcaps to specific biological conditions opens the 
door to targeted and specific drug release, biodegradability and enhanced endosomal escape. The 
first reported biodegradable endcaps were comprised of phenylalanine moieties linked to the PR 
through short cleavable peptides.143 These PRs were shown to exhibit rapid dethreading upon 
exposure to the enzyme papain.  Since then, additional PRs have been shown to undergo 
proteolytic degradation.144  In addition, pH triggered and reduction labile endcaps have been 
introduced to allow PR breakdown in endosomal and lysosomal conditions.145-147 These 
conditions have the advantages of being triggered after internalization. 
Cationic CDs threaded onto PRs have been utilized as efficient gene delivery vectors. 
The main advantage of cationic PRs is the ability to exploit CD rotational and translational 
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mobility to condense nucleic acids. Systems have been reported utilizing α-CD grafted with 
ethyleneimine units of varying length, dimethylaminoethyl and other cations. Multiple forms of 
CD and cores including block co-polymers and polymers with branched architectures have been 
reported.145, 148-150 Coupling these technologies with biocleavable endcaps may have the additional 
advantage of promoting endosomal escape through UC depletion from endosomal membranes.151 
The advantages of modification, biocompatibility, and flexibility have made CD PRs 
attractive for targeted drug delivery. This field aims to localize toxic drug molecules in only 
specific and necessary sites in the body, maximizing therapeutic efficacy and diminishing toxic 
side effects. PRs utilizing doxorubicin (DOX) as an endcap have been designed to form stable 
micelles and reduce tumor burden to mice in vivo.152 PRs with DOX conjugated to the CD 
alcohols have also been reported and assessed in vitro. These systems show extended drug release 
as endcaps are cleaved to allow CD dethreading.153, 154  The flexibility of the systems has the 
potential to enhance targeted cellular uptake as the CDs can slide and rotate to achieve maximum 
binding to receptors of interest. This has been reported using a biotin conjugated PR where 
multivalent recognition in the PR led to enhanced affinity for streptavidin that was five times 
greater than a biotin CD monomer.155 Combining these two aspects could yield a biodegradable 
drug release system that effectively targets diseased tissues and dethreads to release drug 
payloads. 
 
1.6.3. Cyclodextrin Polyrotaxanes and Niemann-Pick Type C  
With all the potential applications of PRs in biomedical applications, a special 
opportunity exists when the host β-CDs are themselves the drugs to be delivered. This is the case 
the NPC disease. Knowing that a main drawback of β-CD therapy is a poor pharmacokinetic 
profile and rapid renal clearance, building β-CD onto larger drug carriers systems has the 
potential to avoid filtration by the glomerular membrane. PRs, with greater hydrodynamic radii, 
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would also rise above the cutoff size necessary to remain in circulation. This would enhance 
bioavailability, decrease dosages, extend time between treatments, and make the β-CDs more 
viable as a potential therapy. HP-β-CD PRs have been shown to efficiently mobilize UC from 
sites of accumulation in human NPC fibroblasts.133, 156 It remains to be seen whether β-CD PR 
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CHAPTER TWO: SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF β-
CYCLODEXTRIN POLYROTAXANES FOR MOBILIZATION OF ACCUMULATED 
CHOLESTEROL FROM NIEMANN-PICK TYPE C FIBROBLASTS
 
 !




2.1.1. Niemann-Pick Type C Disease 
 Niemann-Pick Type C (NPC) disease is one of a large set of lysosomal storage disorders 
that arise secondary to abnormal function within the late endosome/lysosome (LE/LY) 
compartment. In this rare disease, the accumulation of cholesterol and other lipids within the 
LE/LY compartment gives rise to various disease states in the patient.2-4 Often, the defect 
manifests itself in the form of neurological and/or hepatic or pulmonary symptoms that increase 
in intensity over time.5 These can include enlargement of organs, dysarthria, dysphagia, ataxia, 
and other neurological symptoms including epilepsy and dementia.3 NPC typically manifests in 
children and is ultimately fatal, even with current treatment regimens.6  
 The underlying causes of NPC are genetic mutations that disrupt the function or 
localization of either the NPC1 (95% of cases) or NPC2 (5% of cases) proteins. These proteins 
are ubiquitously expressed and are localized to the LE/LY compartment.2, 3 In a normally 
functioning cell, NPC1 and NPC2 are responsible for the efflux of unesterified cholesterol (UC) 
from the LE/LY compartment into the cytosol and are generally thought to function in a common 
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UC efflux pathway.7 The dysfunction of either NPC protein causes a ubiquitous sequestration of 
UC in the LE/LY compartments.6 The accumulation of the UC, in turn, causes lysosomal 
swelling, upregulation of the genes controlling cholesterol synthesis and LDL uptake, elevation in 
intrinsic total cholesterol synthesis and lipoprotein uptake, and neurological effects including 
demylination of brain cell axons and the death of Purkinje cells.4, 8, 9 Additionally, onset of 
macrophage activity in affected tissues results in the release of pro-inflammatory cytokines in 
most organs.8, 10-12 The cumulative impact of these factors is cell death and presentation of the 
NPC disease state. 
 
2.1.2. β-Cyclodextrin as an NPC Therapeutic 
 Since its demonstration by Camargo et. al., an increasing body of evidence shows that 
derivatives of β-cyclodextrin (β-CD), a cyclic heterocycle consisting of 7 glucose subunits, are 
able to initiate the efflux of accumulated UC from the LE/LY compartment of npc1 and npc2 
deficient cells.4, 5, 8-13 Dietschy and coworkers have recently reported several studies that 
demonstrate the ability of β-CD derivatives, HP-β-CD in this case, to mobilize UC in the murine 
model of NPC1 disease.4-6, 9, 10, 14 Upon treatment with HP-β-CD, a normalization of intracellular 
UC levels, suppression of intrinsic cholesterol synthesis, activation of the target genes for the 
LXR nuclear receptors, and suppression of target genes for SREBP were observed in several 
organs. All of these factors contribute to rapid egress of sequestered UC from sites of abnormal 
storage.9, 11, 12  When injected directly into the CNS, similar effects were seen in the brains of 
npc1-/- mice,5, 8 and continuous infusion with β-CD derivatives was shown to prevent expected 
neurodegeneration.7 β-CD has also been shown to have similar positive effects in npc2-/- mice.13 
At the cellular level, addition of β-CD to either npc1-/- or npc2-/- patient fibroblasts has been 
shown to rescue the cholesterol accumulation phenotype of these cells.13, 15 
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 While reversal of UC storage in mice was seen after administration of β-CD, evidence 
indicated that the animals began re-accumulating cholesterol shortly after dosing was 
terminated.9, 10, 12 β-CD derivatives, therefore, overcome cholesterol transport defects in NPC1 
disease, but the alleviation is temporary such that repeated or continuous infusions are needed for 
prolonged effects.8, 10 Increasing the efficiency of β-CD delivery, by improving the 
pharmacokinetics and biodistribution of the dose, would make β-CD much more viable as a 
possible NPC therapeutic. One potential method for achieving these goals would be to deliver CD 
via a high molecular weight, long circulating vehicle. A β-CD formulation offering improved 
circulation time and lower clearance rates could potentially deliver a more efficacious dose and 
be beneficial in NPC treatment.  
 
2.1.3. Polyrotaxanes as NPC Therapeutics 
 Polyrotaxanes (PR) are supramolecular assemblies that have been of considerable interest 
in biomaterials applications such drug and gene delivery and hydrogel formation.16-20 These 
complexes are typically prepared by threading macrocycles noncovalently onto a polymer core to 
produce a pseudopolyrotaxane with subsequent addition of bulky endcaps onto the central 
polymer termini to produce a polyrotaxane. The endcaps prevent macrocycle dethreading and can 
be tuned to be bioresponsive toward changes in pH or toward enzyme activity, allowing for 
control over when and how the PR degrades to release its macrocyclic cargo.21-24 Cyclodextrin-
based PR derivatives have been synthesized using many polymer cores including polyesters,25 
polyamides,26 poly(ethylene glycol) (PEG),27-29 polypropylene glycol (PPG),30 and many di- and 
tri- block copolymers.31   
 In this study, a library of PR derivatives has been synthesized using Pluronic block 
copolymers and β-cyclodextrin as building blocks. Pluronic polymers have a PEG-PPG-PEG 
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triblock copolymer architecture that differ in the relative lengths of the PEG and PPG blocks. 
Molecular weights of the Pluronics used range from 1900-12600 g⋅mol-1. These polymers were 
chosen because of their previous uses in pharmaceutical applications and their known 
biocompatibility.32 Our aim was to increase the efficiency of β-CD delivery into NPC cells using 
biocompatible Pluronic-derived β-CD PR.  
 The PR library was subsequently characterized by solubility tests NMR, NOESY, GPC, 
AUC, AFM, MALDI. Analyses of free β-CD contamination levels in the compounds were made 
by RPLC and HILIC. Dethreading kinetics were studied by RPLC, 1H NMR, and UV/Vis 
analysis. Finally, the capacity of these compounds to mobilize UC in npc1-/- and npc2-/- fibroblasts 
was evaluated by filipin staining and PR localization to LE/LY compartments was studied by 















2.2. β-Cyclodextrin Polyrotaxane Synthesis  
 
2.2.1. Synthesis of Modified Pluronic Copolymers !!
 
Scheme 2.1: Synthesis of β-CD:Pluronic PR. Values of m and n Depend on the Pluronic Base 
Under Investigation. !
 
 The synthesis of F127 Pluronic-based β-CD polyrotaxane will be described in detail 
below (Scheme 2.1). All other β-CD:Pluronic PR were synthesized and purified in the same 
manner, except where noted. The Pluronic precursor was added to a dry round bottom flask under 
a dry N2 atmosphere and then dissolved in benzene before solvent evaporation. This azeotropic 
drying procedure was repeated three times before finally the drying polymer under vacuum at 80 
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 Pluronic F127 (4.0 g) was dissolved in 20 mL DCM and added to CDI (9.5 mmol, 30 eq., 
dissolved in 20 mL DCM) by syringe over the course of 6 h. The solution was stirred for 18 h at 
20 °C before concentration by evaporation and addition to TREN (6.4 mmol, 20 eq., dissolved in 
20 mL DCM) over 3 h. After stirring at 20 °C for 24 h, the solution was concentrated by rotary 
evaporation and the residue precipitated in ether (3 x 350 mL), before collection by centrifugation 
and drying overnight under vacuum. The TREN derivatives of L35 and L64 were isolated as 
viscous yellow liquids, whereas the F127 and F68 derivatves were isolated as white solids. 
TREN-polymers proved difficult to purify completely and, as such, were used with some 
impurity. Extensive purification and dialysis of the final PR compounds would serve to remove 
any impurity retained after these steps.  
 
2.2.2. Polyrotaxane Threading, Endcapping and Purification 
 TREN-F127 (2.5 g) was added to a saturated aqueous solution of β-CD (5.9 mmol β-CD 
in 361 mL H2O). After dissolution of the polymer, the solution was bath sonicated for 10 min at 
65 °C to ensure complete mixing. Finally, the solution was probe sonicated using a ½ inch tip for 
3 min and agitated on a rocker plate for 14 d to promote threading. For liquid polymers L35 and 
L64, a white precipitate formed in the flask almost immediately and increased over time. The 
threading progressed much more slowly for the solid polymers (F127 and F68), with precipitate 
appearing usually after 24 h and increasing thereafter. After completion of the threading reaction, 
TNBS (4 eq, 1.5 mmol, 5.1 mL in a 10% solution) was added to the reaction mixture and left on 
the rocker plate overnight to effect the endcapping reaction.  
 The L35-, L64-, and F68-based PR were collected and washed by centrifugation 3-5 
times with 30 mL of H2O for 3 min at 7000 rpm. After this, the products were dialyzed against 
water in MWCO tubing appropriate for the expected molecular weight of the product. The 
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products were dialyzed for 3 d with an average of six water changes, or until water remained clear 
for two consecutive water changes. 
 
2.3. β-CD:Pluronic PR Characterization !
2.3.1. Confirmation of Endcapping and Threaded Architecture 
 Multiple techniques were used to characterize the β-CD:Pluronic PR products, including 
verification of successful endcapping reactions, characterization of β-CD threading efficiencies, 
determination of PR product molecular weights, and analysis of their purity with respect to free 
β-CD content.  
 All β-CD:Pluronic PR products were poorly soluble in all solvents tested, except DMSO. 
Poor solubility is a well-known property of PEG-based PR compounds.33 Poor solvent access to 
the threaded polymer core, combined with high molecular weights, produce limited solubility of 
these products.20, 24 Pluronic-based β-CD PR were expected to have similar properties. 
 This characteristic was exploited to purify the PR from the β-CD and Pluronic precursors 
that are both quite water-soluble. Free Pluronic polymers, TREN-terminated Pluronic 
intermediates, and free β-CD were removed by repeated aqueous washing of the relatively water-
insoluble PR product. Unsuccessfully- and partially-endcapped PR are also expected to dethread 
upon repeated suspension in water since there is nothing obstructing diffusion of β-CD off the 
unreacted polymer core, eventually rendering these byproducts water soluble and removable by 
the washing and dialysis processes.  
 Multiple lines of 1H NMR evidence suggest that PR formation was successful. Endcap 
peaks were observed indicating successful reaction of TNBS with the terminal amines of the 
TREN-pseudorotaxane intermediate. These peaks were present in NMR spectra of each β-
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CD:Pluronic PR species. There was also evidence of broadening in the β-CD O2H, O3H, H1 and 
O6H protons as well as in the signal corresponding to the Pluronic PPG methyl group (Figure 
2.1). These characteristic changes, previously reported for β-CD PR, is a result of restricted β-CD 
mobility upon threading onto the Pluronic core.33  
 
 
Figure 2.1: 1H NMR Spectra of Free β-CD and PR-F127 Product in DMSO-d6. Peak Broadening     
Shows Inclusions of Polymer Inside β-CD Core. !
 
 Finally, 2D NOESY NMR was performed as an additional confirmation of PR formation. 
Signals corresponding to the inward facing protons (H-3 and H-5) of the β-CD cavity (Figure 2.2) 
and the proton resonances of the Pluronic PPG methyl groups are found to be cross-correlated. 
The close proximity of these substituents suggests that the cyclodextrin molecules are threaded 
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Figure 2.2: Partial 2D-NOESY Spectra of PR-F27. The Characteristic Cross-Peak Between β-CD 
Hydrogens H3/H5 and the PPG Methyl Group is Shown. 
 
2.3.2. Characterization of β-CD Content 
 Initial characterization of the threading efficiency was done using 1H NMR integration 
with subsequent correction for the free β-CD contamination levels present in the sample as 
determined by chromatographic analysis. Since β-CD has seven identical H1 protons at the acetal 
position of each glucose subunit that appear at ~4.8 ppm, the intensity of this signal can be 
directly related to the signal intensity of the Pluronic PPG block methyl group. This method 
indicated that the PR threading efficiencies typically ranged between 62-100%. 
 Initial attempts to produce highly threaded Pluronic PR were less than satisfactory, with 
threading efficiencies often in the range of 20-30%. We attributed these failed attempts to 
aggregation of the Pluronic precursors. Since the critical aggregation concentration for the 
Pluronic precursors used is quite low (0.004-1 wt%), we attempted to disperse the micelles into 
Pluronic unimers in the threading mixture.31 Decreasing the Pluronic feed concentration and 
addition of a probe sonication step into the threading procedure increased the threading 
efficiencies for each of the Pluronic PR cores (Table 1). It is hypothesized that probe sonication of 















































initial threading of β-CD molecules onto the Pluronic unimer which, in turn, prevents the 
immediate reformation of micelles and allows for further threading (Figure 2.3).   
 
 
Figure 2.3: Hypothesized Mechanism of Increased β-CD Threading Upon Probe Sonication. !!
 Quantification of the free β-CD content in a given PR sample is an important parameter 
to measure so that the performance of these compounds can be properly evaluated during in vitro 
and in vivo testing of cholesterol mobilization in NPC models. By having PR compounds 
relatively free of unthreaded β-CD, it can be safely assumed that any observed increases in 
cholesterol efflux or decreases in cholesterol synthesis are a product of β-CD initially entering the 
cell as a PR complex where it is then dethreaded into the active monomeric form. A goal of ≤ 5% 
free CD was selected as an acceptable level of contamination. PR that did not meet this criterion 
were further purified as described. One round of further purification was usually enough to bring 
the PR samples below the 5% free β-CD threshold as determined by RPLC and/or HILIC. 
 







β"CD%PR Base%MW%(kDa) PEG:PPG #%CDs %%Threading %%Yield %%Free%CD 
F127 12.5 200:65 15 71.40% 32.90% 4.40% 
F68 8.35 151:29 14 100% 13.30% 3.60% 
L64 2.9 26:30 12 92% 29.10% 2.40% 
L35 1.9 22:16 5 63% 19.10% 1.20% 
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2.3.3. Characterization of Polyrotaxane Molecular Weight 
 GPC analysis of PR compounds produced molecular weight estimates that were in 
agreement with the masses determined by NMR (after correction for free β-CD). The β-CD:F127 
PR molecular weight for was 30,800 g/mol. GPC analysis indicated a mass of 33,300 g/mol, with 
evidence of free β-CD noted in all samples analyzed.  A mass of 30,000 g/mol was determined by 
both sedimentation velocity and sedimentation equilibrium experiments (Figure 2.4). Taken 
together, this data suggests that the average molecular weight of β-CD:F127 PR is ~31kD. 
Molecular weights for each member of the β-CD:Pluronic PR library corresponded well in both 
GPC and NMR analysis (Table 2).  
 






PR NMR (kDa) NMR (kDa) NMR (kDa) 
F127 30.8 33.3 30.0 
F68 25.5 28.5 27.0 
L64 17.7 17.1 21.0 




Figure 2.4: Sedimentation Equilibrium (SE) Profile of β-CD:F127 PR.  !!!
 MALDI-MS analysis gave additional confirmation of the β-CD:F127 PR molecular 
weights as well as information about the heterogeneity of the system. The spectrum contains a 
mass peak at ~30 kDa representing a threading of 15 CDs as found by other measures. Other 
peaks in the spectrum correspond to members of the β-CD:F127 PR population with greater and 
lesser degrees of threading. Most abundantly, additional m/z peaks corresponding to 18, 8, 7, 6, 
and 1 threaded CD appear (Figure 2.5). As expected, there is some heterogeneity in the amount of 
threading on any given PR monomer. Additionally, MALDI spectra of lower molecular weight 
PR showed evidence of dimer formation. This fits well with the aggregation behavior noted in 





Figure 2.5: MALDI-MS Spectrum of β-CD:F127 PR at Laser Power 6500.  
 
2.3.4. Polyrotaxane Morphology 
 AFM analysis of the β-CD:F127 PR material produced evidence of PR aggregation. To 
try and image non-aggregated particles, PR samples were probe sonicated before being fixed onto 
mica plates. Sonication did not prevent aggregation, but did decrease the size and height of 
imaged particles. It is hypothesized that β-CD:Pluronic PR are forming hollow micelles in 
solution as previously reported in a similar β-CD:Pluronic PR system.34 Consistent with this 
expectation, we found that higher PR concentrations produced larger aggregates. Samples at a 
concentration of 10-5 mg/mL obtained an average diameter of 45.1 nm after probe sonication. 
Samples at 10-7 mg/mL averaged 41.0 nm and concentrations of 10-9 mg/mL gave particles with 
an average diameter of 32.1 nm (Figure 2.6). Thus, higher β-CD:F127 PR concentrations promote 






Figure 2.6:  AFM Images of β-CD:F127 PR at 10-5 mg/mL (A), 10-7 mg/mL (B) and 10-9   mg/mL 




 Diffusion ordered spectroscopy measurements were able to confirm rotaxination and 
provide some insight into how the β-CD:Pluronic PR constructs behave in solution.  The 
diffusion constants (D) for β-CD:L35, β-CD:L64, and β-CD:F68 PR were 5.84 x 10-11 m2/s, 5.30 
x 10-11 m2/s, and 3.38 x 10-11 m2/s respectively. These diffusion constants scale with molecular 
weight and are in reasonable agreement with the diffusion behavior of similar systems.33, 35 
Additionally, the least squares fit of a log(D) vs Log(MW) plot gave a scaling constant of -0.63. 
Scaling constants < -0.6 are indicative of semiflexible wormlike systems,36 showing that the PR 





2.3.5. Polyrotaxane Dethreading Behavior 
 Experiments were performed to characterize the dethreading behavior of the β-
CD:Pluronic PR under acidic and reducing conditions in an attempt to mimic the LE/LY 
environment (Figure 2.7).  Experiments in which β-CD:Pluronic PR were suspended in solutions 
at either pH 7.4 or 5.5 and sampled at intervals showed no increase in free β-CD levels by RPLC 
analysis up to 24 hr after dissolution. This was in agreement with the design of the PR, which 
were intended to be stable under acidic conditions.  
 
 
Figure 2.7: Hypothesized and Experimentally Tested Mechanisms for PR dethreading. A) 
Glutathione Incubation with PR at Acidic and Neutral pH and (B) Acid Catalyzed Dethreading at 
37 °C Showed No Signs of Dethreading. Hypothesized Dethreading (C) By Enzymatic Cleavage 
of Carbamate Linkages Yields Free β-CD In Vitro. !!
 
 Additionally, 1H NMR and UV/Vis studies were conducted to monitor changes in endcap 
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PEG-NH-TNB analog showed no changes in the characteristic TNB peaks even after 48 hr 
incubation with glutathione at 37 °C, indicating that the TNB nitro groups had not been reduced. 
Similarly, the UV/Vis spectra of the F68-TNB endcaps remained unchanged even after 48 h of 
incubation in glutathione at both acidic and neutral pH. As expected, dethreading of β-
CD:Pluronic PR is not triggered by acid-mediated endcap cleavage or glutathione reduction of the 
TNB endcap.   
 Finally, the possibility that β-CD:Pluronic PR were dethreading upon solubilization in 
DMSO and/or incubation with media was investigated. 1H NMR analysis of PR samples showed 
that neither incubation with DMSO/MEM nor DMSO/PBS buffer resulted in any changes in the 
integrated threading efficiency of the samples when compared to PR controls. β-CD:Pluronic PR 
should, therefore, be stable in culture before cellular internalization.  
 
2.4. Niemann-Pick Type C Fibroblast Studies 
 
2.4.1. Polyrotaxane Cholesterol Mobilization 
 Npc2-/- fibroblasts were incubated with each β-CD:Pluronic PR derivative and reductions 
in cellular cholesterol accumulation were monitored over time to evaluate their impact on a 
cellular model of NPC disease.  Initially it was hypothesized that this library of PR constructs, 
which was not designed to be either acid sensitive or reductively labile, would stimulate little or 
no reduction in npc2-/- cholesterol accumulation. Figure 2.8, however, shows that a single dose of 
any β-CD:Pluronic PR, yielding 25 µM β-CD, results in a reduction of approximately 60 to 75%  
in accumulated cholesterol levels by 6 hr, relative to untreated controls. Results were 
quantitatively similar to monomeric β-CD, which decreased cholesterol levels to ~30% of the 
level of untreated cells over the same time period. Similar, although diminished, results are seen 
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in npc1-/- cells (Figure 2.9). Differences in treatment based on protein mutation may be indicative 
of varying sequestration severities.  
 It is worth noting that the levels of CD monomers used in the present studies are within 
the range of effective concentrations shown by Peake and Vance to clear cholesterol from murine 
npc1-/-neurons and glial cells,38 as well as by the data herein to clear cholesterol from human 
npc2-/- fibroblasts.13 Levels that were demonstrated to cause neuronal cell toxicity, e.g. 10 mM 
were not used in the present studies.38 In addition, although the fibroblasts were exposed to 
potentially cytotoxic TNB upon endcap release, no alterations in cell density or viability were 
observed in any of the cell samples.  
 
 
Figure 2.8: Filipin Accumulation in NPC2 Deficient Fibroblasts Treated With β-CD:Pluronic PR.  !!!
 While each of the compounds induces rapid efflux of cholesterol, similar to monomeric 
CD, slight differences in the efficacy of the PRs are apparent. For example L35, carrying 5 β-





















CD monomers, is the most effective (p < 0.05). These differences in relative cholesterol clearance 
by the PRs suggest that endcap cleavage and dethreading of CD is occurring within the LE/LY, 
following bulk phase endocytosis of the intact compounds (Figure 2.8B). If dethreading were 
occurring in the media prior to cellular uptake, approximately equal degrees of cholesterol 
clearance would instead be expected for all the β-CD:Pluronic PR compounds, since each 
treatment would yield 25 µM monomeric β-CD.  
 
 
Figure 2.9: Cholesterol Mobilization from NPC1 Deficient Fibroblasts. 
 
2.4.2. Polyrotaxane Subcellular Localization 
 In order to determine whether the β-CD:Pluronic PR compounds were in fact entering the 
LE/LY compartment, a fluorescein labeled β-CD:F127 PR was synthesized. Thirty minutes after 
addition of the compound to npc2-/- fibroblasts, fluorescein was observed to overlap entirely with 
Lysotracker Blue staining, indicating localization of the compound to the LE/LY (Figure 2.10). 
Therefore, it is likely that the carbamate linkages used to attach the PR endcaps are being cleaved 
by enzymatic activation within the LE/LY. Hydrolysis of carbamate linkages has been previously 
reported and, indeed, has been used as a method for activating prodrugs.39-41 Thus, carbamate 
cleavage would allow for dethreading of β-CD monomers at high concentration within the LE/LY 





Figure 2.10: Fluorescein Labeled β-CD:F127 PR Localizes to the LE/LY In npc2-/- Fibroblasts. 




 We have synthesized a family of β-CD:Pluronic PR compounds as potential therapeutics 
for treating Niemann-Pick Type C disease. The threading efficiency, molecular weight, and free 
β-CD contamination in these analogs have been characterized. Each of the compounds has been 
shown the capacity to trigger the efflux of cholesterol from npc1-/- and npc2-/- fibroblasts in vitro 
via filipin staining studies. The rate and efficacy of β-CD:Pluronic PR mediated cholesterol 
removal has been shown to be comparable to monomeric β-CD treatment alone. Based on these 
findings, β-CD:Pluronic polyrotaxanes warrant further investigation with regard to their safety, 
pharmacokinetics, biodistribution, and durability of response toward cholesterol efflux and/or 















2.6. Materials and Methods 
 
2.6.1. Materials 
 (1,1)-Carbonyldiimidazole (CDI) and 2,4,6-trinitrobenzenesulfonic acid (TNBS) were 
purchased from Research Organics. Tris(2-aminoethyl)amine (TREN),  β-cyclodextrin, Pluronic 
polymers and 2,2’-(ethylenedioxy)bis(ethylamine) were purchased from Sigma Aldrich. The four 
Pluronics used in this study were F127, F68, L64, and L35. All solvents were dried and distilled 
from an appropriate dessicant prior to use unless otherwise noted. Human fibroblasts cells from 
an apparently healthy donor (GM03652) and from an NPC2 patient (GM18455) were from 
Coriell Institute of Medical Research (Camden, NJ). Filipin and fluorescein were purchased from 
Sigma and Lysotracker Blue from Molecular Probes. 
 
2.6.2. Synthesis and Purification of β-CD:Pluronic Polyrotaxanes 
 PR synthesis is described in detail in the text above. The L35-, L64-, and F68-based PR 
were first collected from the reaction mixture by centrifugation for 3 min at 7000 rpm.  They 
were then diluted with 30 mL of H2O, vortexed, and re-centrifuged under identical conditions. 
Water washes were continued in this manner until the washes ran nearly clear; usually 3-5 
repetitions.  The F127-based PR was not able to be collected by centrifugation due to the 
formation of viscous suspensions. Therefore, this product was purified by extensive dialysis 
described below.   
  The products were again suspended in 30 mL H2O and dialyzed against H2O using 
dialysis tubing correlating to the estimated MW of the final product. L35- and L64-based PR 
were dialyzed with MWCO 3500 and 6-8000 tubing, respectively. F68 and F127-based PR were 
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dialyzed against water in MWCO 12-15k tubing. The products were dialyzed for 3 d with an 
average of six water changes, or until water remained clear for two consecutive water changes. 
 Upon completion of dialysis, the purified products were frozen and lyophilized to yield 
yellow-orange powders. β-CD:F127 PR was obtained in 32.9% yield (1.883 g). β-CD:F68 PR, β-
CD:L64 PR, and β-CD:L35 PR gave 13.29% (0.502 g), 29.1% (4.773 g), and 19.1% (1.12 g) of 
solid, respectively.  F127 1H NMR: (400MHz, DMSO-d6, 22°C) δ 8.94-8.76 (br s., 8H, TNB), 
5.73-5.65 (m, 266H, O2H, O3H of CD), 4.8 (s, 133H, H1 of CD), 4.45 (t, 133H, O6H of CD), 3.67-
3.59 (m, 532H, H3, H6, H5, H4 of CD), 3.51-3.48 (m, 995H, PPO and PPG -CH2-), 1.04-1.01 (d, 
195H, PPG -CH3).  
 After the initial purification processes, the PR were analyzed by both RPLC and HILIC, 
with the two methods consistently agreeing within 8%. Initial free CD measurements for β-
CD:F127 PR were 19.87% by HILIC and 26.88% by RPLC. Samples containing > 5% free β-CD 
by RPLC were suspended in 15 mL H2O, vortexed for 2 min, and gathered by centrifugation as 
previously described. After three repetitions, the samples were reanalyzed for free β-CD content. 
This process was repeated until the HILIC and/or RPLC analyses indicated that the free β-CD 
content was ≤ 5% free β-CD. 
 The inability to wash and collect β-CD:F127 PR by centrifugation made them more 
difficult to purify of free, or entrained β-CD contamination. Samples containing > 5% free β-CD 
contamination after initial purification were re-suspended in H2O, vortexed for 3 min, and again 
left to dialyze against either MWCO 12-14k dialysis tubing or a 20K dialysis cassette for 2 d and 
re-tested. This process was repeated until the HILIC and/or RPLC analyses indicated that the free 
β-CD content was ≤ 5% free β-CD. 
 Fluorescein modified β-CD:F127 PR was synthesized by dissolution of 400 mg β-
CD:F127 PR in dry DMSO before activation with CDI (6.1 mmol) and coupling to ethylene 
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diamine (7.4 mmol). A second activation with CDI (6.1 mmol), fluorescein coupling (6.1 mmol) 
and precipitation twice in MeOH yielded the fluorescent PR derivative. The fluorescent PR 
derivative was used without further purification.  
 
2.6.3. Determination of Threading Efficiency by 1H NMR 
 Determination of PR threading efficiencies were initially performed by 1H NMR spectral 
integration. The characteristic β-CD H1 proton at ~4.8 ppm was directly compared to the PPG 
methyl protons of the polymer at 1.0 ppm. The PPG resonance was normalized to the average 
number of hydrogens expected for that specific Pluronic’s methyl group. Given that each β-CD 
monomer has seven acetal protons, the corresponding integration for the number of β-CD H1 
protons present in the sample was divided by seven. This yielded an average number of β-CDs 
per PR. This estimate of threading efficiency was then recalculated once the amount of free, 
unthreaded β-CD in the sample was determined by chromatographic analysis. 1H NMR spectra 
were acquired on a 400 MHz Bruker ARX400 spectrometer, using the solvent peak as the 
reference standard and the chemical shift given in parts per million. NOESY spectra were taken 
on a 500 MHz Bruker DRX500 spectrometer with a 5 mm TBI probe. DMSO-d6 was used as 
NMR solvent unless otherwise noted.   
 
2.6.4. Determination of Free β-CD in β-CD:Pluronic PR 
 Determinations of free β-CD in PR samples were done in two ways. First, PR solutions 
of ~1 mg/mL were prepared in H2O for analysis on a custom made HILIC silica packed column 
with 700 nm nonporous silica nanoparticles that were surface-modified with amide groups.42 
Before analysis, PR were subjected to 2 rounds of vortexing for 2 minutes and bath sonication at 
50 °C for 10 minutes. The temperature of the column oven was maintained at 25 °C. All runs 
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were performed under the gradient conditions of 90-70% ACN with 0.1% formic acid. 
Determinations were made on a Thermo Accela UPLC system (Thermo Fischer Scientific, MA, 
USA) and LTQ Velos LC-MS. Mobile phases A and B were acetonitrile with 0.5% (v/v) formic 
acid and water with 0.5% (v/v) formic acid. Chromatographic separation started at an initial 
mobile phase of 95% A, held for 1 min, then followed by a linear gradient from 80 to 60% mobile 
phase A in 15 min. The solvent composition then changed to 50% A over 0.1 min and was 
maintained for 5 min before being re-equilibrated to 95% A. The flow rate was 150 µL/min.  
 Mass spectrometric data were acquired in the positive ion mode. The ESI conditions were 
as follows: ESI spray voltage, 4 kV; temperature setting, 300°C; sheath gas flow, 30 U (arbitrary 
units); auxiliary gas flow, 8 U.  
 Additionally, PR solutions in H2O (~1mg/ml) were analyzed by RPLC using an 
H2O:ACN gradient elution as described by Agueros, Campanero and Irache.43 Analyses were 
performed using an Agilent Technologies 1200 Series HPLC equipped with an ESA Corona 
Detector and an Agilent Zorbax Eclipse XDB-Phenyl column (2.1 x 1250 mm, 5 µm particles). 
Known concentrations of β-CD were used for both HILIC and RPLC measurements to construct 
standard curves for fitting PR sample data.  
 
2.6.5. Gel Permeation Chromatography 
 Corroboration of NMR molecular weight measurements and threading efficiencies were 
made by gel permeation chromatography (GPC) analysis. PR samples (~30 mg/mL in DMSO) 
were prepared and analyzed as described by Beirne, Truchan, and Rao.44 GPC measurements 
were made using an Agilent Technologies GPC system equipped with an OHpak SB-803HQ 
column (8 mm x 300mm), Dawn Helios II multi-angle light scattering detector (Wyatt 
Technology Corporation), and Optirex RI detector (Wyatt Technology Corporation) using DMSO 
as the mobile phase. The detectors were normalized using 25 kD pullulan and calibrated using 
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11.6 kD and 48.6kD dextran standards. Flow rate was 0.16 mg/mL with a 100 µL injection 
volume. 44  
 
2.6.6. Analytical Ultracentrifugation 
 Analytical ultracentrifugation was done in the Purdue Bindley Bioscience Center on a 
Beckman Coulter XLI (Beckman-Coulter, CA) ultracentrifuge using absorbance optics at 346 nm 
and 422 nm and interference optics at 675 nm. PR were characterized in PBS buffer at pH 7.4 at 
concentrations of 0.1, 0.2, and 0.4 OD. Sedimentation equilibrium (SE) experiments were done at 
speeds of 25,000, 35,000 and 40,000 rpm for a total of 67.8 h and analyzed by the species 
analysis model in SEDPHAT (v. 9.4).45 The system was standardized by running unmodified 
F127 Pluronic (found to be 12,500 g/mol as expected). Sedimentation velocity experiments were 
conducted at 50,000 rpm using a 2 channel charcoal centerpiece for 15 h and analyzed using 
SEDFIT (v. 12.43).46 All experiments were carried out at 20 °C using an Anton 60 Ti rotor. Buffer 
density and viscosity were calculated using SEDNTERP.47 The partial specific volume of 
polyrotaxane without a PEG derivative was calculated to be 0.62 mL/g.48 The partial specific 
volume of the polyrotaxanes with PEG derivatives was 0.85 mL/g, which agrees well with 
published values.49  
 
2.6.7. Atomic Force Microscopy 
 AFM images were taken by depositing and drying 1 µL of probe sonicated PR-DMSO 
solution onto a mica plate. All samples were fixed ~5 min after probe sonication.  Images were 
obtained using a Dimension 3100 AFM from Veeco Instruments (USA). Images were obtained in 
tapping mode using an NSC15/AIBS 325 kHz cantilever with a 46 N/m force constant and an 




2.6.8. Mass Spectrometry Analysis 
 An ionic liquid matrix (ILM) was made for analyzing the PR by MALDI. The ILM was 
made as follows: 2',4',6'-trihydroxyacetophenone monohydrate (THAP) and 1,1,3,3-
tetramethylguanidine (TMG) were mixed at a molar ratio of 1:2 in methanol. The solution was 
then sonicated for 15 min at 40 °C. After removal of methanol by centrifugal evaporation in a 
SpeedVac for 3 h at 20 °C, ILMs were left under vacuum overnight. Final solutions were then 
prepared at a concentration of 90 mg/mL in DMF for use as a matrix. The polyrotaxanes samples 
were prepared at 3 mg/mL in DMF. The samples for MALDI-MS analysis were prepared by 
mixing the PR sample and ILM in a 1:80 ratio. Then, 0.6 µL of the mixture was deposited on a 
mirror polished stainless steel MALDI target and allowed to dry at 20 °C and atmospheric 
pressure overnight. The spectra were acquired at a laser power of 6500 using 600 laser shots in 
linear mode on an AB4800 MALDI TOF/TOF Analyzer. Peak assignments were made by 
addition of modified polymer MW and 1,135n, where n is the potential number of bound CDs. 
Lesser peaks flanking assigned masses can be attributed to variations in MW inherent in the base 
polymer. 
ESI mass spectrometry of the TNB terminated 2,2’-(ethylenedioxy)bis(ethylamine) was 
performed on a Waters ZQ electrospray mass spectrometer in negative ion mode. 
 
2.6.9. Dethreading Analysis 
 Bulk dethreading experiments of β-CD:Pluronic PR were performed by suspending each 
PR in H2O, adjusted to pH 7.4 or 5.5, at concentrations of 1 mg/mL. Samples were placed in a 
constant temperature bath at 37 °C and sampled at 1, 2, 4, 8, 16, and 24 h. Aliquots were analyzed 
by RPLC as described above to monitor the increase in free β-CD in each sample. 1H NMR 
analysis of similarly incubated PR was also conducted to reveal any changes in carbamate peaks 
characteristic of successful endcapping.  
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A short, unthreaded TNB endcapped PEG-bis-amine (MW 570.4 g/mol), was synthesized 
to better visualize any possible changes in the encap. 0.1 g 2,2’-(ethylenedioxy)bis(ethylamine) 
was dissolved in THF. TNBS (4.2 mL, 2.5 eq) was activated with 1 mL 5% NaHCO3 and added 
to the THF solution.  Reaction was allowed to stir for 24 h with a yellow/orange precipitate 
forming within 1 h. Precipitate was collected by vacuum filtration and washed with THF (3x 25 
mL).  Product was isolated as an orange powder (158 mg, 40.8% yield). ESI-MS: Found 569.39 
m/z. 1H NMR spectrum in the presence of glutathione. This compound was subjected to a D2O 
solution of 10 mM glutathione at pH 7.4, incubated at 37 °C, and monitored at intervals for 48 hr. 
The PEG-TNB concentration was 1 mg/mL. 
 TREN-terminated F68 polymer was synthesized as described. 0.26 mL (4 eq) of TNBS 
(10% solution in H2O) was added to an aqueous solution of 0.2 g F68-TREN terminated polymer.  
Reaction mixture was stirred for 18 h, precipitated in ether and collected by centrifugation. 
Product was then dissolved and re-precipitated into ether (2 x 150 mL). Product was collected by 
centrifugation and dried on Hi-vac. Product was collected as a yellow/orange solid (0.198g, 
90.4% yield).  
UV/VIS analyses of TNB endcaps were made using an Agilent HP 8453 UV/Vis 
spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA, USA). PBS solutions of an 
unthreaded F68-TNB polymer were dissolved at 1 mg/mL with 10mM glutathione at either pH 
7.4 or 5.5. Emission spectra were taken at 1, 2, 4, 8, 16, 24, and 48 h, with monitoring at 346 nm 






2.6.10. Polyrotaxane Media Stability 
Two solutions of ~ 12 mg β-CD:F127 PR were prepared in 0.2 mL DMSO. The PR 
solutions were then diluted to 10 mL with either PBS buffer or Minimum Essential Medium at 
pH 7.4 before incubation for 1 hr at 37 °C. After incubation, the samples were dialyzed against 
for 3 d with water changes approximately every 12 h. Samples were then frozen, lyophilized, and 
collected as yellow-orange powders. Analyzed as described in the manuscript, integration of the 
H1 protons for each sample showed 20.9, 21.1 and 20.5 protons for DMSO/media incubated, 
DMSO/buffer incubated and control PR respectively. This corresponds to ~3 CDs for each 
sample and no apparent degradation of the samples in DMSO or media 
 
2.6.11. Diffusion-Ordered Spectroscopy 
 Experiments were performed on a Bruker AVIII300WB spectrometer using a diff50 
diffusion probe with a maximum gradient strength of 30 T/m. The pulse sequence used was a 
stimulated echo diffusion sequence (PGSTE)50 with an additional spoiler gradient in the diffusion 
period. Signal attenuation was achieved by varying the gradient strength while all the timings in 
the pulse sequence were kept constant. The main experimental parameters were as follows. The 
effective gradient pulse duration δ was 1 ms using a sinusoidal gradient shape, the diffusion time 
(Δ) was 20 ms, and the repetition time was 2 s. The gradient amplitude was varied in, 64 steps 
linearly between 9 and 572 Gauss/cm (90 to 5720 mT/m).  For each gradient step 64 scans were 
performed for a total experiment time of about 2 h 15 m. The experimental parameters were not 
optimized for speed; the experimental time could be cut down to less than half an hour. The 





2.6.12. Cell Studies 
 Human fibroblasts from npc1-/-, npc2-/-, or unaffected patients were seeded on 8-well 
tissue culture slides at a density of 6x103 cells, in Eagle’s Minimum Essential Medium with 
Earle’s salts and non-essential amino acids + 15% FBS at 37°C with 5% CO2. Sterile β-
CD:Pluronic PR samples were solubilized in DMSO and diluted in culture media to a 
concentration that would yield 25 µM β-CD. The final DMSO concentration in all preparations 
was ≤ 0.001%.  Treatments were administered to cells 36 - 48 h after plating.  Following varying 
incubation periods, as indicated, cells were rinsed with PBS and fixed in situ with 10% buffered 
formalin. Cell density and viability, determined by trypan blue exclusion, were determined using 
cells collected immediately prior to fixation. No changes in cell numbers or viability (> 95%) 
were found, indicating an absence of toxicity under the range of conditions used in the present 
studies. Fixed cells were washed with PBS and stained with 50 µg/mL filipin in PBS for 1 hr.  
Images were acquired using a DAPI filter set on a Nikon Eclipse E800 epifluorescence 
microscope (Nikon Inc.), equipped with NIS-Elements BR 3.2 software (Nikon Inc.).  Anti-fade 
mounting agents and microscope light settings ensured the absence of photobleaching.  Filipin 
accumulation in cells was determined using NIS-Elements selection tools and calculated as a ratio 
of filipin area to cell area.  The results in β-CD:Pluronic PR and β-CD treated cells were 
normalized to filipin accumulation in untreated npc2-/- fibroblasts and are expressed as mean ± 
SE. 
Fluorescein labeled β-CD:F127 PR was prepared as described above and administered to 
npc2-/- fibroblasts approximately 24 h after plating. Cells were rinsed with PBS 0.5 h or 1 h after 
addition of the compound and incubated with 50 nM Lysotracker Blue (Life Technologies) in 
PBS for 10 min. Cells were rinsed again and fixed in situ with buffered formalin. Images were 
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CHAPTER THREE: IN VITRO EFFICACY OF MIXED β-CYCLODEXTRIN 





3.1.1. Mixed β -CD Polyrotaxanes as NPC Therapeutics 
Polyrotaxanes (PRs) are non-covalent self-assemblies obtained from macrocyclic 
molecules, such as cyclodextrins, being threaded onto polymer axles. Macrocycles are retained 
through bulky stoppers that prevent dethreading. These non-covalent constructs have attracted 
wide interest in supramolecular and polymer chemistry, with particular attention focused on their 
potential applications as sliding ring gels,1, 2 molecular machines,3 and as carriers for drug and 
gene delivery.4, 5 Since the first PRs constructed from α-cyclodextrin (α-CD) and PEG were 
reported by Harada et al.,6, 7 many research efforts have been dedicated to the design of various 
Pluronic®-based PRs using β-cyclodextrin (β-CD) and its derivatives.8-14 Some of these studies 
have been devoted to understanding the formation of cyclodextrin inclusion compounds, but the 
forces that drive the complexation, especially for CD-polymer inclusion complex formation, have 
yet to be fully elucidated.15-19  In addition, many reports have described the influence of 
cyclodextrin modifications on the stability and solubility of the numerous drug:β-CD 
complexes;20, 21 however, none of these contributions have methodically focused on their impact 
on linear polymer complexes. Tonelli and coworkers have shown, while trying to interchange α-
CD between PCL chains and PLLA chains in solution, that the guest-host steric compatibility 
plays an important role in polymer-CD complex formation.22  
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 Thompson and coworkers have previously reported the synthesis of 2-hydroxypropyl-β-
cyclodextrin (HP-β-CD):Pluronic® copolymer based PRs under heterogeneous conditions as part 
of an effort to develop substrate reduction agents as potential Niemann-Pick Type C 
therapeutics.23 This is an attractive and effective synthetic method for threading reactions 
involving highly water-soluble CDs. Since the previously reported β-CD derivative based PRs 
displayed limited solubility in saline solutions at concentrations necessary for practical clinical 
translation, we sought to improve PR solubility by developing a library of PRs from mixtures of 
β-CD derivatives with 4-sulfobutylether-β-cyclodextrin (SBE-β-CD). SBE-β-CD has been widely 
utilized to improve the toxicity profile and water solubility of a variety of molecules in drug 
formulations.24, 25 
 In addition, cholesterol has been incorporated into the PR design for a variety of reasons. 
First, cholesterol is a biocompatible organic compound which the body produces indogenously, is 
non-toxic, and has predictable and well-known metabolic pathways. This is in contrast to TNB 
endcaps of the previously chapter which are potentially toxic foreign compounds. In addition, it 
was hypothesized that utilizing cholesterol as an endcap may provide beneficial improvements in 
uptake, targeting, and/or pharmacokinetics. Cholesterol mediated association with cell 
membranes, which are rich in cholesterol, may drive adsorptive endocytosis. Serum protein 
components known to circulate for extended periods, including serum albumins and low density 
lipoproteins (LDL), have been shown to carry large amounts of cholesterol. Association with 
these proteins may promote extended residence time in the body. Finally, cholesterol mediated 
association with LDL could help with PR uptake, through LDL surface receptors, and trafficking 
to the LE/LY, the ultimate destination of this pathway.  
To understand the effect of macrocycle substituents on therapeutic efficacy, we used PRs 
synthesized from mixtures of SBE-β-CD and HP-β-CD derivatives. Solubility studies with these 
compounds demonstrate that PR water solubility can be significantly improved by incorporation 
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of SBE-β-CD. It is also shown that PRs of a mixed β-CD threading population are therapeutically 
active in an in vitro model of Niemann-Pick Type C disease.  
 
3.1.2. Pendant Polymer Systems as NPC Therapeutics 
 Thompson and coworkers have previously published work describing the use of pendant 
polymer systems to deliver pDNA and siRNA.26, 27 In these systems, a polymeric backbone 
consisting of PEG-poly(vinyl alcohol) (PVA), is modified with acetal-linked pendants. These 
backbone grafted pendants included adamantane (Ad), noradamantane (NAd), cyclohexane 
(Cyc), and octane (Oct) modifications. These pendants exhibit variable affinity for CD cavities 
and would, therefore, be expected to release CD at different rates. It has been shown that, as gene 
delivery vectors, these materials form complexes of varying stability and deliver gene cargo in an 
efficient and non-toxic manner. Re-purposing these systems as a CD-carrying therapeutic for 
NPC disease may be attractive if they can effectively achieve cellular uptake and cholesterol 





Figure 3.1: Pendant Polymer and Cyclodextrin Derivative Structures.  !!!
In addition to the PVA-containing systems, pendant polymers were synthesized using 
Hyaluronic acid (HA) as a backbone. HA is a natural glycosaminoglycan that makes up a large 
portion of the extracellular matrix. It is often used in nanoparticle formulations because it is water 
soluble, modifiable, and provides active receptor mediated endocytosis through CD44.28 These 
features of increased solubility and targeted delivery make this system very attractive as an NPC 
therapeutic. The scaffold is also biodegradable, as the body is well versed in the natural 
breakdown of HA. Covalent modification with adamantane pendants would allow for HA to 
become an effective carrier of a number of CD derivatives after non-covalent complexation. The 






















































































































































3.2. Results and Discussion 
 
3.2.1. Mixed β-CD Polyrotaxane Solubility and Cholesterol Mobilization !
 
Figure 3.2: General Representation of Polyrotaxane with Mixed Threading. Values of X and Y 
Vary With β-CD Derivative Feed Ratio. !!!
 The long-term goal of this work was to generate HP-β-CD PRs of sufficient water 
solubilities to enable Niemann Pick Type C therapeutic studies. We anticipated that the negative 
charges introduced by the SBE-β-CD units in the PR complexes would reduce their aggregation 
and improve their water solubility (Figure 3.2). To test this assumption, the samples obtained 
from HP-β-CD/SBE-β-CD mixtures were dissolved at 50 mg/mL in nanopure water and the 
appearance of the solutions was monitored (Figure 3.3). Our findings show that increasing the 
amount of SBE-β-CD in the PR structure leads to a significant improvement in their water 
solubility, particularly for the samples with SBE-β-CD molar ratios of ≥ 25%. It is well known 
that CD-based PRs are generally insoluble in water due to the aggregation of their rod-like 
structures.29, 30 The incorporation of SBE-β-CD, a highly negatively charged material, leads to 











































































Figure 3.3: Increased Solubility of Mixed Polyrotaxanes. Screening by Yawo Mondjinou. !
 
 Given that incorporation of SBE-β-CD is able to increase the solubility of PR constructs, 
we sought to determine whether PRs of mixed threading were therapeutically active in an in vitro 
model of Niemann-Pick type C disease. PRs carrying an increasing percentage of SBE-β-CD 
were administered to Niemann-Pick C1 (NPC1) deficient fibroblasts to examine their ability to 
mobilize cholesterol from sites of aberrant accumulation. Each PR family member, generated 
with a 0%, 30%, 50%, 60%, or 100% SBE-β-CD feed ratio, was administered at 25 µM total β-
CD concentration and compared to administration of 25 µM SBE-β-CD or HP-β-CD monomers 
alone. Comparisons were made at equivalent β-CD concentrations meaning that, because each PR 
carries greater than 10 copies of β-CD, PR compounds were administered at molar concentrations 
over an order of magnitude lower than for β-CD monomers. 
 Probing cholesterol mobilization 6 h after treatment revealed that these PR family 
members perform roughly equivalently to their respective monomers in cholesterol mobilization 
assays (Figure 3.4). Both HP-β-CD and SBE-β-CD decreased the average Filipin staining in 
npc1-/- fibroblasts to approximately 75% of the untreated control in 6 hours. PRs carrying 100% 
HP-β-CD and 100% SBE-β-CD performed equivalently, each decreasing Filipin staining to  
~78% of control. PRs carrying 30:70 SBE-β-CD:HP-β-CD decreased fluorescence more 




CD performed slightly worse than controls, decreasing fluorescence to 86% and 83%, 
respectively. A broader screen of PR concentrations would be necessary to determine if an 
incorporation of low amounts of charged CD, e.g. 30%, truly enables PRs to mobilize cholesterol 
more effectively than PRs with a greater percentage of SBE-β-CD. DMSO control experiments 
showed no effect of DMSO treatment on Filipin staining. These experiments show that PRs 
generated from mixed threading reactions retain therapeutic activity in vitro. 
 
 
Figure 3.4: Therapeutic Efficacy in npc1-/- Fibroblasts of Mixed Threading Polyrotaxanes 
Carrying Varying Percentages of SBE-β-CD. 
 
 
3.2.2. Cholesterol Mobilization by β-CD Carrying Pendant Polymers  
 PVA:HP-β-CD screens focused on differences in activity as a function of binding affinity 
of the pendant group. Monomeric HP-β-CD control decreased Filipin staining by approximately 






















Control HP-β-CD SBE-β-CD 100% HP-β-CD 
30% SBE-β-CD 50% SBE-β-CD 60% SBE-β-CD 100% SBE-β-CD 
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with weaker binding affinity for β-CD. Pendants with stronger binding affinity, such as Ad and 
NAd, performed less effectively than the positive control, with reductions of approximately 20% 
and 30%, respectively (Figure 3.5). Results seemed to map with binding affinity, possibly due to 
delayed loss of CD from pendent groups with higher affinity.  Insolubility and concerns about the 
potential for bioaccumulation led us to abandon these compounds from further consideration. A 
statistically significant number of biological replicates would be necessary to begin to draw firm 
conclusions. The screens did, however, validate the pendant polymer system as a potential β-CD 




Figure 3.5: Cholesterol Mobilization by HP-β-CD Carrying Pendant Polymers. !
 
 In the HA-pendant polymer studies, incubation with free HA caused little change in the 
Filipin staining profile of the fibroblasts (Figure 3.6). Monomeric β-CD caused a modest, but 
typical, reduction in Filipin staining to about 82% of control.  This reduction was increased to 
about 70% of control upon non-covalent association of the CD to the HA-Ad. This may be due to 





















although this has not ben confirmed. Conversely, while the β-CD therapeutic effect appeared to 
be boosted from complexation with HA-Ad, the other two CD derivatives showed no noticeable 
increase in efficacy. HP-β-CD and HA:HP complex performed similarly in cholesterol removal. 
The same can be said for SBE-β-CD and HA:SBE-β-CD. In other words, treatment with 
complexes of these CD derivatives does not perform any better than treatment with the monomer. 
Complexes perform equivalently at equivalent concentrations, but the hypothesized boost in 
performance from increased uptake was not seen. It is possible that the alcohol modifications are 
interfering with effective complexation of HP-β-CD and SBE-β-CD. It remains to be seen 
whether smaller, less strongly binding pendants would mediate a boost in performance similar to 
that seen in the PVA materials. 
 
 












































 Interestingly, the water solubilities of the PRs were significantly improved due to the 
presence of SBE-β-CD units in the PR product. Varying the ratio of SBE-β-CD carried by PR 
family members, however, does not greatly affect their therapeutic activity in NPC disease. The 
ability to achieve saline solubility, while retaining the ability to mobilize abnormally stored 
cholesterol, make this generation of mixed threading PRs more therapeutically attractive that 
those reported in Chapter 2. This removes the need for the use of DMSO in solubilization and has 
the potential to increase the effective PR concentration that can be administered per injection. The 
use of SBE-β-CD co-threading enhances the potential for PRs to become an easily administered 
delivery vehicle to make β-CD derivatives more attractive NPC therapeutics. 
 In addition, proof of principle has been demonstrated in the use of pendant polymer 
systems as NPC therapeutic vehicles. When using unmodified β-CD, pendant polymers 
outperform their monomeric counterparts at equivalent concentrations. This is not the case when 
CDs are modified. Interestingly, weakly binding pendants may mediate better performance than 
the tightly binding Ad. It remains to be seen if the performance lost by CD modification can be 
regained through the use of weaker binding guests. It is also unclear if the additional efficacy 
exhibited by unmodified β-CD when in complex with HA is due to receptor mediated uptake. 
These findings need more focused investigation with endocytosis inhibitors and flow cytometery 
analysis of PR uptake. Despite the need for further investigation, pendant polymers have been 







3.4. Materials and Methods 
 
3.4.1. Materials 
Pluronic® triblock copolymer L81 (PEG 6, PPG 43) was purchased from Sigma-Aldrich 
and dried by azeotropic distillation from benzene under vacuum before use. β-Cyclodextrin and 
2- hydroxypropyl-β-cyclodextrin (HP-β-CD, 0.8 molar substitution) were also purchased from 
Sigma-Aldrich and were used as received. Sulfobutylether-β-cyclodextrin (SBE-β-CD or 
Captisol®) was generously supplied by Cydex Pharmaceuticals with an average degree of SBE 
substitution of 6.0-7.1 and was also used without further purification. Ultra-pure water (resistivity 
≈ 18.0 MW/cm-1) was generated from a NANOpure Ultrapure water system.  
NPC1 primary fibroblasts were obtained from Coriell Cell Repository (GM18453). Cells 
were cultured in Eagles minimum essential medium (Sigma) with 15% fetal bovine serum and 
5% Penicillin/Streptomycin. Cells were plated on 8-chamber Falcon culture slides (Fischer 
Scientific) for analysis. Filipin complex was purchased from Sigma-Aldrich. Prolong Gold was 
purchased from Life Technologies. 
 
3.4.2. Mixed Polyrotaxanes Study Methods 
Yawo Mondjinou synthesized mixed threading PRs. Cells were plated at 6,000 cells/well 
and allowed to adhere for 36 h before incubation with an equivalent dose of 25 µM β-CD 
regardless of whether it was free, in the control groups, or rotaxanated, in the PR groups. PRs 
with 0% and 30% SBE-β-CD were first solubilized in DMSO before dilution to 25 µM CD. Final 
DMSO concentration was ≤0.001% (v/v). After 6 h incubation, cells were washed 4 times with 
500 µL PBS and fixed with 4% paraformaldehyde for 45 minutes. Cells were then stained with 
150 µL of freshly prepared Filipin (50 µg/mL) for 45 minutes. Stained cells were washed 4 times 
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with 500 µL PBS before addition of Prolong Gold antifade reagent and mounting. Fluorescent 
imaging was done on a Nikon 90i microscope with a DAPI filter set. Results were plotted as an 
average Filipin stained area per cell as a percent of the untreated control group. Reported values 
are the average of 3 separate experiments ± SEM. 
 
3.4.3. Pendant Polymers Study Methods  
 NPC1 primary fibroblasts were obtained from Corriell Cell Repository (GM18453). Cells 
were cultured in Eagle’s minimum essential medium with 15% fetal bovine serum and 5% 
Penicllin/Streptomycin. Filipin was from Sigma-Aldrich. Hyaluronic acid (357 kDa) was 
obtained from Sigma before modification with adamantylamine by Aditya Kulkarni through EDC 
coupling.  
 PVA pendant polymer materials were synthesized as described previously.26 Stock 
solutions of HA and PVA pendant polymers were dissolved in PBS or 10% DMSO/PBS, 
respectively. Stock β-CD, HP-β-CD, and SBE-β-CD solutions were prepared in PBS and mixed 
such that the pendant: β-CD derivative ratio was 1:1. Each solution was diluted to 1 mL and 
allowed to incubate for 1 h at RT to allow β-CD inclusion. Finally, each pendant polymer: β-CD 
complex was diluted to 25 µM β-CD in media before addition to cell culture. Treatments and 
controls were all done in triplicate for the HA-Ad materials. 
 Cells were plated at 6,000 cells/well and allowed to adhere for 36 h before incubation 
with a 25 µM β-CD equivalent treatment. After the specified amount of time, cells were washed 4 
times with PBS and fixed with 4% paraformaldehyde for 45 minutes. Finally, the cells were 
stained with 50 µg/mL Filipin for 45 minutes. Fluorescent imaging was performed using a Nikon 
90i microscope with a DAPI filter set. Results were plotted as an average Filipin stained area per 
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4.1.1. Nanomaterials and Pharmaceuticals  
Since the inception of the field, there has been great excitement and effort to exploit the 
potential impacts of nanomaterials (NMs) in the fields of health and medicine.  An immense 
amount of research has been conducted into the use of NMs for a broad range of applications. 
There are aspirations for NM translation into drug delivery applications, medical imaging, disease 
diagnostics, and vaccine administration.  There exists in the fields of nanomaterials and 
nanomedicine the potential to revolutionize the way we diagnose and treat human disease.  
 A main driver of interest in NMs in medical fields is their ability to encapsulate and 
otherwise alter the way traditional small molecule therapeutics behave within the body. Typically, 
upon entrance into the biological milieu, hydrophilic small molecule drugs will be easily filtered 
from the blood and/or metabolized because of their small size. This limits the applicability of 
these molecules because of their shortened residence time and bioavailability. Hydrophobic 
drugs, on the other hand, have the tendency to associate with serum proteins and circulate for 
longer periods in blood. However, these drugs are easily captured and degraded by the 
mononuclear phagocyte system (MPS) before being excreted by the body through bile or urine.1  
This necessitates delivery of a correspondingly larger drug dose to exhibit the desired clinical 
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effect. Increasing the administered dose of a drug increases the risk of off-site toxicity and 
adverse side effects, as small molecule drugs often permeate the body non-specifically. 
Lipinski’s rule of five is generally used as a rule of thumb when considering the clinical 
potential of drug leads. By providing a simple set of guidelines to summarize the chemical 
characteristics most likely to generate a favorable pharmacokinetic profile and survive oral 
administration, drug candidates that adhere to these characteristics are more likely to achieve 
clinical translation and market acceptance.2, 3!Drug leads with unfavorable chemical signatures 
often go unpursued regardless of effective in vitro performance. Given that the odds of a drug 
candidate identified by high-throughput screening (HTS) ultimately leading to clinical use are 1 
in 100,00. The ability to alter the pharmacokinetic profile of a drug candidate would mean that a 
greater number of HTS hits could be pursued and potentially reach therapeutic use.4  On top of 
this, having this ability would give new life to previously shelved candidate compounds.  
NMs potential comes from their ability to alter the physiochemical properties of their 
cargo.  Drugs that are too hydrophobic could be made more soluble by encapsulation or 
attachment to nanoparticle (NP) platforms. This would make them much easier to administer and 
increase drug concentrations at the delivery site. Additionally, packaging of a drug into a NP 
formulation has the ability to prevent rapid clearance from the body, through renal or hepatic 
filtration, and to protect them from destruction through metabolism. This will greatly increase the 
bioavailability of the drug, improving circulation and mean residence times, and making them 
efficacious at lower doses. Treatment costs and off-target side effects could also be reduced.5 In 
addition to controlling side effects by lowering necessary dosages, NPs would likely not freely 
diffuse through the tissues of the body, limiting the build up of drug at off-target sites by 
improving tissue specificity.6  While not a definite solution to the problems of rapid clearance, 
off-site accumulation and toxic side effects (there is certainly concern about the toxicity of the 
NMs themselves), the potential to positively impact these areas is real. In fact, in 2006, more than 
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250 nanotechnology products were in the pharmaceutical pipeline, with some already being used 
in the clinic.5, 7   
Along with a diverse set of potential applications is an even more diverse set of materials 
from which NMs can be generated. These include (in a non-exhaustive list) carbon based 
materials like nanotubes (CNTs) and fullerenes, lipid based materials including micelles, 
liposomes and solid lipid nanoparticles (SLNPs), polymeric NMs like polymerosomes, 
filomicelles and dendrimers, and metal containing NMs including gold nanoparticles (AuNPs), 
quantum dots (QDs) and iron oxide containing NPs (Figure 4.1). Each of these materials would 
have a specific set of physicochemical properties depending on their composition, size, shape, 
and surface properties resulting in a unique physiochemical signature overall. The variety of NMs 
that could theoretically be generated is vast. There are a number of considerations that must be 
addressed when designing a NM platform for clinical translation- each potentially affected by 
these physiochemical differences.  
 
 
Figure 4.1: Nanomaterials Can Be Made From a Wide Range of Components. Selected Examples 
Include A) Dendrimers,8 B) Carbon Nanotubes,8 C) Polymer Micelles, D) Quantum Dots, E) 
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4.1.2. Preclinical Profiling of Nanomaterials 
A full pre-clinical profile of a potential NM is necessary to understand the materials 
biological interactions within the body, design the most appropriate material for the application, 
and give the best possible awareness of potential toxicities.  This begins with an understanding of 
the pharmacokinetic profile, including circulation time, biodistribution, and clearance. Secondly, 
it is important to study interactions of NMs with blood components, including the potentially 
deadly effects they can have on red blood cells (RBCs) and platelets. Finally, interactions of NMs 
with the immune system, including phagocytic uptake, complement activation, and antigenicity 
will contribute in large part to material performance and toxicity. Knowledge of the systems 
performance in each of these areas is advantageous to exclude potentially toxic materials from the 
pipeline and build the most appropriate NM system for the application to give it the best chance 
for clinical success (Figure 4.2).  
 
 
Figure 4.2: Pre-clinical Profiling of Nanomaterials Can Help Identify Appropriate Systems for the 
Intended Application and Avoid Unnecessary Toxicities.  !
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When designing systems for a biomedical application, it must be understood that all of 
the above factors will be variously affected by the physiochemical properties of the nano-scale 
material under investigation. The size, shape, surface chemistry, charge, and degradability of the 
NM will all play a role in how it circulates, deposits, clears, interacts with serum proteins, and 
mediates toxic side effects. Because the large composition space available to NM designers, these 
properties can vary greatly such that screening must be done in vitro and in vivo on a case-by-
case basis. Ideally, NM systems could be rationally designed based on the known performance 
trends of similar materials, however, this desire is not yet reality due to an absence of 
understanding of NM structure-property relationships. The existing data is often fragmentary 
because of the sporadic profiling of variable NM systems. Knowledge of overall trends 
explaining how NP physical parameters affect the various aspects of in vivo performance is 
therefore far from complete. What follows is a review of the known trends in how NP 
physicochemical relationships affect pharmacokinetics, biodistribution, toxicity, and protein 
adsorption. 
 
4.2. Overview of Protein Adsorption !
4.2.1. Introduction 
It has recently been understood that protein coronas form around NMs immediately upon 
exposure to serum and are relatively stable over time.9, 10 As materials circulate, quickly binding 
proteins will be quickly replaced by those that bind more tightly. Surrounding this first layer of 
strongly adsorbed proteins, called the “hard corona”, is a softer layer of proteins held in place by 
hydrophobic or ionic interactions. This layer is variable and constantly in flux (Figure 4.3). 
Different architectures have been shown to more effectively recruit surface proteins of specific 
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identities, including serum albumins, immunoglobulins, and complement proteins, or to recruit 
them in varying abundances.11-14 The relative quantities of adsorbed proteins do not often 




Figure 4.3: Upon Injection, Nanomaterials Will Rapidly Accumulate a Serum Protein Corona. 
The Identities of the Proteins in this Layer Will Principally Affect the In Vivo Performance of the 
System. !!!
It is no longer sufficient to consider only the surface chemistries of a NM system when 
drawing conclusions about in vivo system performance. Because interaction with the body 
(including immune cells, serum proteins, epithelial barriers, cell membranes and organs) is 
mediated not only by the NM surface, but also by the collection of adsorbed proteins, the true 
functional unit of the system is the NM:Protein Corona complex. The composition of these 
coronas has the potential to influence pharmacokinetics to either reduce or extend circulation 
time, if NMs recruit opsonins or dysopsonins, respectively. Clearance will be affected if NMs 
recruit proteins of the immune system. Toxicity can be brought about by recruitment of proteins 
that would promote complement activation or hemolysis. Finally, biodistribution can be dictated 
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Vascular Wall 







by adsorption of lipoproteins, transferrin or other proteins with cell receptors.14 NM protein 
corona is emerging as a major determinant of how nanomaterials behave in the body.15 
 
4.2.2. Trends in Protein Abundance 
Protein adsorption onto a NM surface has been shown to depend in large part on surface 
charge and hydrophobicity.16, 17 A study comparing liposomes with neutral lipids found that those 
materials with C16 chain lipids picked up more proteins those composed of their C14 
counterparts.18 In addition, protein adsorption onto charged or hydrophobic NM surfaces is rapid, 
while neutral or hydrophilic surfaces display slower opsonization.19 Comparison of poly (ethylene 
glycol) (PEG)-poly (lactic-co-glycolic acid) (PLGA), PEG-poly (lactic acid) (PLA), and PEG-
poly (caprolactone) (PCL) NPs (with similar PEG grafting densities) showed differences in the 
relative amounts of protein adsorption with increasing core hydrophobicity,20 showing that even 
effective PEG shielding cannot completely mitigate hydrophobic effects. 
Strongly charged NMs, either positive or negative, will pick up proteins more strongly 
than neutral particles of the same composition.1 One study found that positively charged particles 
picked up a lower abundance of proteins than negatively charged particles.21 Another study from 
the same group showed the opposite trend.16 Both studies used polystyrene particles, identical 
incubation conditions, and detection by 2D gel electrophoresis. In this case, varying particle size 
may be the explanation for differential adsorption with larger particles picking up a greater 
quantity of adsorbed proteins regardless of charge.  
A similar result was found when specifically comparing the surface adsorption of 
particles of varying sizes. Smaller particles were found to adsorb a smaller quantity of serum 
protein than were larger particles. In addition, a greater percentage of PEG coverage led to a 
steady decrease in adsorption.22 This suggests that particles can be expected to pick up proteins in 
proportion to their available surface area.  
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4.2.3. Trends In Protein Identity 
 Beyond affecting the total amount of protein bound, particle size can also affect the 
identities of the proteins binding in highest abundance. SiNPs of varying sizes (12 nm – 71 nm) 
recruit vastly different abundances of similar proteins as shown by Tezner et al. The smallest 
particles (12 nm) picked up apolipoprotein (Apo) C-III, ApoF, C4b, and Vitamin K-dependent 
protein S as well as others in more than 5 fold greater quantities relative to 71 nm particles. In 
contrast, 71 nm particles adsorbed prothrombin, Complement factor H-related protein 1, and 
gelosin in an enhanced abundance.12 These proteins represent a variety of processes including 
complement pathways, coagulation pathways, lipoprotein dysopsonins, and cellular components 
that could lead to differing biological affects for the various particles.  
Particle composition and architecture can also affect corona identities. Protein binding is 
different for SWCNT and DWCNT as evidenced by their differential activation of immune 
system complement pathways.23 Monopoli et al. found similar results when comparing 200 nm 
particles composed of either Si or polystyrene (PS).14 Incubating each particle with 55% serum 
revealed that the particles shared only 9 of their 15 most abundant proteins, with the differences 
including each particle’s two most abundant proteins. SiNPs picked up ApoA-I and histidine-rich 
glycoprotein in greatest abundance while PS NPs favored fibrinogen α- and β-chains.  
PEG grafting density can also play a role in altering the adsorbed protein composition. 
Walkey et al. used AuNPs with varying PEG grafting densities (from 0 to 1.12 PEG/nm2) to 
confirm that, as expected, increasing PEG density would correspondingly decrease the total 
protein adsorbed.24 Interestingly, they also found changes in the protein corona identity and 
composition. This included a substantial decrease in complement C3 from 30% to 5% w/w of 
total protein and an increase in kininogen from <2% to >13% when comparing naked AuNPs to 
the most PEGylated AuNP.24  PEG grafting may preferentially shield certain proteins, possibly 
dependent on binding efficiency to the NM core material. 
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4.3. Nanomaterial Pharmacokinetics  !
4.3.1. Circulation Time 
The circulation time of a NM refers to the time spent actually in contact with blood flow 
within the body. This includes the time from injection until removal of the material from the 
blood stream by phagocytic uptake, excretion from the body, or deposition in a particular organ.  
This is important for therapeutic applications of NMs because it is a large contributing factor to 
the bioavailability and toxicity of a therapeutic agent. One attractive aspect of the use of NPs over 
traditional drug candidates is the ability to extend a drug’s circulation time by preventing rapid 
removal from the blood by excretion or degradation. This keeps the drug in the body, increasing 
its bioavailability and, therefore, the potential for the drug to end up at the target site of action.5  
Conversely, an increased circulation time for a nanoparticulate formulation translates into a 
corresponding increase in the blood contact time. This extends the interaction with blood 
components, including blood cells and serum proteins, and increases the chances of triggering 
blood-related toxicities. Blood circulation is a main indicator of just how much the performance 
of an encapsulated drug is altered by NM encapsulation. 
A material’s circulation time is governed by a number of factors. A primary mechanism 
of NP removal from the blood are sieving of the material by excretory organs including the 
spleen, liver, and kidney.25 Depending on the size, surface chemistry, and other physical 
properties of the carrier, they may be removed from circulation through splenic, hepatic, or renal 
pathways as blood flows through these organs. Second, systems can be cleared from circulation 
by penetration into other organs of the body.  This can include, but is not limited to, lymph nodes, 
lungs, heart or brain tissue. Penetration into these organs will depend on what physiological 
barriers the materials are able or unable to penetrate. Finally, foreign substances are actively 
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pursued by phagocytic cells of the immune system and removed for degradation. Materials in 
blood can interact with serum proteins called opsonins, including immunoglobulins and 
complement proteins, which mark them for removal by professional phagocytes in the blood, 
such as monocytes, or as they pass through tissue, such as Kupffer cells in the liver or dendritic 
cells in the lymph nodes.5 A combination of these and other factors will dictate whole blood 
circulation time of a given NP system. 
 
4.3.2. Trends In Circulation Time 
 The first, and most extensively studied among these characteristics is the overall 
hydrodynamic size of the system in question. NMs will be subject to size based sieving dictated 
by the biological filtration capacity of a given organ. Very small particles will be quickly filtered 
through the kidney in a manner similar to hydrophilic small molecules. Using quantum dots, Choi 
et al. have shown that this cut-off is ~5.5 nm.26 NMs below this size will generally be lost through 
the urine, while materials with a greater diameter will be retained. Additionally, NMs must be 
small enough to avoid being filtered by the spleen and liver. Generally, the spleen contains 
filamentous filtration with a spacing of roughly 300-500 nm and the liver contains fenestrae and 
phagocyte-lined sieve plates with ~150-200 nm spacing.27, 28!In comparing liposomes of two 
sizes,  ~60 nm and ~220 nm, Moghimi, et al. found that the larger materials were cleared from 
blood circulation more quickly.29 The difference can be seen in materials when simply changing 
the chain lengths of surface grafted NM coatings. For instance, increasing the molecular weights 
of PEG used to coat quantum dots from 750 Da to 5 kDa increases the circulation time from ~1 
minute to hours.30 
 Additionally, particle shape and, in particular, aspect ratio (AR), has been shown to 
influence circulation time. Filamentous, rigid-rod micelles circulate in blood for greatly extended 
periods when compared to their spherical counterparts. Non-degradable versions of these 
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filomicelles were shown to circulate up to one week after injection (Figure 4.4).31 This greatly 
outlasted spherical micelles of the same composition, which persisted on the timescale of hours or 
days. 31, 32 Increased evidence for this was recently shown by Shuckla et al. using Tobacco 
Mosaic Virus (TMV) composed soft-matter rods with ARs varying from 3.5 to 16.5. In this study, 
the particles with the lowest AR reached maximum tissue accumulation and left circulation three 
times faster than the particles with the largest AR.33 It has been proposed that this is a result of 
slowed uptake kinetics by macrophages due to high AR. Blood flow alignment and shortened 
contact time also decrease the rate and efficiency of phagocytosis. Phagocytosis will be discussed 
more extensively in Section 4.4.2. 
 
 
Figure 4.4: Nanomaterial Shape Can Affect Circulation Time. A) Rod-Like Polymer Micelles 
Circulate For a Greatly Extended Period When Compared to Spherical Stealth Vesicles. B) 
Longer, Higher Aspect Ratio Micelles Circulate Longer Than Their Shorter Counterparts.31 !
 
 Particle surface charge and chemistry has also been shown to affect removal of NMs 
from the blood, even when keeping the composition, flexibility and size of the systems as 
constant as possible. Changing the surface charge on poly (amidoamine) (PAMAM) dendrimers 
from cationic to anionic significantly increased the circulation time of the materials in rats. Only 




injected dose was recovered for the anionic counterpart.34  Additionally, the rate of blood 
clearance of negatively charged liposomes was much quicker than PEGylated neutral 
liposomes.35 This result is probably reflecting a combination of surface charge neutralization and 
surface shielding mediated by PEG grafting. 
PEGylation has become a common strategy for increasing the circulation time of a given 
NM system. It is thought that this is brought about by slowing the adsorption rate of serum 
proteins onto the NM surface through shielding effects. In an illustrative study by Panagi et al., 
naked PLGA NPs were rapidly sequestered by liver macrophages, with a blood T1/2 of less than a 
minute, while their PEGylated counterparts exhibited half-lives on the order of 7 h.36 In 
comparing liposomes, PEGylation was shown to increase the area under the curve (AUC) by six-
fold relative to plain liposomes and 36-fold relative to free drug.37 PEG grafting has been so 
widely employed on a large variety of NM platforms that it has become a standard “stealthing” 
for extending circulation time.  
 
4.3.3. Biodistribution and Clearance 
Biodistribution is the family of organs into which a NM platform deposits after clearing 
the blood. These are the areas of the body which will be most exposed to both the components of 
the NM and the cargo it contains. Being aware of the distribution patterns for a particular material 
is essential for screening the toxicological properties a system will display in a given application. 
Ideally, a NM system will distribute preferentially into organs or areas of interest for a given 
therapeutic application. An unfavorable biodistribution will result in large percentages of the 
injected dose depositing in locations other than the desired active sites and, therefore, being less 
efficacious.  
Knowledge of the NM biodistribution allows for anticipation of potential organ-specific 
toxicities, as the areas of the body with the highest concentration of deposited material are the 
!!
98 
most likely to experience toxic side effects. While NM systems are theoretically capable of taking 
up residence in any number of organs with any pattern of distribution, there are organs more 
commonly implicated in NM uptake because of their roles in blood filtering (e.g., the MPS).25 
Finally, understanding the kinetics and routes NMs use while exiting the body allows for 
determination of total residence time within the body (e.g., as hepatic clearance often takes much 
longer than renal filtration), and will determine whether material retention is likely to cause toxic 
side effects. Materials that bio-accumulate in the body are much more likely to do organ damage 




Figure 4.5: Upon Injection Into the Blood Stream, Nanomaterials are Transported Through the 
Heart and Lungs Before Distribution Into the Other Organs.25 !
 
 
Upon venous injection into the blood stream, NMs will be carried with blood flow 
through the heart before continuing out into the rest of the body.25 Accumulation in heart tissue is 
usually highly undesirable as cardiac side effects can be quickly fatal. NMs are next carried 
through the lungs as blood becomes oxygenated. Passage through the lung requires navigation of 
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microcapillary beds that can be as narrow as 2 µm in diameter.38 From there, blood flow, and the 
NM systems they carry, branches out in varying percentages to supply the other tissues of the 
body (Figure 4.5). It is typically desirable for NMs to localize into specific target organs in order 
to localize treatment of the disorder. 25 In this case, materials and physical properties for a system 
must be selected to exploit a tissue’s innate physical properties such that a satisfactory 
concentration of therapeutic can be achieved.  
For conditions of the central nervous system (CNS), selective targeting will involve 
systems that are capable of transcytosing the strict physical constraints of the blood-brain-barrier 
(BBB) and the blood-cerebrospinal fluid (CSF)-barrier. These impediments are comprised of 
selective tight junctions that stringently regulate the passage of solutes from whole blood into the 
brain. Because these areas have evolved to only allow penetration of important and necessary 
small molecules, NM systems often struggle to achieve appreciable brain and CNS 
concentrations.39 
 Kidneys function by filtering unwanted components from the blood into the urine where 
they can be excreted.  Migration of NMs into the urine necessitates passage of a glycocalyx and a 
collagen mesh before passage through a 5-6 nm glomerular filtration membrane.40 For NM 
systems with physicochemical properties sufficient to allow glomerular passage, rapid renal 
filtration can be expected. Often, attempts are made to prevent this filtration by raising NM 
hydrodynamic diameters above this 5-6 nm size cutoff and prolong blood circulation.  
 While they may be the targets for a NM based therapy themselves, organs known to 
either actively or passively scrub the blood of toxins and foreign material more often become 
inadvertent hosts to increased dosages of NMs. The liver and spleen both function within the 
MPS to actively remove pathogens and foreign materials from the blood. They are both home to 
resident macrophages that actively seek opsonin-coated pathogens as the blood passes by these 
scavenging cells.25  Splenic sieving is characterized by gaps that can be large, but typically do not 
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exceed 500 nm.27 The organ is, therefore, set up to slow the passage of materials of large size and 
high AR, making it effective at removing older more rigid RBCs and pathogens. The resident 
macrophages of the liver, Kupffer cells, make up 80-90% of the total macrophage population.25 
These cells remove foreign materials from whole blood as it enters the liver sinusoids and 
attempts to degrade them before biliary excretion. Loss of NMs through this pathway occurs at a 
much slower pace (5-10% of the injected dose over 8-48 h) than through renal filtration, often 
giving rise to concerns for organ specific toxicities because of extended NM residence.25   
 
4.3.4. Trends in Biodistribution 
Similarly to how it affected circulation time, overall hydrodynamic size can also affect 
biodistribution. Often, studies testing the structure property relationships of NM size are focused 
on tumor uptake applications. In a study of variously sized liposomes containing 
phosphatidylcholine, cholesterol, and ganglioside GM1, Liu and coworkers found that liposomes 
in the 70-200 nm size regime circulated most extensively and deposited to a greater degree in 
tumor tissue. Liposomes of ~400 nm in diameter were shifted toward filtering by, and deposition 
in, the spleen (40-50% ID), while liposomes of less than <70 nm led to deposition of 70% ID in 
the liver.41 In a study with PPG-PEG polymer based NMs, it was found that particles greater than 
250 nm in diameter displayed biodistribution profiles that were characterized by splenic and 
hepatic deposition. Interestingly, decreasing the NP size below 150 nm led to a greatly increased 
deposition of the materials in the bone marrow.42  
Decreasing NM diameters to much smaller size regimes (e.g., <20 nm), has been shown 
to facilitate movement across biological barriers that are off limits to larger particles. This 
includes enhanced extravasation through blood vessel walls, penetration across the BBB, and 
movement through stomach epithelium.6 For instance, AuNPs in the range of 10-50 nm dispersed 
into the majority of body tissues in mice at 24 hours. Increasing the NM size to 100-200 nm 
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produced restricted deposition to the liver, lung, spleen, and kidneys.43, 44 These increasingly 
small sizes can lead to deposition in less common organs and tissues, as well as more rapid 
clearance through renal filtration.   
 The effects of surface charge and PEGylation are again evident when investigating 
biodistribution. Upon injection into the blood stream, positively charged particles can induce 
aggregation of negatively charged serum proteins. These NP:protein aggregates are increasingly 
likely to deposit in lung microcapillaries and induce either transient or long term sequestration.45 
Cationic PAMAM dendrimers have been found to accumulate preferentially in the kidney and 
liver. Accumulation of these materials was also associated with organ-related toxicities.46, 47 
Toxicities can be mitigated by neutralizing charge through PEGylation.48 
The deposition of hydrophobic naked poly (cyanoacrylate) NPs occurred preferentially in 
the liver and spleen. Upon PEGylation, the biodistribution of these materials was shown to shift 
toward a splenic deposition.49  Changing the core unit of cationic dendrimers from PAMAM to 
the more hydrophobic monomer polypropylene imine (PPI), led to an increased deposition in the 
liver.50 Adding to this, hydrophobic pristine CNTs accumulate primarily in the liver.51 This may 
be due to rapid recruitment of opsonins in serum onto exposed hydrophobic surfaces of the CNT 
leading to increased MPS recognition. It has been shown that this type of interaction can promote 










4.3.5. Degradability and Clearance 
While NMs with small hydrodynamic diameters are capable of being excreted through 
the urine after renal filtration, larger materials must either be degraded by the body to suitable 
sizes before renal filtration or excreted through bile and feces. Degradable materials are generally 
preferred over non-degradable scaffolds because of the latter’s potential to bio-accumulate and 
cause long-term toxicity. These materials are often sequestered by macrophages when they 
cannot be metabolized for excretion. Non-degradable PAMAM dendrimers have been shown to 
persist in the body with only 15% ID clearing after 48 hours.53 Treatment with pristine, non-
degradable SWCNTs led to stable accumulation in the lung, liver, and spleen 90 days after 
injection as shown by transmission electron microscopy (TEM) (Figure 4.6). Lack of clearance 
coincided with an observable increase in blood lactate dehydrogenase and alanine transaminase—
parameter changes that are indicative of liver specific toxicity over time.54 While it is true that 
degradable NMs are preferred, one must be aware of the possibility that these compounds can 
yield intermediate degradation products with unexpected toxic side-effects themselves.55  
 
 
Figure 4.6: Non-Degradable Nanomaterials Can Bioaccumulate for Greatly Extended Periods of 
Time. Histopathological Analysis shows SWCNT Accumulation in the Organs of Mice After 90 
Days. Arrows Indicate SWCNT Aggregation.54 !
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4.4. Immune System Interaction !
4.4.1. Overview 
 The innate and adaptive arms of the immune system are biological defense pathways 
responsible for protecting the body from foreign materials and pathogens (Figure 4.7). Broadly, 
these systems function to either rapidly clear antigens (innate immunity) or to generate proteins or 
cells that specifically recognize antigens over a much longer term (adaptive immunity), 
respectively. Within both pathways, immune responses can be initiated and carried by either 
cellular action or protein cascades. Often, these two components will work in tandem, linked and 
dependent on one another.56 
 The innate immune system is the portion of the immune system responsible for the quick 
and non-specific removal of pathogens. These systems are general, respond in similar manners to 
every potential threat, and confer no specific long-term immunity towards repeat pathogens. Cells 
of this immune pathway are largely professional phagocytes (e.g., macrophages, neutrophils and 
dendritic cells) that engulf and digest foreign material. These cells exist in blood circulation but 
also as organ resident macrophages, including Kupffer cells of the liver and B-cells of the spleen. 
Protein-mediated innate immunity begins as relevant proteins, known collectively as opsonins 
and including the general antibodies classes Immunoglobulins M and A (IgM and IgA), that 
initiate first encounter with potential pathogens in circulation. These proteins will both signal 
professional phagocytes that the pathogens they have marked need to be removed and activate 





Figure 4.7: The Nonspecific Components of Innate Immunity Act Quickly to Neutralize 
Pathogens by Removing Them From Circulation and Destroying Them. Adaptive Immunity 
Involves the Generation of Antigen Specific Antibodies for Long Term Resistance.57 !
 
 
 The adaptive immune system’s main role is to generate long-term immunity to repeat 
challenges from recurring pathogens. The main cellular components are dendritic cells (DCs), T-
Cells and B-cells whereas the main protein components are the antigen-specific antibodies, 
known as the Immunoglobulin G (IgG) class.58 In the presence of foreign materials, DCs can 
become activated to initiate a cascade that leads to the generation of antibodies tailored to singly 
recognize particular antigens present on the foreign surface. IgG will be a long-term presence in 
the body at low levels even after clearance of the pathogen. In this way, they are ready to quickly 
recognize and remove subsequent challenges by target materials.  
NMs, representing foreign intruders into the biological milieu, are prime candidates for 
immune system recognition and interaction. This interaction can drastically alter a system’s PK, 
toxicity, and potential for long term administration. Professional phagocytes will quickly clear a 
NM that is readily recognized and marked by opsonins, thereby greatly diminishing the 
circulation time for a given system. NMs that elicit activation of protein-mediated complement 
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pathways can bring about severe hypersensitivity reactions.58 Toxic side effects such as these will 
limit a NMs potential application. Finally, antigenic responses generated toward NM specific 
antigens will cause increasingly rapid clearance with each systemic administration and greatly 
limit the potential for repeated or long-term material administration. 
 
4.4.2. Trends In Phagocytosis 
Uptake by professional phagocytes is one of the better-studied aspects of NM in vivo 
performance. Because of this, there are some general trends that can be used when designing 
systems for specific purposes. Phagocytes are likely to take up hydrophobic particles more 
rapidly than are their hydrophilic counterparts. This results in preferential deposition in the liver 
of particles that are not coated with shielding layers.59-61  This is most often addressed by grafting 
of hydrophilic neutral polymers onto NP surfaces, most commonly PEG.62 In fact, modification 
with PEG-containing poloxamines reduced the phagocytic uptake of hydrophobic solid lipid 
nanoparticles (SLNs) to 8-15% of their initial levels.63 A likely explanation is that hydrophobic 
surfaces rapidly bind serum proteins that promote phagocytosis. PEGylation blocks this rapid 
adsorption and prolongs serum contact before phagocyte recognition.  
In addition to hydrophobic particles, macrophages are more likely to take up charged 
NMs. In vitro macrophage experiments show that uptake of highly positively charged layer-by-
layer poly-L-lysine, chitosan, heparin sulfate NPs was decreased by a factor of three upon PEG 
grafting.64 By making a family of cholic acid-PEG micelle NPs ranging from -26.9 mV to 
+37.0mV in surface charge, Xiao et al. showed that uptake of particles with surface charges of 
+18.5 mV, +29.5 mV and +37.0 mV were 1.9x, 3.5x and 5.9x higher than a neutral control. This 
suggests that the higher the positive surface charge, the more efficient the phagocytosis. 
Interestingly, negatively charged NPs in this study were taken up by macrophages at levels that 
were similar to the neutral control.65  
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Finally, size and shape can affect removal of NMs from circulation by phagocytes. Zahr 
et al. studied the in vitro macrophage uptake of PEG5k-cyanoacrylate-co-n-hexadecyl 
cyanoacrylate of increasing size (80 nm, 171 nm, 243 nm). After incubations of one and two 
hours, macrophage uptake increased with greater diameter.22 In addition, it has been argued that 
particle shape is more important than size in affecting phagocytosis.66 Rod-like NMs with higher 
ARs avoid macrophage uptake more effectively than their spherical counterparts. Discher et al. 
showed that rod-like flexible filomicelles align with fluid flow and effectively avoid uptake by 
immobilized macrophages (Figure 4.8D,F).31 In flow, they argue, the contact time between 
macrophage and NM is shortened.  Another study showed that shorter MWCNT were more 
effectively taken up by macrophages than longer MWCNT.67 Additionally, time-lapse video 
microscopy of the interactions between polystyrene particles of varying shapes and alveolar 
macrophages showed less effective internalization for particles of higher AR (Figure 4.8A-C,E).66 
The authors argue that phagocytosis is dependent upon local shape at the point of NP contact, 
with contact along the broad side of a rod-like NM leading to inefficient actin remodeling and 
failed phagocytosis. These experiments were done, however, in the absence of fluid flow. In any 
case, a combination of the above factors, decreased contact time with flow alignment, and 
inefficient local remodeling, means that high AR particles are likely to evade phagocytic uptake 




Figure 4.8: Nanomaterial Shape Plays a Role in Phagocytosis. A-C) Stills From Time-Lapse 
Images of Phagocytes Engulfing Variously Shaped NMs.66 B) Uptake is Frustrated By Contact 
Along the Long Axis.66 D) Immobilized Macrophages are Less Able to Take Up NMs in Flow 
Conditions Due to Decreased Contact Time.31 E) Point of Phagocyte Contact Dictates Speed of 
NM Uptake Based on Time-Lapse Imaging Analysis.66 F) Uptake of Rod-Like Filomicelles is 
Decreased as Rod Lengths Increase.31 
 
4.4.3. Overview of the Complement System 
The complement system is a protein mediated immune pathway that functions alongside 
cell-based systems (Figure 4.9). Complement activation can proceed through three different 
pathways, known as the classical, lectin, and alternative pathways. Activation of classical and 
lectin cascades is initiated by antibody binding, IgG/IgM or IgA to the NM surface, while the 
alternative pathway is initiated by spontaneous binding of complement component C3b to foreign 
surfaces. Both paths lead to either pathogen recognition by professional phagocytes or a 
corresponding protein cascade that culminates in a membrane attack complex that attempts to 
lyse foreign cells.56 Extensive activation of any complement pathway can lead to hypersensitivity 






Figure 4.9: The Complement System is a Protein-Mediated Immune Response That is Divided 
Into Three Distinct Pathways.68 !
4.4.4. Trends in Complement Activation   
 Size and shape have not yet been shown to be determining factors in NM-mediated 
complement activation beyond the fact that NM size and shape affect protein adsorption. Systems 
that tend toward increased interaction with serum proteins are, therefore, more likely to interact 
with complement proteins and trigger the corresponding pathways.  
It has been shown that charge and hydrophobicity can mediate complement activation can 
determine which pathways are selectively activated. Polycationic cyclodextrin NPs,69 poly-lysine 
polymers, and cationic liposomes all activate complement.70 In a study comparing variously 
charged liposomes, Chonn et al. discovered that positively charged liposomes selectively 
activated the alternative pathway, while negatively charged particles activated the classical 
pathway. Neutral liposomes did not appreciably activate complement.71 This difference must be 
explained by selective interaction with specific pathway initiating proteins based on charge. In 
contrast, positively charged, negatively charged, and neutral PEG-PLGA particles all activate the 
alternative pathway equally. It is clear that more than just surface charge can affect activation, 
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including surface topology and accessibility.72 In an analogous finding, SWCNT and DWCNT 
were both found to activate complement by classical pathways. Only DWCNTs, however, were 
found to activate the alternative pathway.23 
In changing the surface chemistry of polypropylene sulfide (PPS) NPs, Reddy et al. 
found evidence of how differing surface chemistry can change complement activation. PPS NPs 
coated with either hydroxyl- or methoxy- terminated Pluronic copolymers both activated the 
alternative complement pathway. The particles with hydroxyl- surface chemistry, however, 
activated the pathway four times as effectively (Figure 4.10B). The authors propose that free 
alcohols are better able to act as nucleophiles to effectively bind C3b, the first protein in the 
alternative cascade.73 Likewise, modification of naked CNTs with either ε-caprolactam or L-
alanine reduced activation of the classical pathway by 90% and 75%, respectively, potentially due 
to lack of available nucleophiles on the surface.74  
 PEGylation, again, is a well-studied strategy capable of reducing complement activation, 
likely due to decreased protein deposition overall.75, 76 Increasing the density of PEG grafting to 
modulate conformational changes from the “mushroom” to the “brush” regime reduces 
complement activation further (Figure 4.10A).77 Multiple studies have also shown that using 
higher molecular weight PEG as a corona, usually 20 kDa, more effectively prevents complement 
activation.78, 79 Bertholon et al. have also shown that polysaccharide coatings can have similar 
effects in reducing complement activation. Grafting of both dextran and chitosan onto poly 
(isobutylcyanoacrylate) NPs reduced complement activation when saccharide coatings were in 
the “brush” regime.80 Of interest is the fact that chitosan coatings were more effective than those 
comprised of dextran. It is argued that high grafting density left the polysaccharide alcohols 





Figure 4.10: Surface Chemistry Affects Nanomaterial Complement Activation. A) Increased 
PEGylation Decreases Activation of Every Complement Pathway.77  B) Methoxy-Coated NMs 
Activate the Alternative Pathway to a Lesser Degree than do Polyhydroxylated NMs.73   !
4.4.5. Nanomaterial Immunogenicity  
NM antigenicity can be a main factor in determining a system’s ability to be used 
extensively in the body for therapeutic applications in treatment of chronic conditions.56 An IgG 
response to a NM surface will translate into more rapid clearance and altered biodistribution with 
repeat administration, thus limiting the number of times the NM can be applied. Some surfaces 
are more likely than others to elicit memory immune responses; the goal of the therapeutic 
application should be taken into consideration. Vaccine technology, for instance, could exploit 
such surfaces for more powerful immune response. In some cases, NMs can function as adjuvants 
and help initiate immune response and reinforce lasting immunities.58 Beyond this, most NM 
systems would do well to avoid IgG generation. This section will cover immune recognition and 
antibody generation as it factors into a NM’s PK, BD, and wider potential applications. In this 
area, there have not been extensive and rational screens to determine broad trends in anti-NM 








4.4.6. Trends in Immunogenicity 
Increased hydrophobicity or charge does not seem to increase generation of NM specific 
antibodies, despite increasing interaction with serum proteins. Upon administration of dendrimers 
with cores of differing hydrophobicities, neither PAMAM- or PPI- based systems elicited specific 
antibody production.46, 81 In addition, in looking at accelerated blood clearance (ABC) as an 
indication of antibody recognition, Wang et al. saw no difference in the clearance rates of 
subsequent liposome doses after pretreatment with positive, negative, or neutral liposomes.82 
While one study detected antibody production upon challenge with hydrophobic fullerenes,83 
other studies have failed to generate the same response.84 Finally, no antibody response was 
found upon treatment of AuNPs.85 
Although a common strategy for extending NM circulation times, PEGylation can illicit 
IgG responses. It has been shown that anti-PEG IgG and IgM can be generated after 
immunization of mice with varying lengths of methoxy-PEG.86 PEGylation contributes to the 
ABC of PEGylated PLA NPs87, liposomes88, and micelles89. In a comparison of PEG with other 
hydrophilic masking polymers, Ishihara et al. found that PEGylation led to ABC of micelles, 
while polyvinylpyrrolidone grafting did not.90 Kaminskas et al. studied whether size of the 
PEGylated particle would affect ABC of subsequent NM doses. They found that pre-treatment of 
mice with PEGylated liposomes led to ABC of subsequent injections of either PEG-liposomes or 
PEG-micelles (Figure 4.11). The inverse was not true. Pre-treatment with PEG-micelle did not 
accelerate the clearance of a subsequent challenge of either liposomes or micelles.89 This suggests 





Figure 4.11: Size May Effect Nanomaterial Immunogenicity. A) Pretreatment of Rats with 
PEGylated Liposomes (Filled Circles) Leads to Accelerated Blood Clearance of a Second Dose 
of Liposome (Open Circles). B) Pretreatment of Rats with PEGylated Micelles (Filled Triangles) 
Does Not Affect the Circulation Time of a Subsequent Micelle Dose (Open Triangles).89 
 
4.5. Blood Compatibility 
A final set of information is generally necessary for an initial preclinical understanding of 
a NPs course. These aspects relate to toxicities affecting blood cells. Blood is the biological fluid 
responsible for carrying nutrients and oxygen throughout the body and transporting waste 
products for removal. It is also home to a vast number of soluble proteins and components of the 
immune system.25  Whole blood is ~45% cells by volume. This includes red blood cells, white 
blood cells, platelets and cells of the immune system. The remaining ~55% is a combination of 
dissolved electrolytes and soluble proteins known as plasma.25 Evidence of NP interaction with 
blood components, including red blood cells (RBCs) and platelets, can be early indications of 
toxic side effects that would prohibit clinical administration. Negative indications in either of 
these explorations would be cause to re-evaluate the physiochemical properties of a NM system. 
 
4.5.1. Red Blood Cells and Hemolysis Overview 
RBCs are a main component of whole blood and are responsible for the distribution of 
oxygen (O2) to, and the removal of carbon dioxide (CO2) from, tissues. Upon traveling to the 
lungs, RBCs pick up O2 as it diffuses through their cell membranes. The O2 is stored in the iron 
metalloprotein hemoglobin (Hgb) that RBCs contain in high concentrations. The cells then travel 
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through the body and oxygenating tissues before transporting CO2 waste back to the lungs. RBCs 
are large when compared to serum proteins, 6-8 µm in diameter, and make up the majority of 
whole blood’s cellular fraction.91 This means that NM systems injected into the blood stream are 
all but certain to come into contact with RBCs in circulation. As the circulation time of a NM is 
extended, this potential for RBC interaction is likewise increased.  
A main concern in the interaction of NMs with RBCs is the potential for membrane lysis, 
known as hemolysis. Because RBCs distribute oxygen from the lungs to the tissues of the body, 
hemolysis can result in starving the body of the oxygen it needs. Additionally, the release of 
hemoglobin into free circulation in the blood stream can lead to oxidative damage of the walls of 
blood vessels. Hgb can also damage the kidneys as it is filtered from circulation and contribute to 
renal failure over time.91 On top of the potential toxicities, hemolysis can lead to NM systems 
becoming decorated with Hgb and cellular fragments, rendering them more likely to be 
recognized by phagocytes and contributing to their removal from the body.  
 
4.5.2. Trends In Hemolysis 
 Particle size and geometry appear to play a role in NM blood compatibility. Yu et al. 
studied the effects of geometry on the hemolytic activity of silica nanoparticles (SiNPs) of 
different shapes and porosities.92 They tested a range of materials, including non-porous and 
mesoporous spherical particles and mesoporous nanorods of ARs 2, 4, and 8. The naked SiNPs all 
had negative surface charges. The non-porous spherical and shorter rod-like particles were less 
hemolytic than their longer counterparts at higher concentrations. The authors attributed this to 
increased surface charge and decreased exposed surface area. In addition, it was found that NPs 
exhibited AR dependent hemolysis with spherical particles lysing the greatest percentage RBCs 
(nearly 100% at 250 µg/mL) and the highest AR being the least lytic (20-25% lysis for AR=8) 
(Figure 4.12A).92 Spherical SiNPs of small sizes (~100 nm) have been shown to be less toxic than 
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larger counterparts of ~600 nm.93 The larger particles induced changes in RBC membranes and 
triggered hemolysis. It has been suggested that high surface curvature, like that found in smaller 
NPs and high AR nanorods, changes hemolysis by affecting binding energies and the ability of 
RBC membranes to wrap around NPs.93  
 
 
Figure 4.12: Shape and Charge Effect RBC Hemolysis. A) Bare, Negatively Charged, SiO2 
Particles Exhibit Decreased Hemolysis as With Increased Aspect Ratios. Black = Non-Porous 
Spherical Particles. Red = Porous and Spherical. Orange, Green, Blue = Increasing Aspect Ratios. 





Interestingly, in the Si nanorod study above, when SiNP surface charges were inverted by 
amine modification, all NPs were equally hemolytic (Figure 4.12B).92 This suggests a strong 
connection between hemolysis and charge. In agreement with these studies, cationic amine-
terminated PAMAM dendrimers show hemolysis even after a one-hour incubation with RBCs at 
concentrations as low as 10 µg/mL. Their carboxylic acid-terminated anionic counterparts were 
not hemolytic until concentrations above 1 mg/mL. Similar results have been reported for 
negatively charged and PEGylated chitosan/polyglutamic acid (CPGA) NPs of varying sizes from 
100 nm to 1000 nm. In all cases, CPGA all showed less than 1% hemolysis.94 In general, cationic 




holds for human RBCs.95 In these instances, charge neutralization by amine capping or 
PEGylation reduces RBC hemolysis.96 This is also true for polymer NPs that must be stabilized 
by hydrophobic surfactants. By replacing lauric acid stabilization with PEG modification, NP 
mediated hemolysis was reduced by ~60%.97 The mechanism by which PEG dampens both 
charge and hydrophobic surfactant induced hemolysis can be explained by corona shielding 
effects that prevent or slow down NM/RBC interactions. 
 
4.5.3. Platelets and Thrombogenesis Overview 
 Platelets are bone marrow derived cells whose main function is to repair breaks in 
vascular lining. These cells are 2-3 µm in diameter and do not contain a nucleus. When breaks in 
blood vessel walls occur, platelets are activated by the exposed extracellular matrix.98 This leads 
to shape change through actin reorganization, release of soluble factors intended to recruit nearby 
platelets, and adherence and aggregation in the exposed area. In this way, platelet activation and 
aggregation serves to paper over breaks in vascular lining, thereby preventing blood loss and 
maintaining homeostasis (Figure 4.13). Unfortunately, unnecessary activation of platelets can 
lead to occlusion of blood vessels through the formation of non-essential blood clots. This 













Interaction of NMs with platelets has the potential to disrupt the normal function of the 
clotting system. This could come about either by initiating or preventing platelet activation. 
Activation of platelets by NM systems would increase the potential for formation of intravascular 
blood clots, while interference with normal coagulation cascades would increase the patient’s 
chances of hemophilic complications5. Indications that either of these side effects are possible 
would be cause to re-evaluate the physiochemical properties of a NM system such that they will 
no longer interfere with the body’s natural thrombogenic mechanisms. 
 
4.5.4. Trends in Platelet Activation and Thrombogenesis 
Radomski et al. investigated the effects of geometry and architecture on platelet 
aggregation and rat vascular thrombosis by comparing spherical C60 fullerenes (C60CS), 
SWCNT, multi-walled carbon nanotubes (MWCNT), and a mixed population of industrial carbon 
nanoparticles (MCN) at equivalent concentrations.100 They found that MCN incubation induced 
aggregation most effectively and initiated rapid clot formation. SWCNTs were less effective than 
MCN, but more effective than MWCNTs. Upon incubation, C60CS particles did not induce any 
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platelet aggregation even at increasing concentrations. Specific conclusions about differences 
between the materials could not be drawn because of the differential surface chemistries and size 
distributions of the materials. CNT aggregates may simply be more effective at mediating cell-
cell contacts and interactions than C60CS.101 Similar results were found by Bihari et al. for 
SWCNTs in an in vivo mouse thrombogenesis model.102 Additionally, both MWCNTs and 
spherical SiNPs were found to sensitize platelets toward further agonism. The materials activate 
platelets through similar pathways, showing that materials with differing sizes, shapes, and 
surface characteristics can act similarly.103  
 In a study of the effects of surface charge and size on the platelet activation of hollow 
spherical CPGA NPs, Dash et al. synthesized negative, neutral, and PEGylated NPs of 100 nm, 
300 nm, 500 nm, and 1000 nm diameters. The authors found that particles of 500 nm and 1000 
nm showed negligible platelet activation, regardless of surface chemistry. Reducing NP size to 
100 nm and 300 nm significantly increased platelet activation mediated by negatively charged 
particles, but a similar effect was not seen in the neutral and PEGylated groups (Figure 4.14).94 









Figure 4.14: Size and Surface Charge Affect Platelet Activation Based On the Time to Clot 
Formation. A) Smaller Particles are More Thrombogenic Than Larger Particles When Negatively 
Charged. B) Negatively and Neutrally Charged Particles Can Be More Thrombogenic Than 
PEGylated Particles of the Same Size.94 
 
 
In a further study of the effect of surface charge, Bihari et al. tested the thrombogenic 
potential of amine- and carboxyl-modified polystyrene particles (SPs). They found that positive 
SPs increased the rate of vessel occlusion after thrombus induction, while negative (SPs) induced 
a rate decrease. This is in agreement with studies showing that polycationic polymers aggregate 
platelets more effectively than natural agonist adenosine diphosphate.104 However, another model 
system in the same paper showed no effect on clot formation for either particle. Because differing 
induction methods were used to trigger thrombosis in different ways, the authors suggest that NPs 
have the ability to modulate certain pathways over others.102  In contrast to the previous results, 
work showing that carboxyl-QDs activate coagulation cascades more effectively than amine-QDs 
in in vitro studies suggests different trends at different size regimes.105  
As shown above for hollow CPGA NPs, charge neutralization by PEGylation can reduce 
platelet activation in some cases. In contrast, for surfactant coated PLGA NPs, PEGylation did 
little to reduce the affects the NMs had on blood coagulation times and blood clot strengths when 
dosed above 1% w/v.97 Coating polyvinyl chloride resin particles in a PEG corona, however, 
completely mitigated the thrombogenic potential of the hydrophobic naked particles.106 
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Differences in the effects of charge, hydrophobicity, and PEGylation points to a need for 
increased systematic scanning of physiochemical properties and a likely dependence on multiple 
coalescing properties.   
 
4.6. Polyrotaxanes For In Vivo Applications 
Polyrotaxanes (PRs) are nanomaterials comprised of macrocyclic hosts non-covalently 
threaded onto polymer cores. Once threaded, the polymer termini are modified with bulky 
blocking groups to prevent macrocycle dethreading.107 The guests can slide laterally along the 
polymers or rotate around it, but they are locked onto their cores until cleavage of PR endcaps 
allows for macrocycle loss from the polymer termini. As discussed in chapter 1, PRs are of 
interest because they can be made from a wide range of polymers and macrocycles, including 
those that are biocompatible, biodegradable or generally recognized as safe (GRAS) by the 
FDA.108-110 In general, PRs have potential applications in drug delivery, gene delivery, diagnostic 
imaging, vaccine development and many others. The Thompson Lab has recently reported PR 
materials synthesized from GRAS Pluronic co-polymers and β-cyclodextrin or hydroxypropyl-β-
cyclodextrin (HP-β-CD) with applications in gene delivery and as therapeutic candidates for a 
rare disease Niemann-Pick Disease Type C (NPC).110-113  
 Little is known, however, about the performance of PRs in vivo. Kumeno et al. has shown 
that PRs composed of HP-α-CD threaded onto PEG with L-phenylalanine capping agents 
inhibited the increase of intracellular calcium in platelets. This means that PRs of this 
composition and structural properties may, while not inducing platelet aggregation, interfere with 
normal clotting of blood.114 Secondly, a recent paper by Tamura and Yui showed that PRs 
composed of HP-β-CD and Pluronic P123 did not cause any appreciable hemolysis in rat 
erythrocytes.115 Finally, a number of studies have used PR-drug conjugates to attempt to slow 
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tumor growth.116, 117 Kang et al. showed that PR-DOX-Micelles increased the maximum tolerated 
dose of DOX by 2-fold.118  
  Given the limited sample size and restricted set of materials used, information needs to 
be gathered about the PK, BD, and toxicity of PR materials before they can be useful scaffolds 
for clinical translation. Additionally, because PRs can be synthesized with a variety of polymer 
precursors and capping reagents, and threaded with a variety of macrocycles, there is the potential 
for generation of families of PRs with varying average molecular weights, surface chemistries, 
macrocycle copy numbers and threading efficiencies. These PRs would then have a range of 
hydrophobicities, surface charges, rigidities, shapes, and surface areas. Even within a single PR 
synthetic product, a distribution of materials will exist, given the inherent MW distribution of the 
polymer precursors and the distribution in PR macrocycle copy number. This, in itself, will lead 
to a range PR sizes and masses. Knowing if structure-property relationships exist in the in vivo 
performances and toxicities of PR materials with differing physiochemical properties will aid in 
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5.1.1. Nanoparticle Systems and Preclinical Profiling 
Nanoparticles (NPs) continue to hold great potential to impact a wide range of 
biomedical disciplines including drug delivery, diagnostic imaging and vaccines. Vastly different 
resources and preparation techniques can be used to produce NPs containing varying materials, 
including lipids,1 polymers,2 and metal NPs,3 with a variety of sizes, surface chemistries, and 
shapes.4 As the field has developed, a large range of materials have been tested in vivo to draw 
conclusions about what determines a NPs course through in the body. It has become evident that 
changes in physical and chemical properties affect the residence times, toxicities, and fates of 
nanomaterials upon in vivo injection.4-7 As such, it is beneficial to determine structure-property 
relationships between or within classes of NPs to determine how changes in overall properties 
will affect in vivo performance. 
Clinical translation requires as much understanding as possible about the NP system’s 
course and its effects on the body. Journey through the biological milieu means contact with a 
vast number of bodily components all with the potential to determine NP circulation times and 
drive NP-mediated side effects. Upon injection, NPs enter the blood stream, where they may 
interact with serum proteins, blood cells, and the immune system.8, 9 There is potential for a wide 
range of toxic effects including red blood cell lysis, thrombogenesis, or complement activation, 
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all of which can increase the chances of anemia, renal failure, stroke, and inflammatory 
responses.9-11 Ideally, NPs for drug delivery applications would be non-toxic to biological 
components in whole blood circulation. For magnetic resonance imaging, NPs should be long 
circulating, non-toxic, and avoid immune system activation. 
Additionally, information about clearance and biodistribution can guide both the 
targeting of specific organs for therapy or imaging and the monitoring of organ specific toxicity.  
NPs with different physical characteristics are known to deposit and clear differently from the 
body.12, 13 Once there, they have the potential to induce toxic effects if they are not cleared 
effectively. Carbon nanotubes have been shown to deposit in the liver for extended periods, 
increasing the potential for long term toxicity.14 Quantum dot challenges (e.g., Cds, CdSe) have 
raised concerns about nephrotoxicity because of their heavy metal cores and renal filtration.15, 16 
This is also a concern for Gd3+ carrying MRI materials where kidney deposition of Gd3+ can 
cause renal failure, particularly in elderly patients or others at risk for nephrogenic systemic 
fibrosis.17 Knowing the types of physical and chemical characteristics that lead to predictable 
biodistribution patterns will inform the use and safety screening of NP vehicles under 
consideration for drug delivery or imaging applications.   
Finally, the NP corona is emerging as a major determinant of how nanomaterials behave 
in the body.18 It has recently been understood that hard protein coronas form around nanoparticles 
immediately upon exposure to serum and are relatively stable over time.19, 20 The composition of 
these coronas has the potential to influence pharmacokinetics; if NPs recruit opsonins or 
dysopsonins, clearance; if NPs recruit proteins of the immune system, and biodistribution; if NPs 
recruit lipoproteins or other proteins with cell receptors.21 Different architectures have been 
shown to differentially recruit surface proteins, including serum albumins, immunoglobulins, and 
complement proteins, or to recruit them in different abundances.10, 21-23 Knowledge of a NPs hard 
protein corona will go a long way toward explaining or predicting in vivo performance.  
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5.1.2. Polyrotaxanes For In Vivo Use 
Polyrotaxanes (PRs) are nanomaterials comprised of macrocyclic hosts non-covalently 
threaded onto polymer cores. Once threaded, the polymer termini are modified with bulky 
blocking groups to prevent macrocycle dethreading.24 The guests can slide laterally along the 
polymers or rotate around it, but they are locked onto their cores until cleavage of the PR endcaps 
from the polymer termini. PRs are of interest because they can be made from biocompatible, 
biodegradable, or generally recognized as safe (GRAS) starting materials.25-27 The Thompson Lab 
has recently reported PR materials synthesized from GRAS Pluronic co-polymers and β-
cyclodextrin or 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and applied these materials to 
problems in gene delivery and as therapeutic candidates for treatment of the rare disease, 
Niemann-Pick Disease Type C (NPC).27-30  
 Little is known, however, about the performance of PRs in vivo.  Information needs to be 
gathered about the pharmacokinetics (PK), biodistribution (BD), and toxicity of PR materials 
before they can be useful scaffolds for clinical translation. Additionally, because PRs can be 
synthesized with a variety of polymer precursors, there is the potential for families of PRs with 





Figure 5.1: Pluronic Triblock Chemical Structure and Representative Images the Polymer Family 
Utilized in this Study. Orange Represents PEG blocks and Black Represents PPG blocks. !
 
 We sought to define structure-property relationships by synthesizing a family of 
gadolinium (Gd3+) carrying PR materials from a set of poly(ethylene)glycol (PEG)-
poly(propylene)glycol (PPG)-PEG Pluronic co-polymers of varying molecular weights and 
hydrophilic/lipophilic ratios (Figure 5.1). These materials have hydrophilic PEG flanks and 
hydrophobic PPG cores.25 Based on the findings from these studies, conclusions can be drawn 
about the effects of total molecular weight, threading efficiency, and polymer hydrophilicity on 
PK, BD, toxicity, immune response, and protein hard corona composition. Development of 
structure-property relationships related to the performances of PR materials will help with 
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5.2. Polyrotaxane Family Pharmacokinetics !
5.2.1. Polyrotaxane Family Characterization  
 To maximize the amount of potential property variation amongst the PR family to be 
screened, five Pluronic co-polymer cores were chosen having largely disparate average molecular 
weights (12.5 kDa – 1.9 kDa) and varying hydrophilic-lipophilic balances (HLBs) as determined 
by the relative PEG-PPG block lengths (HLB 2-29) (Table 5.1). After HP-β-CD threading and 
Gd3+:DOTA grafting, NMR analysis was used to determine the average molecular weight and 
threading efficiency of the PR family members. Threading efficiency is determined by 
comparison to the theoretical number of HP-β-CDs that could fit onto the co-polymer’s PPG core 
if it were fully threaded. Overall average molecular weights of the PR family members ranged 
from 53 kDa to 19 kDa and HP-β-CD threading efficiency ranged from 67% to 20% coverage of 
the PPG segment. PR characterization is summarized in Table 5.1.    
 
Table 5.1: HP-β-CD Polyrotaxane Family Characteristics 
 !
 
 Representative PR structures are shown in Figure 5.2. The most highly threaded PR, L81, 
is also the highest molecular weight, despite having a low molecular weight core. The central 
triblock co-polymer carries 14 copies of HP-β-CD. Threading of this polymer may proceed to a 
Total MW # CDs % Threading Gd Wt % MW PEG PPG 
F127 44 kDa 14 44% 3.4 12.5 kDa 200 65 
F68 26 kDa 3 20% 4.9 8.3 kDa 151 29 
L35 19 kDa 4 50% 1.0 1.9 kDa 21 16 
L64 29 kDa 6 40% 1.4 2.9 kDa 26 30 
L81 53 kDa 14 67% 0.4 2.8 kDa 6 43 
Polyrotaxane Characteristics Polymer Core Characteristics  
!!
136 
greater extent because of high hydrophobicity brought on by short PEG flanks. The overall most 
hydrophilic polymer, F68, yielded the lowest threading efficiency at 20%. The long PEG units of 
F68 flanking a short PPG core may slow the threading rate relative to the other polymers of lower 
HLB. The highest MW polymer core, F127, gave rise to the second highest molecular weight PR, 
although with significantly less HP-β-CD threading efficiency than L81 at 44%. This may again 
be due to the interference of lengthy PEG flanks.  Finally, co-polymer L35 gave rise to the PR 
that was the lowest in MW while also being the second most highly threaded. This set of 
materials was then studied to gain insight into the roles of MW and threading efficiency on their 
biological behavior.  
 
 




5.2.2. Synthesis and Characterization of IR800CW-PR Family  
 In addition to Gd3+-carrying PRs, a near-infrared fluorescent (NIR) PR was synthesized 
to study constructs with different surface chemistry in a parallel manner. The NHS-ester form of 
the NIR dye IR800CW was conjugated to the PR scaffolds after amination using a carbonyl 
diimidazole/2,2’-(ethylenedioxy)bis(ethylamine) sequence in DMSO. Each reaction was allowed 
to run overnight. PR intermediates were purified by dialysis against water for two days with four 
water changes, followed by lyophilization. IR800CW coupling was completed by dissolving the 
amine-modified PRs in DMF before addition of 0.5 eq of IR800CW-NHS with stirring overnight. 
Product purification by dialysis against water was performed before lyophilization.  Every step 
involving dye was carried out in the absence of light. The final products were deep blue fibrous 
powders.  
 IR800CW was chosen for use in these experiments because of its exceptional extinction 
coefficient for near IR absorption and efficient emission properties. These factors would allow for 
sensitive imaging with diminished interference from autofluorescence. The dye was conjugated to 
each PR base in good yield (Table 5.2).  Targeting 0.5 equivalents of dye per PR was done in 
order to prevent the stochastic addition of multiple fluorophores to the PR structure and potential 
quenching of emission due to close spacing of IR800CW substituents. Fluorescence 
measurements show that four members of the family carried between 0.83 and 1.21 copies of the 








5.2.3. Gadolinium-Carrying Polyrotaxane Pharmacokinetics and Biodistribution  
  Given the range of physical properties exhibited by these PR derivatives, the next aim 
was to elucidate how differences in architectures may confer differences in the circulation time, 
biodistribution, and clearance of the constructs.  Pharmacokinetic profiles for the members of the 
PR family are shown in Figure 5.3. All members of the family show a biphasic PK curve with  
rapid accumulation and slower clearance phases. Circulation time appears to be most affected by 
the PRs threading extent. L81, with the highest threading and the highest molecular weight, is the 
longest circulating PR with an average of ~52% of the injected dose remaining in the blood at 30 
minutes, ~21% remaining at 6 h and ~4.6% remaining at 24 h after injection. In this case, 2 of the 
3 mice in the group had detectable Gd3+ in their blood at 24 h. The second longest circulating 
construct is L35 with ~23% of the injected dose remaining at 30 min, ~9% at 6 h and ~1% at 24 
h. Again, 2 mice in the group had detectable levels of Gd3+ in their blood on average at 24 h post-
injection. This is an interesting and insightful case because L35 also exhibits the second highest 
threading and, the lowest overall molecular weight, suggesting that the flexible rod-like 
characteristics may be more important than PR molecular weight. The third longest circulating 
PR is F127, with only ~4% of the injected dose remaining at 30 min and ~1% at 6 h. Only one of 









threading efficiencies of 20% and 40%, were both cleared rapidly from blood circulation by 3 h 
and 30 min, respectively.  
 
 
Figure 5.3: Blood Residence Times of HP-β-CD Polyrotaxane Family Members. n = 3. !!!
It appears, then, that HP-β-CD coverage ratio is more important than overall molecular weight (or 
polymer molecular weight) in determining circulation time. In fact, the second longest circulating 
construct is the least massive overall. This may be because an increased HP-β-CD coverage of the 
co-polymer cores imparts an increased rigidity to the constructs. Similar results have been 
reported for flexible-rod micelles that have been shown to reside in the blood stream for extended 
periods by aligning with blood-flow and avoiding macrophage uptake.5 The increased blood 
residence is likely not coming from PEG shielding effects since the longest circulating agent, 
L81, has the shortest PEG flanks (average of 3 units on each side), while the PRs with the longest 

























 As observed in the pharmacokinetics experiments, we show that biodistribution at 24 h is 
again affected by PR threading efficiency.  There is little to no detectable residence of any PR in 
the brain or heart (Figure 5.4). Each PR takes up residence to some extent in both the kidney and 
the spleen, but without any clearly discernable structure-property trends. PRs of lesser threading 
are shown to take up residence in the lung preferentially to other organs, including the liver. F68 
and L64 showed lung deposition of ~36% ID/organ and ~46% ID/organ, respectively, while the 
more highly threaded PRs, L81 and L35, deposited only ~10% ID/organ and ~0.5% ID/organ in 
the lung, respectively.  Conversely, the more highly threaded PRs showed deposition in the liver 
preferentially to all other organs. PRs L81 and L35 showed liver deposition of ~67% ID/organ 
and ~57% ID/organ, respectively, while F68 and L64 showed deposition of 23% ID/organ and 
19% ID/organ.   
 
 
































 Strong lung deposition of less efficiently threaded PRs may be due to PR aggregation in 
via their exposed PPG blocks. These aggregates, driven by the amount of available hydrophobic 
core, could then be too large to effectively pass through microcapillaries of the lungs. This may 
also explain the rapid loss of F68 and L64 from the bloodstream, as the lungs would quickly sieve 
the dose after injection and passage through the heart. More highly threaded PRs, then, are able to 
effectively shield their hydrophobic central blocks and pass through the lungs for final deposition 
into the liver for hepatobiliary excretion. This differential deposition may be useful in designing 
PR systems to specifically target lung or liver tissue.  
 
5.2.4. Biodistribution and Residence Time of Near-Infrared Labeled Polyrotaxanes  
 Images taken 30 minutes after injection of the NIR-PRs reveal intense fluorescence 
emission from the murine bladder, indicating rapid clearance through the urine (Figure 5.5). This 
may be from the renal filtration of either low molecular weight PR species (i.e., members of the 
PR population having a low degree of HP-β-CD threading), contaminating or dethreaded HP-β-
CD-IR800CW, or very rigid PRs that are able to move through the glomerulus along their 
longitudinal dimension. Subsequent images reveal buildup of the remaining PR species largely in 
the liver and kidneys. The liver is likely the predominant site of accumulation that is most visible 
in the time-course images because it scavenges the PR extensively and is superficial to the skin. 
For all PRs, the fluorescence persists in the mice until 120 h, suggesting that the PRs achieve 





Figure 5.5: Live Animal Images 30 minutes (L64-F127) and 1 h (L35) after NIR-Polyrotaxane 
Administration Via Tail Vein Injection !!
 
Figure 5.6: Tissue Residence of NIR-Polyrotaxanes 24 h-120 h After Administration.   !
 
 Differences existed in the rate at which PR family members left the tissues. To determine 
these rates, radiant efficiency (RE) of the mouse was tracked over time as a fraction of maximum 
RE at 30 min (Figure 5.7). PRs F68 and L35 cleared the body similarly, with 10% RE remaining 
at 24 h. Both L81 and F127 were excreted slightly more slowly, with ~25% of the original RE 
IR800CW-L35 PR IR800CW-F127 PR 
IR800CW-L64 PR IR800CW-L81 PR IR800CW-F68 PR 
24 h 48 h 
120 h 
F127 - IR800CW L35 - IR800CW 
24 h 48 h 
120 h 
X 108 X 108 
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remaining at 24 h. In contrast to these, L64 was found to clear very slowly.  A full 80% of the 
maximum RE was retained 24 h after injection. The cause of this retention is unknown and 
further study would be necessary to elucidate causal links.  
 
 
Figure 5.7: Rate of NIR-Polyrotaxane Whole Body Fluorescence Loss. n = 3. !!!
 Ex vivo fluorescence analysis shows PR accumulation in liver, kidney, spleen, lungs, and 
intestines (Figure 5.8). Individual mice were sacrificed sequentially, giving single mouse 
timepoints for each PR at 24 h, 48 h, and 120 h. The majority of the dose in each case was 
deposited into the liver, with lower fluorescence found in all other organs except for F68 that 
displayed higher kidney fluorescence than the liver at 48 h. The set of organs taking up 
IR800CW-PR is consistent with the findings from the Gd3+:DOTA-PR study, however, the strong 
lung deposition of PRs L64 and F68 is not seen in this study. This is likely due to of differing 
surface chemistries brought on by PR modifications.  
 While both sets of post-modifications would be negatively charged, a main difference is 
the fact that IR800CW-PRs were designed to carry only a single modification where as the 





































PR with both a larger overall size and a higher overall charge, both of which could lead to 
increase protein deposition. This may lead to increased transient deposition of large PR:protein 
aggregates in the lung. Additionally, this high charge may lead to a more rapid HP-B-CD 
dethreading, exposing more PR hydrophobic core and driving aggregation faster than in the 
IR800CW-PR family. Further investigation will be necessary to define the exact mechanisms by 
which this difference is being mediated. 
 
 
Figure 5.8: Ex Vivo Biodistribution of NIR-Polyrotaxanes at 48 h.  !!
5.2.5.  Metabolism and Clearance of Gadolinium-Carrying Polyrotaxanes 
 Excretion of the PR systems through the feces was studied by ICPMS digestion and 
analysis of mouse feces at discrete intervals after PR injection (Figure 5.9). At 0-1 h and 1-6 h, 
the feces from 3 mice in each of the PR groups was collected from the cages, pooled, and 
homogenized. In all cases except for L64, the amount of Gd3+ excreted increased from 0-1 h to 1-
3 - Liver 
1 - Heart 
2 - Lung 
4 - Spleen 
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6 h, due to the time required for liver uptake and processing of the PRs prior to excretion. By 24 
h, the more highly threaded PRs were excreted in greater amounts than those with lower degrees 
of threading. This is consistent with the findings that the more highly threaded PRs avoid lung 
deposition and renal filtration, thus providing greater opportunity for liver clearance after 24 h. 
 
 
Figure 5.9: Clearance of HP-β-CD Polyrotaxane Family Members in the Feces as Measured by 
ICPMS. n = 3 for 24 h. !!!
 NIR evidence of early PR clearance from the body led to questions about what form of 
PR was able to rapidly clear the body. Intact PR scaffolds should be large enough in 
hydrodynamic size to avoid glomerular filtration. The possibility existed that the PRs were being 
metabolized, degraded, or otherwise dethreading in circulation to release free CD monomers 
capable of being filtered through the kidneys. In contrast, it is conceivable that PRs with either 
very low threading or very high threading efficiencies are eliminated via the urine either by not 
achieving sufficient size, or by traversing the glomerular membrane along their longitudinal axis, 
respectively.  
 To study this, urine samples were collected from mice 1 h after tail vein injection of 




















dethreaded modified Gd3+:DOTA-β-CDs released from metabolized PRs would be able to 
permeate the membrane while intact Gd3+:DOTA-PRs would not. The study compared PR F127 
and ProHance, which would be expected to bypass the dialysis membrane easily. At 1 h, >97% of 
the Gd3+ in the ProHance sample was dialyzable (Figure 5.10), whereas only ~27% of the Gd3+ in 
the PR sample was dialyzable under the same conditions. Therefore, the majority of the PR dose 




Figure 5.10: Gd Content of F127 PR and ProHance in Urine After 1 h Before (Blue) and After 
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5.3. Gd3+:DOTA Polyrotaxane Toxicity and Blood Compatibility  !
5.3.1. General Toxicity and Serum Chemistry 
 Nanoparticles for biomedical applications should be designed to minimize side effects 
upon parenteral administration. A study seeking to assess the systemic toxicological profile of the 
PR family members was undertaken by measuring the body weights of PR treated groups over a 
3-week treatment course (Figure 5.11). All groups of 9-week old mice received an initial PR 
injection at Day 0. Additionally, groups treated with L35, L64, and L81 were challenged a second 
time with an injection at Day 14. With termination of the experiment at Day 21, it was observed 
that all groups were steadily gaining weight at rates that were similar to 15% DMSO:PBS-treated 
controls. All groups were in within the weight limits for 12-week-old mice provided by Harlan 
Laboratories. Therefore, PR treatment did not exhibit acutely toxic effects on mouse 
development.  
 
Figure 5.11: Mouse Body Weight Growth of PR Treatment Groups. n = 3. !
!!
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 Given the biodistribution of PR materials, blood chemistry tests were undertaken as an 
indicator of liver, kidney, and lung function. Equal volumes of mouse serum collected at 21 d 
after PR injection were pooled for each group to obtain mean values (Figure 5.12). Blood 
creatinine and blood urea nitrogen (BUN) were taken as markers of kidney function and were 
within normal limits for Balb/C mice, showing no evident kidney toxicity. This is an important 
consideration given the potential use of Gd3+:DOTA-PRs as MRI contrast agents, since renal 
damage is a main concern for currently approved Gd3+ contrast agents.17 
 
 
Figure 5.12: Kidney and Liver Function Tests !
 
 Additionally, alkaline phosphatase (ALKP) and alanine transaminase (ALT) were studied 
as markers of liver damage (Figure 5.12). ALT was within normal limits indicating no evident 
liver damage. ALKP was low or slightly below normal limits in most cases, including the PBS 
control. While the reason for the low ALKP values is unknown, the presence of low ALKP values 
in the control, and the fact that liver damage would be expected to elevate ALKP values, suggests 
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a marker of potential lung toxicity caused by PR deposition. In all cases, PR treated groups had 
ECO2 values similar to PBS control, indicating no acute lung toxicity (Figure 5.13).  
 
 
Figure 5.13: Serum Carbon Dioxide Levels  
 
 
5.3.2. Polyrotaxane Mediated Red Blood Cell Hemolysis 
 One of the most important aspects of blood compatibility is the effect of an injected NP 
on circulating RBCs. NP-mediated RBC lysis can lead to a decrease in the levels of circulating 
hemoglobin and, therefore, a lack of oxygen delivered to the tissues Oxidative damage to the 
walls of blood vessels and the kidneys can also contributing to renal failure over time.31 To test 
for possible PR mediated hemolysis, increasing concentrations of each PR were incubated with 
human red blood cells and compared to a positive control of 1% Triton X-100. No evidence of 



















Figure 5.14: HP-β-CD Polyrotaxane Mediated Red Blood Cell Hemolysis. 
 
5.3.3. Polyrotaxane Immunogenicity 
 Interaction of PR constructs with components of the immune system will have a major 
impact on their ability to circulate extensively in the body, ultimately influencing their clearance, 
metabolism, and distribution.32 Of particular importance for applications requiring repeated 
injections or long-term administration-- including drug delivery applications, use as imaging 
agents, or in the treatment of Niemann Pick Type C-- is the production of memory 
immunoglobulin G (IgG) antibodies to particular antigens present on the PR surface. Eliciting an 
IgG response would limit the capability of PRs to be administered long term, as they would be 
cleared more rapidly upon re-injection.33 Because it has been previously shown that NPs featuring 
PEGylated surfaces can induce the production of anti-PEG IgG,33 we sought to determine 
whether the PEG flanks of the Pluronic-based PR polymer cores would similarly elicit an immune 
response.  
 Anti-PEG IgG production was tested 14 d and 21 d after injection of the PR materials at 0 
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were re-challenged with a second injection before termination of the experiment at 21 d. All PRs 
elicited some minimal amount of IgG production at 14 d beyond control, except for the longest 
circulating PR L81. This may be because of the short (~3 units) PEG flanks that L81 features, as 
6-7 repeating PEG units are believed to be necessary for IgG recognition.34 There is little 
difference between the PRs that elicit immune responses in this experiment, suggesting that there 
is no structure-property effect with regard to anti-PEG antibody production. At 21 d, PRs L35 and 
L64 show little evidence of anti-PEG IgG production beyond PBS control, even with a second PR 
administration. PRs F127 and F68 showed an enhanced IgG production at 21 d. PR F68, in fact, 
showed a greatly enhanced IgG presence in blood from an average of 104 u/mL at 14 d to an 
average of 269 u/mL at 21 d. This may be due to the fact that these PRs contain much longer PEG 
flanks, 100 units for F127 and 75 units for F68. Furthermore, the low degree of HP-β-CD 
threading onto F68 may lead to greater PEG recognition by the immune system because the 
laterally and rotationally mobile CDs are capable of exposing more of the Pluronic core. In other 
words, the larger number of HP-β-CDs carried by F127 relative to F68, (14 vs. 3 HP-β-CDs 
respectively) may be serving to slow PR recognition by the immune system through PEG block 
shielding. PR induced anti-PEG production is, therefore, influenced by the lengths of the PEG 
blocks exhibited by the core co-polymer as well as either PR threading efficiency or HP-β-CD 
copy number.  An in vivo PR application necessitating repeated or long term administration would 






Figure 5.15: Anti-PEG IgG Generation in HP-β-CD Polyrotaxane Treated Mice. n = 3. 
 
5.4. Polyrotaxane Hard Corona Proteomics 
 It has been shown that nanoparticles recruit protein coronas immediately upon injection 
into blood and that the makeup of the coating may affect in vivo performance.21 Because of this 
newfound understanding about the deterministic effects of protein recruitment, we sought to 
determine whether differences in protein architecture would lead to differential recruitment of PR 
surface proteins.  
 Total protein was found to vary across PR architectures as evidenced by total iBAQ 
counts (Figure 5.16). F127 and F68 absorb equivalent quantities of protein despite their varying 
CD copy numbers and threading efficiencies. L35 and L81, on average, have the lowest levels of 
total protein. It is unknown how this protection is mediated, although the high threading 
efficiency exhibited by these PRs may protect the constructs through lateral and rotational 
shielding. A decreased propensity to interact with serum proteins, by whatever mechanism, could 
partially explain the extended circulation time of these two highly threaded constructs. In 
contrast, L64 contains the highest average protein abundances although the standard error in this 
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transthyretin (TTR) deposited on the PR surface. Two of the three biological replicates of the L64 
samples accumulated large amounts of TTR, while a third only showed modest levels. In any 
case, a strong accumulation of serum proteins onto L64 may explain the preference of this PR for 
lung deposition. TTR is known to drive aggregation of TTR and other serum proteins when 
partially denatured35. If this denaturation and aggregation were being preferentially driven by 
contact with L64, the corresponding increase in PR size could lead to permanent or transient 
deposition in lung microcapillaries.  
 
 
Figure 5.16: Total Protein Deposition onto Gd3+:DOTA-PRs.  !
 
To elucidate differences in the total corona composition amongst the PR family members, 
the proteins showing adherence to the PR surface were divided into their respective classes. 
These groups included complement proteins, serum albumin, coagulation proteins, 
immunoglobulins, lipoproteins, and other.  When expressed as a percent of the total corona, it can 
be seen whether PR family members are preferentially acting within certain pathways of interest. 
A large percentage of complement proteins or immunoglobulins, for instance, would indicate a 
































percentages of dysopsonins would be positive indications for increased circulation time and 
bioavailability. 
PR L81 bound the greatest amount of serum albumin, accounting for 17.1% of total 
protein corona composition on average (Figure 5.17). The serum albumin levels were similar for 
F127 and L35 as well, which may help to explain the longer circulation of these species over F68 
and L64. F127, F68 and L35 also picked up the largest percentage of immunoglobulins and 
complement proteins. In these cases, the sugar residues of these more highly threaded PRs may 
facilitate antibody recognition. Exposure of nucleophilic alcohols, such as those present on CD, 
has been shown to promote activation of the alternative complement pathway.36 Finally, L35 and 
L64 adsorbed significantly more proteins in the coagulation pathway than did F127, F68, or L81.  
 
 
Figure 5.17: Average Percent of Total Gd3+:DOTA-PR Corona !!!
Overall, the PR library members adsorbed lipoproteins in the largest amounts (Figure 
5.17). This protein class represents the most significant portion of the corona (39-70%) in all 
































F68 respectively. Since lipoproteins typically carry esterified and unesterified cholesterol through 
the blood stream as a lipid-protein complex, their association with the cholesterol endcaps of the 
PRs may mediate this large deposition of a low abundance family of serum proteins. If this is 
true, these proteins may help promote cell uptake through receptor-mediated endocytosis upon 
binding to the relevant surface receptor. Why the large deposition of lipoproteins onto F127 and 
F68 does not lead to an extended circulation time is unknown.  
The largest single protein class on the surface of L64 is the group of  “other” proteins 
(Figure 5.17). This group includes proteases, inhibitors, ion and hormone carriers, and many other 
proteins. Significantly, this group also included TTR. TTR made up such a large portion of this 
adsorbed protein corona on L64 such that it alone is responsible for ~36.9% of the total protein 
corona content. TTR is an amyloidogenic protein when it partially denatures and can drive the 
aggregation of further TTR and other serum components. If some characteristic of L64 is 
recruiting and denaturing TTR, it would explain the high levels of TTR and the increased 
amounts of total protein. Further, this aggregation may play a role in the lung sequestration of 
L64, as large particles may have issues navigating lung microcapillaries.  
The top twenty proteins on the surface of each PR are listed in Tables 5.2-5.6. The PRs 
share a significant number of proteins. Ten proteins are common amongst each family member’s 
most abundant. Despite their differences in physiochemical properties, the common components 
of the PRs appear to be driving recruitment of common proteins. L64 had the most unique 
proteins with three. L35 and L64 share the most proteins between those that are not present on 
other PRs. This may be because of the similarity of their polymer cores. The most abundant 
proteins for F127, F68, L35, L64 and L81 are apolipoprotein A-I, apolipoprotein A-I, vitronectin, 




Table 5.3: Twenty Most Abundant Proteins in the F127 PR Corona !
!!!
Table 5.4: Twenty Most Abundant Proteins in the F68 PR Corona !
!!!!!
Protein ID Average % Corona 
Apolipoprotein A-I 23.68948669 
Complement C3 8.263679457 
Serum albumin 8.220708843 
Apolipoprotein A-II 7.051049504 
Apolipoprotein C-III 5.251471188 
Apolipoprotein C-I 5.213928823 
Apolipoprotein C-II 4.642077285 
Ig kappa chain C region 4.499298055 
Apolipoprotein E 4.059720575 
Ig gamma-1 chain C region 2.983669078 
Apolipoprotein A-IV 2.4906027 
Alpha-2-HS-glycoprotein 1.849838394 
Complement component C9 1.76530601 
Clusterin 1.343077522 
Transthyretin 1.188196742 
Complement component C8 gamma chain 1.177818036 
Ig lambda-1 chain C regions 1.129279556 
Ig gamma-2 chain C region 0.842647227 
Apolipoprotein D 0.812863719 
Alpha-1-antitrypsin 0.77790649 
Protein ID Average % Corona 
Apolipoprotein A-I 31.99542965 
Apolipoprotein A-II 9.218839973 
Apolipoprotein C-III 6.672272054 
Apolipoprotein C-II 6.659471591 
Apolipoprotein C-I 6.290285153 
Complement C3 6.13462544 
Alpha-2-HS-glycoprotein 4.46555885 
Serum albumin 3.993341851 
Apolipoprotein E 2.655028306 
Apolipoprotein A-IV 2.448874185 
Ig kappa chain C region 2.033188027 
Complement component C9 1.538969444 
Clusterin 1.485710311 
Ig gamma-1 chain C region 1.202353223 
Complement component C8 gamma chain 1.134662774 
Apolipoprotein D 1.127944085 
Prothrombin 0.813765188 
Serum amyloid A-4 protein 0.797553547 
Transthyretin 0.788184866 
Ig lambda-1 chain C regions 0.644944697 
!!
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Table 5.5. Twenty Most Abundant Proteins in the L35 PR Corona !
!!!
Table 5.6: Twenty Most Abundant Proteins in the L64 PR Corona !
!!
Protein ID Average % Corona 
Vitronectin 12.83014065 
Apolipoprotein C-III 7.994388561 
Serum albumin 6.900445584 
Apolipoprotein C-II 6.722644919 
Apolipoprotein A-II 6.460543675 
Ig kappa chain C region 5.106817942 
Hyaluronan-binding protein 2 4.756287373 
Complement C3 4.653739172 
Apolipoprotein A-I 4.456003931 
Clusterin 3.557088095 
Ig gamma-1 chain C region 3.123661581 
Apolipoprotein E 2.78340154 
Apolipoprotein C-I 2.694849924 
Ig lambda-1 chain C regions 1.925077969 
Prothrombin 1.913831307 
Ig mu chain C region 1.371190996 
Inter-alpha-trypsin inhibitor heavy chain H2 1.220287554 
Platelet factor 4 1.155834789 
Apolipoprotein D 1.14725169 
Transthyretin 1.040334076 
Protein ID Average % Corona 
Transthyretin 36.92882834 
Apolipoprotein C-III 5.640337171 
Apolipoprotein A-I 5.343226422 
Prothrombin 4.491836376 
Serum albumin 4.453993079 
Apolipoprotein C-II 3.932134511 
Apolipoprotein A-IV 3.646873692 
Hyaluronan-binding protein 2 3.404816171 
Vitronectin 3.20820959 
Inter-alpha-trypsin inhibitor heavy chain H2 2.468669522 
Clusterin 2.390341589 
Apolipoprotein A-II 2.116701292 
Ig kappa chain C region 2.007984058 
Complement C3 1.904499153 
Inter-alpha-trypsin inhibitor heavy chain H1 1.447922545 
Alpha-2-HS-glycoprotein 1.424555287 
Alpha-1-microglobulin 1.42007729 
Inter-alpha-trypsin inhibitor heavy chain H3 1.206435029 
Ig gamma-1 chain C region 1.005444601 
Apolipoprotein E 1.004896536 
!!
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Table 5.7: Twenty Most Abundant Proteins in the L81 PR Corona !
!!!!
 Finally, a number of individual proteins abundances were changing in statistically 
significant (p < 0.05) manners between the PR scaffolds. A principle component analysis of the 
data revealed good separation between the groups at this significance level, thus enabling 
meaningful comparisons (Figure 5.18).  Proteins that generally make up high-density lipoprotein 
(HDL) are overrepresented on PR F127 and F68 (Figure 5.19). The other PRs pick up less 
abundant lipoproteins, including ApoF and ApoJ, which can make up low-density lipoprotein 
(LDL), but also have other functions. Additionally, the coronas of F127 and F68 contain 
significantly higher amounts of complement components that contribute to the terminal 
membrane attack complex (MAC) formation, including complement C5, C6, C7 and C8. The 
other members all overexpress classical pathway component C4. As discussed above, L64 shows 
vastly enhanced levels of TTR. 
Protein ID Average % Corona 
Serum albumin 17.11418567 
Apolipoprotein C-III 10.94908584 
Apolipoprotein A-I 7.466318677 
Ig kappa chain C region 7.203133214 
Apolipoprotein C-I 7.167013517 
Complement C3 6.622339883 
Apolipoprotein C-II 6.557470377 
Ig gamma-1 chain C region 4.653725509 
Clusterin 4.096785956 
Apolipoprotein E 2.366180581 
Apolipoprotein A-II 2.053647321 
Ig lambda-1 chain C regions 1.777470732 
Transthyretin 1.66188389 
Complement C4-B 1.646949368 
Alpha-1-antitrypsin 1.440540318 
Ig gamma-2 chain C region 1.208887267 
Complement component C9 1.084131271 
Apolipoprotein A-IV 0.985567942 





Figure 5.18: Principle Component Analysis Plot Comparing Polyrotaxane Protein Coronas. Good 
Separation Exists Between Biological Replicates at p = 0.05. Black = L64, Pink = L35, Red = 
L81 Teal = F68, Blue = F127. !!
 
Figure 5.19: Protein Heat Map. Enriched Proteins Are Shown in Red. Under-Represented 
Proteins Are Shown In Green. p = 0.05. !
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 This chapter detailed the preclinical profiling of a family of Gd3+:DOTA-modified!and 
near IR IR800CW-labeled HP-β–CD PRs. The analyses PR biodistribution, circulation time, 
metabolism, excretion, hemolytic potential, immunogenicity, serum chemistry testing, and hard 
protein corona composition were performed as a function of Pluronic polymer core type. It has 
been shown that PRs of greater threading efficiency circulate for an enhanced period of time and 
deposit preferentially in the liver. In contrast, PRs with lower degrees of threading leave 
circulation quickly and deposit to a greater extent in the lungs. In all cases, subsets of PRs are 
able to quickly leave circulation by renal filtration by a mechanism that is unclear at this time. In 
the case of F127, the majority of this cleared PR content appears to be unmetabolized. PRs do not 
exhibit any hemolytic potential, do not affect the growth rate of mice after administration, and do 
not affect the natural serum chemistry in ways that would be indicative of organ damage. Anti-
PEG IgG generation was found to be dependent on the length of the flanking PEG blocks. 
Finally, PRs constructed from differing polymer cores do exhibit differential recruitment of 
serum proteins. PR L64 exhibits an increased deposition of serum proteins, while PRs L81 and 
L35 show reduced deposition. In all cases, it was observed that PRs recruit significant amounts of 
lipoproteins. The polymer core, and less so the CD copy number or threading efficiency, appear 
to influence the variable recruitment of specific proteins from serum amongst the family 
members. Additional work must be done before a comprehensive preclinical profile would be 
complete and specific conclusions could be drawn about the physiochemical origins of specific 







5.6. Materials and Methods !
5.6.1. Materials 
 HP-β-CD and Pluronic co-polymers were purchased from Sigma-Aldrich. Polymer 
average molecular weights and hydrophilic-lipophilic balances were determined by the 
manufacturer. Claritas PPT grade gadolinium standard was purchased from Fischer Scientific. 
TraceMetal Grade nitric acid was purchased from Thermo Fischer Scientific. All dilutions were 
made with either 18MΩ water or 2% HNO2 in 18MΩ water.  
 
5.6.2. Polyrotaxane Characterization 
 For analysis of the amount of gadolinium in the materials, ~1 mg samples of each PR 
were dissolved in 70% HNO3 at a concentration of 2 mg/mL. Samples were allowed to digest 
overnight. Each PR solution was then diluted to a concentration of 10 ppb Gd3+ based on the 
theoretical amount expected based on NMR integration of the DOTA peaks. A final nitric acid 
concentration of all samples was 2%. The Pluronic methyl peak was integrated to the average of 
protons for the given polymer with all additional peaks relative to this standard. Estimation of the 
average number of HP-β-CDs resident on a given PR was done by comparing the integrals of the 
HP-β-CD H-1 peak and the Pluronic core methyl group.  
 
5.6.3. In vivo Studies of Pharmacokinetics and Biodistribution 
 Male Balb/c mice were purchased from Harlan Laboratories (Indianapolis, IN) and 
allowed to acclimate for 2 weeks before PR administration. Injection was done at 9 weeks of age 
with mice weighing 22-24 g. Anesthesia was done using isofluroane gas. All experiments were 
done with approval from the Purdue Animal Care and Use Committee (Protocol # 1112000342).  
!!
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 PRs were solubilized in sterile DMSO and sonicated for 10 min before dilution to 15% 
DMSO with sterile PBS to give a final PR concentration of 2 mg/mL for Gd3+ materials and 4 
mg/mL for IR800CW materials. Each PR was administered via tail vein in a 100 µL injection to a 
group of 3 mice. Blood draws of ~50 µL were taken at 0 h, 0.5 h, 1 h, 2 h, and 6 h after 
administration for analysis of PR pharmacokinetics. At 24 hours, mice were sacrificed by cervical 
dislocation and cardiac blood draw. Liver, spleen, kidney, lungs, heart, and brain tissue were 
dissected for ex vivo analysis of biodistribution. Organs were weighed and snap frozen in liquid 
nitrogen. Blood, serum, and organs were all stored at -80°C until digestion and analysis were 
performed.  
 Live animal NIR imaging was done using an IVIS Lumina II at 0, 0.25, 0.5, 1, 2, 6, 24, 
48 and 120 h after PR administration. Dissection of one mouse in each group at 24, 48 and 120 hr 
was done to remove the liver, spleen, kidneys, heart, lungs, and intestines for ex vivo 
fluorescence analysis immediately after dissection. 
 
5.6.4. PR Metabolism and Excretion 
 During the performance of the pharmacokinetics experiments, feces and urine were 
collected to follow the excretion of PR materials as they cleared from the body. Cages were lined 
with filter paper after injection. At selected intervals, feces were collected from the cage floor and 
the filter paper was collected and stored for urine extraction. Pooled urine and feces produced by 
3 mice in each group were collected at 0-1 h 1-2 h and 2-6 h time periods. At 24 h, each of the 3 
mice were placed on individual petri dishes; the spontaneously produced urine and feces were 
collected from each individual for analysis. 
 For pooled feces, samples were homogenized mechanically before digestion. Pooled 
urine was extracted from filter paper by soaking in 40 mL of PBS for 48 h on a rocker plate with 
!!
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periodic vortexing. Filter paper fibers were separated by vacuum filtration and the filtered extract 
lyophilized. The resulting powders were dissolved in 1 mL water and 10-20 µL of this solution 
was added to 100 µL HNO3 for digestion. All unused samples were stored at -80°C. 
 To study PR metabolism, urine samples were dialyzed against 3.5 kDa MWCO 
membranes such that intact PRs would be retained and degraded PRs would be dialyzed away. 
Either individual or pooled urine (10-20 µL) was added to 10-100 µL Slide-A-Lyzer MINI 
dialysis cups (Thermo Scientific). Dialysis cups were presoaked in H2O for 30 m before urine 
addition and dialysis against 350 mL of PBS buffer for 24 h with 1 buffer change.  The remaining 
solution was then collected, digested, and analyzed by ICPMS. Gadolinium values collected in 
these experiments were compared to bulk urine Gd3+ values for each time point to calculate 
percent loss. 
 
5.6.5. Digestion and Inductively Coupled Mass Spectrometry (ICPMS) Analysis 
 Blood, serum, and urine samples (5-20 µL) were typically digested by addition of 100 µL 
of 70% nitric acid (HNO3). HNO3 mixtures were incubated at 80°C for 16 h to give pale yellow 
solutions before dilution to 5-8 mL such that the final nitric acid content was 2%. Organs were 
thawed, sectioned, weighed and homogenized before digestion with 100-200 µL HNO3 at 80 °C 
for 16 h – 48 h. Livers, brains and kidneys required longer digestion times than did lungs, 
spleens, and hearts. After digestion, hearts and brains were diluted to 5 mL volumes. Spleens, 
kidneys and lungs were diluted to 5 mL volumes and then further by 1:10. Livers were diluted to 
10 mL volumes and further by another 1:15. All final solutions were filtered through 0.2 µm 
PTFE syringe filters (Macherey-Nagel, Bethlehem, PA). Final nitric acid concentration of all 
samples was 2%. ICPMS analysis for 156Gd and 158Gd content was done using an ELEMENT-2 
Mass Spectrometer (ThermoFinnigan, Bremen, Germany) in the medium resolution mode. The 
!!
164 
samples were introduced into the plasma using an Aridus desolvating system with a T1H 
nebulizer (Cetac Technologies, Omaha NE). 
 
5.6.6. Anti-PEG IgG Antibody Production and Body Weight Analysis 
 A second set of mice was used to probe for the production of anti-PEG antibodies after 
challenge with the PR constructs. All groups contained three mice and were challenged once with 
100 µL 2 mg/mL PR injections at Day 0. Blood (~50 µL) was collected at Day 14 and screened 
for anti-PEG IgG antibodies. On Day 14, groups treated with L35, L64 and L81 were re-
challenged with an additional 100 µL PR injection. At Day 21, mice were sacrificed, blood was 
collected by cardiac blood draw and blood was allowed to clot and separated by centrifugation 
before serum analysis by ELISA. For body weight analysis, all animals were weighed before 
injection, and then at Days 1, 5, 9, 14 and 21. Values are presented as average body weight ± 1 
SEM.  
 
5.6.7. ELISA Studies 
 ELISA studies for antibody production were done using a Mouse Anti-PEG IgG ELISA 
kit purchased from Life Diagnostics, Inc (West Chester, PA) and were conducted according to the 
manufacturers protocol. Briefly, serum was diluted 1:100 or 1:50 and added to a BSA-PEG 
coated 96 well plate in duplicate. After incubation for 1 h, secondary anti-mouse IgG-HRP 
conjugate was added before incubation for 45 min. Final TMB substrate incubation for 20 min 
was followed by addition of stop solution and quantifying absorption of the plate at 450 nm with 
correction at 570 nm. 
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5.6.8. Serum Chemistry  
 Terminally drawn serum from the three animals in the antibody production study was 
pooled (150 µL each mouse) for each PR group. Mean values for the groups were determined for 
ALT, ALKP, creatinine, blood urea, electrolytes, and blood CO2. Analysis was performed by the 
Purdue Veterinary Teaching Hospital Clinical Pathology Lab (West Lafayette, IN). Samples were 
run on a Vitros 5,1 FS from Ortho Clinical Diagnostic (Rochester, NY) per the manufacturer’s 




5.6.9. Hemolysis Assay 
 Human red blood cells (RBCs) were purchased from Zen-Bio, Inc (Research Triangle 
Park, NC) and stored at 4°C until use. RBC were washed 4 times with 150 mM NaCl and 
subsequently diluted 1:50 before testing. Each PR was dissolved in DMSO and sonicated for 15 
min before dilution with PBS and sonication for an additional 15 min. Final DMSO 
concentrations were 1%. PRs were then serially diluted in 1% DMSO to give solutions of 800 
µg/mL, 100 µg/mL, and 20 µg/mL. Aliquots of washed RBCs (190 µL) were then incubated with 
10 µL PR for 1 h at 37°C. Final PR concentrations were 20 µg/mL, 5 µg/mL, and 1 µg/mL, with 
final DMSO concentrations of 0.05%. 1% Triton X-100 was used as a positive control. After 
incubation, cells were pelleted by centrifugation for 5 m at 600 x g and 100 µL of supernatant 
was collected. All experiments were done in triplicate. Hemolysis was analyzed using a Nanodrop 
ND-1000 (Thermo Scientific, Wilmington DE) by probing released hemoglobin absorption at 415 




5.6.10. Protein Corona Analysis 
 Normal human serum was purchased from Complement Technology, Inc (Tyler, TX) and 
thawed immediately before use. PRs (100 µg) were taken up in PBS and sonicated for 10 min 
before incubation with undiluted human serum (1:1 v/v) for 1 h at 37°C. After incubation, 
samples were centrifuged for 10 min at 4000 x g and PR pellets were washed four times with 150 
µL cold PBS. Three separate incubations were done for each PR family member.  
Tryptic peptides were separated on a nanoLC system (1100 Series LC , Agilent 
Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment 
column (5 x 0.3 mm, 5 µm) for concentration and the enrichment column was switched into the 
nano-flow path after 5 min. Peptides were separated with the C18 reversed phase ZORBAX 
300SB-C18 analytical column (0.75 µm × 150 mm, 3.5um) from Agilent. Column was connected 
to the emission tip from New Objective and coupled to the nano-electrospray ionization (ESI) 
source of the high-resolution hybrid ion trap mass spectrometer LTQ-Orbitrap XL. (Thermo 
Scientific). The peptides were eluted from the column using acetonitrile /0.1% formic acid 
(mobile phase B) linear gradient. For the first 5 min, the column was equilibrated with 95% H2O 
/0.1% formic acid (mobile phase A) followed by the linear gradient of  5% B to 40% B in 65 min. 
at 0.3ul/min, then from 40% B to 100% B in additional 10 minutes. Column was washed with 
100% of ACN/0.1%FA and equilibrated with 95% of H2O/0.1%FA before next sample was 
injected (total method time = 95 min.).  A blank injection was run between samples to avoid 
carryover.  
The LTQ-Orbitrap mass spectrometer was operated in the data-dependent positive 
acquisition mode in which each full MS scan (30,000 resolving power) was followed by eight 
MS/MS scans where the eight most abundant molecular ions were selected and fragmented by 
collision induced dissociation (CID) using a normalized collision energy of 35%.  
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Database searching was conducted using MaxQuant for LFQ (Label Free Quantitation –
LFQ). The Human (SwissProt) annotated database was used for the search.  Initial Spectral 
Counting was performed using the Mascot Database search results.  Statistical Analysis (Multi 
regression Analysis) was performed using Qlucore software package.  
 
5.6.11. Statistics 
 Biodistribution significance was assessed by two-way ANOVA 
 
5.6.12. Calculations 
 Percent injected dose calculations are based on the experimentally determined Gd3+ load 
of each PR, a concentration of 2 mg/mL PR, an injection volume of 100 µL, and an average total 
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CHAPTER SIX: PRECLINICAL CHARACTERIZATION OF POLYROTAXANES 




 The studies described in Chapter Five focused on a systematic investigation of the effects 
of the polymer core on PR pharmacokinetic profile, biodistribution and toxicity.  By varying 
polymer lengths and hydrophilic/lipophilic ratios while maintaining a constant β-cyclodextrin (β-
CD) type gave information on the overall contribution of molecular weight, threading efficiency, 
and polymer character. Further PR complexity can be introduced through the utilization of 
alternative β-CD derivatives. This chapter will discuss this area of PR design space by focusing 
on charge and surface chemistry through incorporation of β-CD derivatives as mixtures of species 
on a Pluronic L81 core. 
 
6.1.1. Common β-CD Derivatives 
 Native β-CD consists of a ring of glucose molecules with unmodified primary and 
secondary alcohol rims (Figure 6.1).1 In the body, this would exhibit a rigid, β-1,4 glucosyl 
structure that would be available for potential recognition by the immune system. Additionally, 
free alcohols of carbohydrate origin with the complement system.2 Finally, unperturbed 
placement of the primary and secondary alcohols along the β-CD periphery allows for effective 
hydrogen bonding between β-CD units along the PR axis such that it could confer a greater 
rigidity and decreased solubility to the final constructs. Chemical modification of these sites 
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interrupts the intermolecular hydrogen bonding, thereby altering PR solubility, surface chemistry, 
and, overall structure. 
 2-Hydroxypropyl-β-Cyclodextrin is one of the most commonly available modified β-CD 
derivatives (HP-β-CD).3 HP-β-CD features non-specific modifications of both the primary and 
secondary rim alcohols with hydroxypropyl- (HP) substituents (Figure 6.1). Little control can be 
obtained over the number or location of the HP modifications. This means that any number of the 
hydroxymethyl groups, secondary rim alcohols, or the secondary alcohols of the newly added HP 
groups may be sites of HP modification. Because of this, HP-β-CD is a heterogeneous mixture of 
as many as 60+ modified CDs, having a range of overall diameters and molecular weights. 
Incorporation of HP-β-CD onto a PR scaffold, as was done in Chapter 5, would break up, and 
potentially completely disrupt, PR backbone hydrogen bonding while retaining the reactive 
alcohol functionalities on the CD substituents.   
 
 
Figure 6.1: β-CD Derivatives Used in Mixed Rotaxanation Reactions !!!
In addition to HP-β-CD, methyl-β-cyclodextrin (Me-β-CD) and 4-sulfobutylether-β-
cyclodextrin (SBE-β-CD) are also widely available (Figure 6.1).4!  Me-β-CD features 
permethylated CD surface alcohols. Their utilization would completely block CD hydrogen 
bonding along the PR axis, as well as block any potential reactivity of surface alcohols with 






























































































hydrophobic overall. In contrast, SBE-β-CD features a high negative charge because of the 
sulfonate groups presented at the distal end of the butyl ether rim modifications of the β-CD 
monomers carry. Incorporation of SBE-β-CD onto a PR scaffold would not only greatly weaken 
inter-CD hydrogen bonding due to reduced number of hydroxyl groups, and may also introduce 
some amount of CD-CD electrostatic repulsion. These sulfonate groups have the potential to 
enhance PR solubility and drastically change the way PRs behave and interact with blood 
components. Incorporation of any of these derivatives, β-CD, HP-β-CD, Me-β-CD, or SBE-β-
CD, exclusively or in mixtures will yield families of PRs with widely disparate surface 
chemistries and physiochemical characteristics relative to the Gd3+:DOTA HP-β-CD PRs. 
 
6.1.2. Performance Effects of Varying CD Incorporation  
For the purpose of scanning these parameters, Pluronic L81 was chosen as the scaffold 
and remained constant as the CD derivative content and their mixtures were scanned. Utilizing 
this core allows for comparison with the best performing material from the studies in Chapter 5, 
i.e., the Gd3+:DOTA carrying HP-β-CD-L81 PR that was found to exhibit the longest circulation 
time of the materials studied. It is also non-immunogenic and showed a favorable protein corona 
deposition that included serum albumin and lipoproteins. Seeing how these aspects of Gd3+-HP-
L81 performance change due to loss of Gd3+ chelator modification and incorporation of different 
CD derivatives will provide insight into the overall physiochemical aspects that most influence 
their biological performance.  
Various aspects of the preclinical profile and in vitro performance were studied as the CD 
composition was varied. Hemolysis assays were used to assess the hemolytic potential of various 
PR structures. A more select group was used to study the effects on protein recruitment to the 




6.2. Results and Discussion  !
Table 6.1: Properties of Mixed β-CD PRs !
!!
 
6.2.1. Mixed Polyrotaxane Mediated Red Blood Cell Hemolysis !
  As discussed previously, NP mediated RBC lysis is important because it can lead to a 
decrease in circulating hemoglobin, a lack of oxygen delivered to the tissues, oxidative damage to 
blood vessels and kidneys, and contribute to renal failure over time.5 To study the effects of 
varying CD chemistry on RBC interaction, an expanded family of β-CD PRs was utilized. This 
collection included PRs carrying exclusively β-CD, HP-β-CD, Me-β-CD, and SBE-β-CD. In 
addition, PRs were tested carrying a 50:50 feed mixture of SBE-β-CD and either β-CD, HP-β-
CD, or Me-β-CD. Increasing concentrations of each PR were incubated with human red blood 
cells and compared to a positive control of 1% Triton X-100. No evidence of hemolysis greater 
than control was seen at any concentration for any PR (Figure 6.2).  
PR CD Feed Ratio Total CD SBE-β-CD Other CD MW 
β-CD 100:0 18 0 18 26 kDa 
HP-β-CD 100:0 11 0 11 22 kDa 
Me-β-CD 100:0 8 0 8 16 kDa 
SBE-β-CD 100:0 34 34 0 73 kDa 
β-CD/SBE-β-CD 50:50 21 8 13 37 kDa 
HP-β-CD/SBE-β-CD 50:50 19 10 9 38 kDa 
Me-β-CD/SBE-β-CD 50:50 19 6 13 40 kDa 
HP-β-CD/SBE-β-CD 70:30 27 8 19 58 kDa 




Figure 6.2: Hemolytic Potential of Mixed Threading Rotaxanes 
 
 
6.2.2. Polyrotaxane Hard Corona Analysis  
Similarly to the way the PR core affected protein deposition onto the nanomaterial’s 
surface, there are also differences in protein amounts and identities when changing the CD 
derivative composition. Overall, total protein levels were greatly reduced relative to the 
Gd3+:DOTA PRs in Chapter 5, indicating some involvement of the Gd3+:DOTA modifications in 
recruitment. In addition, total amounts of adsorbed protein vary greatly across the CDs studied 
(Figure 6.3). Unmodified β-CD amassed the largest quantity of surface proteins, possibly because 
of the rigidity of the hydrogen bonded backbone and the availability of reactive surface alcohols 
on the CD rim.  HP-β-CD PRs had the second highest protein adsorption, potentially for similar 
reasons.  Decrease in HP-β-CD relative to unmodified β-CD PR may be mediated by a brush-like 
shielding originating from the HP modifications.  Me-β-CD and mixed threading PRs picked up 
roughly the same amount of protein despite very different surface chemistries. Decreased 
adsorption in Me-β-CD may originate from the capping of surface alcohols. Because of the 
reduction relative to β-CD PRs and HP-β-CD, it appears that incorporation of charged CDs also 
!!
176 
reduces adsorption by some mechanism. Further careful study is necessary to definitively 
pinpoint the mechanisms behind these differences.  
 
 
Figure 6.3: Total Protein Adsorption onto PRs of Varying CD Derivatives !!!! When comparing protein groups, CD variation again led to changes in preferential 
protein family deposition (Figure 6.4).  Similar to the Gd3+:DOTA HP-β-CD PR family, PRs 
carrying unmodified β-CD, Me-β-CD, HP-β-CD, and the SBE-β-CD mixture had high levels of 
adsorbed lipoproteins. Levels of these proteins were similar to Gd3+:DOTA L81 PRs. The corona 
featuring the lowest percentage of lipoprotein content was unmodified β-CD PR with this family 
accounting for ~30% of the total corona. Incorporation of unmodfied CD appears to drive the 
recruitment of other protein families, reducing the percentage occupied by lipoprotein 
dysopsonins. In addition, because this PRs family and Gd3+:DOTA modified PRs adsorb similar 
percentages of lipoproteins, it appears that association with these proteins is modified by the PRs 
and not by the DOTA modificaitons. 
 Notably, β-CD PR and HP-β-CD PR achieve significantly greater immunoglobulin 
deposition than their counterparts. This may be due to recognition of the 1,4-glucose architectures 
































HP-β-CD PR represent the largest fractions of serum album of the group while mixed SBE-β-CD-
carrying scaffolds exhibit the lowest albumin recruitment. The charge on these PRs may be 
preventing albumin-mediated recognition of the cholesterol PR endcaps. HP-β-CD PRs also 
featured significantly diminished levels of complement adsorption despite available alcohols on 
the  CD surface. Conversely, Me-β-CD PRs were amongst the highest complement protein 
recruiters despite the reduction of alcohol surface chemistry. All four scaffolds exhibit 
significantly diminished deposition of coagulation pathway proteins. 
 
 
Figure 6.4: Average Percent of PR Protein Corona  !!!! The most abundant protein in the corona of unmodified β-CD and HP-β-CD PRs is serum 
albumin. In both cases, the second most abundant protein is immunoglobulin kappa, reflecting the 
high percentage of their coronas represented by albumins and immuglobulins. Both architectures 
feature large numbers of lipoproteins in their top 20 proteins. Additionally, both PR coronas 



























100% Me-β-CD PR 
100% β-CD PR 
50:50 HP-β-CD:SBE-β-CD PR 
 100% HP-β-CD PR 
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 Me-β-CD and mixed SBE-β-CD PR share their top three most abundant proteins. These 
proteins are complement C3, apolipoprotein E, and serum albumin, respectively. Complement C3 
is the most abundant protein despite the reduction of reactive surface alcohols, which have been 
shown to drive covalent attachment of complement C3b to nanomaterial surfaces.2 The high 
percentage of apolipoprotein E on Me-β-CD the mixed threading PR, 16.9% and 12.2% 
respectively, increases the chances for these architectures to cross the BBB. The similarities of 
the proteins and corona percentages for these two PR, shows that they have similar bio-
interactions despite the differences in surface chemistry.  !!
Table 6.2: Twenty Most Abundant Proteins in the L81 β-CD PR Corona !
 !!!!!!!
Protein ID Average % Corona 
Serum albumin 16.53602536 
Ig kappa chain C region 15.00432799 
Complement C3 11.74536491 
Ig gamma-1 chain C region 7.757086463 
Apolipoprotein E 5.161341666 
Apolipoprotein A-II 4.808387011 
Apolipoprotein D 4.074641027 
Apolipoprotein A-I 3.408645335 
Ig lambda-1 chain C regions 3.358983503 
Apolipoprotein B-100 2.938530875 
Complement component C9 2.077125525 
Ig gamma-2 chain C region 1.801673851 
Transthyretin 1.609643609 
Alpha-1-antitrypsin 1.401363144 
Apolipoprotein C-I 1.370046556 
Clusterin 1.286344099 
Ig lambda-2 chain C regions 1.184513069 
Haptoglobin 1.173103474 
Serotransferrin 1.119652755 
Complement C4-B 1.090155363 
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Table 6.3: Twenty Most Abundant Proteins in the L81 Me-β-CD PR Corona !
 !!
Table 6.4: Twenty Most Abundant Proteins in the L81 HP-β-CD PR Corona !
!!!
Protein ID Average % Corona 
Complement C3 17.35131077 
Apolipoprotein E 16.92263363 
Serum albumin 10.91695191 
Apolipoprotein B-100 6.069452089 
Ig gamma-1 chain C region 5.337392476 
Ig kappa chain C region 5.311549879 
Apolipoprotein A-II 5.010290265 
Apolipoprotein D 3.573277261 
Complement component C9 3.421953775 
Apolipoprotein A-I 2.773780863 
Complement C4-B 2.147698529 
Serum paraoxonase/arylesterase 1 1.574657144 
Apolipoprotein C-II 1.53214378 
Apolipoprotein C-III 1.49304561 




Serum amyloid A-4 protein 0.928412544 
Ig lambda-1 chain C regions 0.864075528 
Protein ID Average % Corona 
Serum albumin 21.76828436 
Ig kappa chain C region 19.04835025 
Apolipoprotein A-II 10.81040494 
Apolipoprotein A-I  7.919583224 
Apolipoprotein E 7.066407588 
Apolipoprotein C-II 4.992757233 
Apolipoprotein C-III 3.944752799 
Ig gamma-1 chain C region 3.311732771 
Transthyretin 1.985551149 




Ig alpha-1 chain C region 1.482215949 
Clusterin 1.035208084 
Ig lambda-1 chain C regions 0.931474445 
Ig kappa chain V-III region 0.773907913 
Apolipoprotein D 0.753715631 
Ig gamma-2 chain C region 0.647140603 
Ig lambda-2 chain C region 0.604695051 
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Table 6.5: Twenty Most Abundant Proteins in the L81 50:50 HP-β-CD:SBE-β-CD PR Corona !
 !!
6.3. Conclusions ! The expanse of the design space available in PR construction warrants systematic 
investigation of the numerous available parameters. This study shows that utilizing guest β-CD 
macrocycles of varying surface modifications does little to affect the hemolytic potential of PR 
scaffolds at the tested concentrations. In contrast, these changes will significantly impact the size 
and composition of surface bound protein hard coronas. These differences are more evident in the 
total protein abundance and the relative amounts of various protein families. The actual identities 
of the proteins in the corona, however, can be very similar. This indicates that the overall PR 
structure may be similar enough in most cases to promote recruitment of similar proteins onto the 
PR surface.  
 
 
Protein ID Average % Corona 
Complement C3 19.76495094 
Apolipoprotein E 12.28036258 
Serum albumin 9.427281564 
Apolipoprotein A-II 6.865297508 
Apolipoprotein C-II 6.692607783 
Ig gamma-1 chain C region 5.92949059 
Ig kappa chain C region 4.87297314 
Apolipoprotein B-100 4.636129789 
Complement component C9 3.846580792 
Apolipoprotein D 3.114959404 
Apolipoprotein A-I 2.537299079 
Complement C4-B 2.083473432 
Trypsin-3 2.050791718 
Apolipoprotein C-III 1.876260875 
StAR-related lipid transfer protein 13 1.437949237 




Ig lambda-1 chain C regions 0.797377646 
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6.4. Materials and Methods !!
6.4.1. Hemolysis Assay 
 Human red blood cells (RBCs) were purchased from Zen-Bio, Inc (Research Triangle 
Park, NC) and stored at 4°C until use. RBC were washed 4 times with 150 mM NaCl and 
subsequently diluted 1:50 before testing. Each PR was dissolved in DMSO and sonicated for 15 
min before dilution with PBS and a further 15 min of sonication. The final DMSO concentration 
was 1%. PRs were then serially diluted in 1% DMSO to give solutions of 800 µg/mL, 100 
µg/mL, and 20 µg/mL. Aliquots of washed RBCs (190 µL) were then incubated with 10 µL PR 
for 1 h at 37°C. Final PR concentrations were 20 µg/mL, 5 µg/mL, and 1 µg/mL. The final 
DMSO concentration was 0.05%. Triton X-100 (1%) was used as a positive control. After 
incubation, cells were pelleted by centrifugation for 5 m at 600 x g and 100 µL of supernatant 
was collected. All experiments were done in triplicate. Hemolysis was analyzed using a Nanodrop 
ND-1000 (Thermo Scientific, Wilmington DE) by probing the released hemoglobin absorption at 
415 nm.  Results were normalized to the Triton X-100 positive control. 
 
6.4.2. Protein Hard Corona Proteomics 
 Normal human serum was purchased from Complement Technology, Inc (Tyler, TX) and 
thawed immediately before use. PRs (100 µg) were taken up in PBS and sonicated for 10 min 
before incubation with undiluted human serum (1:1 v/v) for 1 h at 37°C. After incubation, 
samples were centrifuged for 10 min at 4000 x g and PR pellets were washed four times with 150 
µL cold PBS. Three separate incubations were done for each PR family member.  
Tryptic peptides were separated on a nanoLC system (1100 Series LC , Agilent 
Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment 
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column (5 x 0.3 mm, 5 µm) for concentration and the enrichment column was switched into the 
nano-flow path after 5 min. Peptides were separated with the C18 reversed phase ZORBAX 
300SB-C18 analytical column (0.75 µm × 150 mm, 3.5um) from Agilent. Column was connected 
to the emission tip from New Objective  and coupled to the nano-electrospray ionization (ESI) 
source of the high-resolution hybrid ion trap mass spectrometer   LTQ-Orbitrap XL. (Thermo 
Scientific). The peptides were eluted from the column using acetonitrile /0.1% formic acid 
(mobile phase B) linear gradient. For the first 5 min, the column was equilibrated with 95% H2O 
/0.1% formic acid (mobile phase A) followed by the linear gradient of  5% B to 40% B in 65 min. 
at 0.3ul/min, then from 40% B to 100% B in additional 10 minutes. Column was washed with 
100% of ACN/0.1%FA and equilibrated with 95% of H2O/0.1%FA before next sample was 
injected (total method time = 95 min.).  A blank injection was run between samples to avoid 
carryover.  
The LTQ-Orbitrap mass spectrometer was operated in the data-dependent positive 
acquisition mode in which each full MS scan (30,000 resolving power) was followed by eight 
MS/MS scans where the eight most abundant molecular ions were selected and fragmented by 
collision induced dissociation (CID) using a normalized collision energy of 35%.  
Database searching was conducted using MaxQuant for LFQ (Label Free Quantitation –
LFQ). The Human (SwissProt) annotated database was used for the search.  Initial Spectral 
Counting was performed using the Mascot Database search results.  Statistical Analysis (Multi 
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CHAPTER SEVEN: FUTURE DIRECTIONS
 !
7.1. Introduction ! Given the attractive features of the polyrotaxane (PR) systems outlined in the chapters 
above, there are a number of directions in which PR technology can expand and mature. There is 
potential for PR utilization in a number of biomedical applications that could follow from this 
work. More directly, there are a number of ways the physiochemical design space of PR scaffolds 
can be mapped further. Studies could be conducted into how these parameters further affect a 
variety of PR functions, properties, and characteristics beyond those already initiated above. 
What follows is a concise discussion of potential experimental directions most directly following 
this work.    
 
7.2. Potential Lines of In Vivo Experimentation !
7.2.1. Completion of a Preclinical Profile for Gadolinium-Carrying PRs ! While a large portion of a preclinical profile has been completed for gadolinium (Gd3+) 
carrying hydroxypropyl-β-cyclodextrin (HP-β-CD) polyrotaxanes (PRs) of varying Pluronic 
cores, there remains work that could be done to fully flesh out the safety profile of these 
materials. Firstly, it remains to be seen whether these scaffolds interfere in any way with the 
body’s clotting mechanisms. As discussed in Chapter Four, initiation or prevention of blood 
clotting would be indicative of potential adverse reactions upon administration. This could be 
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studied using either a coagulometer to directly measure time to clot formation in comparison to 
positive and negative controls, or by incubating PRs with platelets and subsequently studying 
either calcium flux or the appearance of specific surface antigens that would give the necessary 
indications of platelet activation relative to agonist controls. 
 Additionally, elucidating trends in how PR physiochemical properties affect the rate of 
macrophage uptake could factor into the choice of PR for a given application. Incubation of PR 
scaffolds with macrophages in an in vitro time course study would be helpful in this regard. The 
ability to do this with immobilized macrophages may be particularly useful given the inferred 
rod-like structure of PRs in solution.1  ! Finally, there exist many ways in which our understanding of PR toxicity could be 
enhanced. Serum chemistry studies have been done after single or double injections of PR 
scaffolds. This should be extended to a broader hematology profile that includes complete blood 
count, hemoglobin levels, and many of the other blood toxicology screens that cannot be done on 
serum. Additionally, studying glomerular filtration rate by tracking the levels of aspartate 
aminotransferase and alanine aminotransferase in the blood and urine over time, as well as tissue 
sectioning and histological analysis would give a better indication of kidney damage. This is 
especially necessary in the case of Gd3+:DOTA PRs where gadolinium-mediated nephrotoxicity is 
a possibility.2 Doing these studies over longer time periods with multiple PR administrations is an 
important study that must be performed to evaluate the safety profile of these scaffolds upon 
repeated administration 
 
7.2.2. Preclinical Profiling for Alternative PR Architectures 
 Preclinical profiles could also be built for PRs hosting other CD derivatives or containing 
alternative central polymers. Of particular interest, because of its ability to significantly increase 
PR solubility, would be how SBE-β-CD incorporation affects the pharmacokinetics, 
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biodistribution and safety parameters. This solubilizing effect has the caveat that increasing 
charge is likely to significantly alter biodistribution, circulation time, macrophage uptake, 
hemolysis, immunogenicity, and many other aspects of the PR fate in vivo. These considerations 
would need to be fully studied before moving forward with PRs containing higher SBE-β-CD 
content. 
 In addition, it will be wise to study PRs containing polymers that are not Pluronic based. 
These cores are likely to be non-degradable and a more attractive core would be one that the body 
could process into excretable blocks. For instance, PRs containing polyesters or polycarbonates 
would be much more viable, from a therapeutic standpoint, than those used herein. Secondly, 
there is reason to believe that the PR scaffold would benefit from the excision of poly (ethylene 
glycol) (PEG) from the design to minimize the potential for anti-PEG antibody production, 
particularly in applications where repeated dosing will be required. The fact that we see the most 
favorable PR pharmacokinetic profile exhibited by the PRs with the shortest PEG blocks supports 
this hypothesis. For example, PRs F68 and F127 both leave blood circulation quickly, with no 
boost in circulation from the large PEG blocks they contain. Also, PRs with long PEG blocks 
appear to be more immunogenic when compared to their counterparts. This would suggest a 
decreased likelihood for these PRs to be administered over the long term without experiencing an 
accelerated blood clearance.   
 Finally, there is opportunity to study the administration of more complex PR 
formulations. Analysis of the PR protein corona indicates that these scaffolds have a propensity to 
associate with serum lipoproteins (LPs). Incubation of PR systems with high-density lipoprotein 
(HDL) or low-density lipoprotein (LDL) particles may drive this PR:LP association into a more 
controllable form. Pre-forming the protein complex will likely affect the pharmacokinetics and 
toxicity properties relative to freely administered PR that will associate with many different blood 
protein partners based on stochastic interactions. In fact, this may allow for LDL receptor-
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mediated uptake into cells, an opportunity that would be highly attractive for treatment of 
Niemann-Pick Type C Disease. 
 
7.2.3. Therapeutic Efficacy of PR Scaffolds in Niemann-Pick Type C Disease ! While PR systems have been shown to be efficacious in in vitro NPC disease models, the 
in vivo efficacy has yet to be directly studied. Lead compounds from the preclinical profiles 
discussed above will need to be screened in NPC model organisms, initially NPC mice and 
followed by NPC cats. Efficacy will need to be assessed by measurement of total cholesterol in 
the organs of the body. This is most likely to be accomplished by gas chromatographic analysis of 
saponified organs and comparison to untreated control.3 An additional measure of interest will be 
any increase in survival of Purkinje cells of the brain because of the neurodegeneration associated 
with NPC. These will need to be visualized by immunohistochemical labeling of sectioned neural 
tissues. Finally, if testing in the cat model, there would need to be a study of the amelioration or 
enhancement of ototoxicity. β-CD derivatives have been shown to engender significant hearing 
loss in these animals.4 If PRs can overcome or delay this toxicity it would be a significant and 
important step beyond the capabilities of the small molecule HP-β-CD drug.  ! An additional area of study will be how these therapeutic effects change with routes of 
administration. Currently, β-CD administration is done through injections into the cerebral-spinal 
fluid surrounding the spinal cord. PR compounds could, ideally, be administered through a less 
invasive and painful route. Intravenous and intraperitoneal administration would be likely be the 
first routes tested in vivo, despite not being the least clinically invasive methods. The therapeutic 
effects mediated by these routes of administration would then be comparative benchmarks for 
more attractive routes of parenteral administration. Oral administration will need to be 
systematically studied as this would be one of the last detrimental to a patients quality of life. It 
may be necessary to attempt PR formulation with polymer coatings capable of surviving the 
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acidity of the stomach and gastrointestinal tract.5 Finally, a similarly attractive option would be to 
administer PRs subcutaneously (SC). Efficacy after SC injection would mean that there is 
potential to formulate PRs into an injection pen or as an adhesive or microneedle patch that could 
be administered at home. This is a significant amount of potential in this area given that PRs have 
already been shown to promote transdermal migration.6 Finally, intranasal administration could 
be studied as a means to achieve blood-brain-barrier (BBB) penetration 
 BBB penetration will need to become a focus of PR treatment studies in order to avoid 
spinal injections.  This could potentially be done in many ways. Surface modification of PRs with 
materials which have a propensity to cross the BBB or which have BBB specific receptors is one 
potential route toward enhanced uptake. Decoration of PR scaffolds with transferrin or 
Apolipoprotein E (ApoE), either covalently or through non-covalent (i.e. avidin-streptavidin) 
interactions could facilitate transcytosis across the BBB.7 PRs could also be simply formulated 
with ApoE through flow mixing or association with lipoprotein particles that contain large 
amounts of the protein.8 Finally, there are polymeric materials, including polysorbate 80, that 
engender enhanced BBB uptake through osmotic shrinkage mechanisms that and could be 
included in the PR formulations.9  !
7.2.4. In Vivo Tissue Penetration and Cellular Association ! Also of interest to NPC therapy is the extent to which PRs achieve tissue penetration 
beyond simply macrophage uptake. This will give an idea of how widely PRs will be able to 
affect therapeutic responses in the various cells of the body. This type of screening could be done 
initially in two ways using fluorescently modified PRs. First, tissue digestion and flow cytometry 
could be used to give a statistically significant look at the entire population of an organ’s cells. 
Macrophages could be marked with antibodies for specific surface markers. F4/80 is a surface 
protein that labels macrophages present in the liver, kidney, lung, spleen, and brain that could be 
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utilized.10 After administration of labeled PRs, tissues would be harvest, digested, labeled, and 
flow data would be acquired measuring the macrophage associated PR fluorescence against PR 
fluorescence given by other cells. Secondly, PR penetration beyond exterior organ interfaces 
could be studied by immunohistochemical examination of tissue sections. Images would allow for 
visualization of whether PRs are deposited along external organ membranes, for instance in the 
airways of the lungs, or perfused more deeply into the tissue. Evidence that PRs are associated 
only with macrophages or are not penetrating tissue would need to be addressed by system design 
changes. !
7.3. Potential Lines of In Vitro Experimentation !!
7.3.1. Internalization Pathways ! When studying the mechanisms by which PRs interact with the cell, it will be important 
to understand how PR systems are internalized. These routes could easily be probed through the 
use of fluorescently labeled PRs and small molecule inhibitors. Blocking endocytosis pathways 
sequentially and tracking PR uptake by flow cytometry would give the necessary information. 
Clathrin-independent and clathrin-dependent endocytosis can be inhibited by the small molecules 
geninstein and chlorpromazine, respectively. In addition, rottlerin is a potent inhibitor of 
macropinocytosis. Alternatively, siRNA gene silencing could be used to selectively inhibit 
specific pathways. Establishing trends in internalization pathway for PRs of varying CDs and 
polymer content would enable tailoring of PR scaffold to the necessary applications. Knowing if 
PR uptake is by a receptor-mediated pathway could also inform design choices to reinforce or 




7.3.2. Kinetics and Mechanisms of PR Therapeutic Effects and Intracellular Dethreading  
Along with studying the mechanisms by which PRs enter the cell, it would be useful to 
know the timescale by which they enter the cell and the kinetics by which their therapeutic effects 
occur. This information will be especially important for NPC applications. It would allow for 
selection of materials that are rapidly internalized and degraded. Maximum therapeutic potential 
could be achieved by selecting for materials that are able to trigger cholesterol efflux from sites of 
sequestration most effectively. 
Understanding the mechanisms by which PRs mediate their cholesterol mobilization will 
require knowledge of how and when PR systems release their CD cargo. The current hypothesis 
is that endcap cleavage is driven by endolysosomal esterases. This could be tested by the use of 
esterase inhibitors or carbamatase siRNA knockdowns.  The kinetics of this release could be 
measured by cell lysis at specific time points followed by analysis of free CD content by HPLC.  
 
7.4. Additional Applications and Therapeutic Models. !
7.4.1. Magnetic Resonance Imaging ! Magnetic Resonance Imaging (MRI) is an important means by which three-dimensional 
structures or body organs and tissues can be investigated. It has applications in a wide range of 
disease diagnostics.11 MRI images are often improved by the use of contrast agents, including 
Gd3+. Unfortunately, these agents are often small molecule scaffolds that clear rapidly from the 
body.11  Alternatively, macromolecular contrast agents that do not biodegrade may exhibit 
extended residence time in the body and raise the potential for Gd3+ related nephrotoxicity.12-13  
As discussed in Chapter 5, PR scaffolds can be modified with Gd3+ and, therefore, could serve as 
effective MRI contrast agents. Long circulation achieved by PRs would allow for increased 
contrast enhancement over time and breakdown of the PR scaffolds into biocompatible and 
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excretable components that would avoid bioaccumulation and potential heavy metal mediated 
toxicity. Design parameters would need to be scanned, as discussed above, to find long 
Gd3+:DOTA PRs capable of long circulation and favorable metabolism to find the most effective 
potential MRI scaffolds.  
 
7.4.2. Tumor Penetration 
As an extension of the use of PRs as MRI agents, these compounds could also be used as 
tumor penetrating drug delivery or diagnostic systems.  In particular, constructs from the 
pharmacokinetic and MRI screening experiments described above could be used in 
immunodeficient mouse tumor models to see if they provide sufficiently enhanced tumor uptake, 
residence, and contrast.  These studies would yield an efficient and biocompatible MRI contrast 
agent for use in cancer diagnostics. Similar animal models could be used to test the effectiveness 
of cancer treatment with PRs modified with small molecule drugs. Using synthetic schemes 
similar to those we have previously used, PRs could be modified with anti-tumor therapeutics 
(i.e. doxorubicin) and administered to tumor bearing mouse models. Growth rates of the tumor 
mass and the average lifetimes of mice treatment and control groups would provide information 
into the therapeutic effectiveness of the system. In this area, PRs have to potential to become 
generalizable drug delivery scaffolds. 
 
7.4.3. Alzheimer’s Disease ! Using PR constructs to treat NPC is desirable because therapeutic activity comes from 
the β-CD derivatives they inherently carry as part of their scaffold. This means there is no need 
for post-modification with drugs and the actual therapeutic represents a large percentage of the 
mass of the administered dose. This same potential exists in Alzheimer Disease (AD) where β-
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CD derivatives have recently been shown to be therapeutically useful in diminishing amyloid-β 
plaques and slowing neurodegeneration.14 Pursuing this line of experimentation would allow the 
re-purposing of existing materials for another life-threatening neurological disorder.  
In this same literature, data exists showing effective use of gene delivery to prevent 
memory loss in rats and non-human primates.15 Therapeutic delivery of brain-derived 
neurotrophic factor (BDNF) was done with a lentiviral vector that acted without affecting plaque 
deposition. Many of the PR constructs listed above have the potential to be modified with cations 
and used to deliver genes, including BDNF. This would deploy a dual therapy upon dethreading, 
i.e. plaque dissolution and BDNF remediation. In fact, the Thompson Lab has published multiple 
papers on the use of PRs as gene delivery vectors.16, 17 There exists in AD therapy an opportunity 
to bring to bear single or multifunctional therapeutic options using the scaffolds presented and 
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Figure A.1:  1H NMR spectra of (1) β-CD, (2) F68-TREN, (3) β-CD:F68 PR 
 
β-CD:F68 PR 1H NMR: (400Mhz, DMSO-d6, 22°C) δ 8.9-8.89(br. s., 8H, TNB), 5.74-5.63 (m, 
196H, O2H, O3H of CD), 4.83-4.77 (s, 98H, H1 of CD), 4.46-4.39 (t, 98H, O6H of CD), 3.65-3.55 
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Figure A.2:  1H NMR spectra of (1) β-CD, (2) L64-TREN, (3) β-CD:L64 PR 
 
β-CD:L64 PR 1H NMR: (400Mhz, DMSO-d6, 22°C) δ 8.891-8.814 (s., 8H, TNB), 5.76-5.6 (m, 
168H, O2H, O3H of CD), 4.84-4.76 (s, 84H, H1 of CD), 4.52-4.38 (t, 84H, O6H of CD), 3.67-3.59 
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Figure A.3:  1H NMR spectra of (1) β-CD, (2) L35-TREN , (3) β-CD:L35 PR 
 
β-CD:L35 PR NMR: (400Mhz, DMSO-d6, 22°C) δ 8.93-8.91(s., 8H, TNB), 5.75-5.65 (m, 98H, 
O2H, O3H of CD), 4.84-4.78 (s, 49H, H1 of CD), 4.45 (t, 49H, O6H of CD), 3.67-3.59 (m, 532H, 
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Figure A.5: NOESY Spectra of β-CD:F68 PR.  
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Figure A.10: β-CD:L64 PR GPC Traces. 
 

































Figure A.15: AFM Images of (A) β-CD:F68 PR  at 10-5 mg/mL, (B)  β-CD:L64 PR at 10-5 








Figure A.17: β-CD:F68 PR MALDI Mass Spectrometry.  
 













Figure A.20: HILIC Free β-Cyclodextrin Standard Curve 
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Figure A.22: 1H NMR of Unthreaded F68-TNB !
y = 1321.7x 
R² = 0.96298 
y = 1407.4x 
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Figure A.25: 1H NMR of Short PEG – TNB. !!!
!
















































































































Figure A.27: 1H NMR spectra for A) PR Incubated with DMSO/Minimum Essential Media, B) 





Figure A.28: Self-Diffusion Coefficients Vs. Molecular Weight for β-CD:L35 PR, β-CD:L64 PR, 
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Fitted function: f (x) = A * exp (-D * x^2 * gamma^2 *
littleDelta^2 (bigDelta-littleDelta/3)* 10^4
used gamma: 26752 rad/(s*Gauss)
used little delta: 0.0010000 s
used big delta: 0.020000 s
used gradient strength: variable
Random error estimation of data: RMS per spectrum (or trace/plane)
Systematic error estimation of data: worst case per peak scenario
Fit parameter Error estimation method: from fit using calculated y uncertainties
Confidence level: 95%
Used peaks: peaks from
C:\Users\klz\NMRData\klz\DavidHThompso
nLab\32\pdata\101\peaklist.xml
Used integrals: peak intensities
Used Gradient strength: all values (including replicates) used
Peak name F2 [ppm] A error D [m2/s] error A error D [m2/s] error
2      1.049 1.32e+05     2724 5.84e-11 1.959e-12     0.00    0.000     0.00    0.000
3      1.029 1.31e+05     2714 5.80e-11 1.968e-12     0.00    0.000     0.00    0.000
4      3.512 1.64e+05     4694 5.77e-11 2.075e-12 2.17e+05 1.469e+04 7.84e-10 7.504e-11
C:\Users\klz\NMRData\klz\DavidHThompsonLab\32\pdata\1\2rr
Diffusion Analysis
Page 3 of 4
 
Fitted function: f (x) = A * exp (-D * x^2 * gamma^2 *
littleDelta^2 (bigDelta-littleDelta/3)* 10^4
used gamma: 26751 rad/(s*Gauss)
used little delta: 0.0010000 s
used big delta: 0.020000 s
used gradient strength: variable
Random error estimation of data: RMS per spectrum (or trace/plane)
Systematic error estimation of data: worst case per peak scenario
Fit parameter Error estimation method: from fit using arbitray y uncertainties
Confidence level: 95%
Used peaks: peaks from
C:\Users\klz\NMRData\klz\DavidHThompso
nLab\13\pdata\101\peaklist.xml
Used integrals: peak intensities
Used Gradient strength: all values (including replicates) used
Peak name F2 [ppm] A error D [m2/s] error
1      4.836 3.55e+05     1178 9.86e-11 7.476e-13
2      4.826 3.35e+05     1161 1.00e-10 7.894e-13
3      3.637 4.99e+05     2698 1.02e-10 1.256e-12
4      3.507 9.34e+05     8701 5.68e-11 1.246e-12
5      1.048 3.47e+05     1047 5.30e-11 3.807e-13
6      1.029 3.75e+05     1350 5.38e-11 4.601e-13
C:\Users\klz\NMRData\klz\DavidHThompsonLab\13\pdata\1\2rr
Diffusion Analysis











Figure A.32: Filipin Staining Experiments Showing Cholesterol Efflux From npc2-/- Fibroblasts. 
 
Fitted function: f (x) = A * exp (-D * x^2 * gamma^2 *
littleDelta^2 (bigDelta-littleDelta/3)* 10^4
used gamma: 26752 rad/(s*Gauss)
used little delta: 0.0010000 s
used big delta: 0.020000 s
used gradient strength: variable
Random error estimation of data: RMS per spectrum (or trace/plane)
Systematic error estimation of data: worst case per peak scenario
Fit parameter Error estimation method: from fit using arbitray y uncertainties
Confidence level: 95%
Used peaks: peaks from
C:\Users\klz\NMRData\klz\DavidHThompso
nLab\22\pdata\101\peaklist.xml
Used integrals: peak intensities
Used Gradient strength: all values (including replicates) used
Peak name F2 [ppm] A error D [m2/s] error
1      4.836 3.46e+05     2016 9.32e-11 1.241e-12
2      4.825 3.49e+05     1833 9.82e-11 1.176e-12
3      3.635 4.68e+05     3339 9.54e-11 1.554e-12
4      3.508 4.60e+06 4.098e+04 3.60e-11 8.395e-13
5      1.049 2.99e+05     1285 3.38e-11 3.880e-13
6      1.030 2.93e+05     1732 3.49e-11 5.464e-13
C:\Users\klz\NMRData\klz\DavidHThompsonLab\22\pdata\1\2rr
Diffusion Analysis
Page 3 of 5
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Figure B.1: IR800CW PR Standard Curve. !!!
 



























Figure B.3: IR800CW F68 PR Timecourse. !!
!
Figure B.4: IR800CW L64 PR Timecourse. !!
24 h 48 h 
120 h 





Figure B.5: IR800CW L81 PR Timecourse. !!!
!
Figure B.6: IR800CW PR 24 h Organ Distribution. !
24 h 48 h 
120 h 
L35 L64 L81 
F68 F127 
1 - Heart 
2 - Lung 
3 - Liver 
4 - Spleen 
6 - Intestine 





























Figure B.7: IR800CW PR 120 h Organ Distribution. !!!
!
Figure B.8: IR800CW PR Organ Distribution Radiant Efficiency. !!
L35 L64 L81 
F68 F127 
1 - Heart 
2 - Lung 
3 - Liver 
4 - Spleen 
5 - Kidney 
1 2 
3 4 5 
6 
6 - Intestine 
1 2 
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Figure B.9: Gd3+:HP PR Organ/Body Weight Ratios 21 Days After Administration. !!!!
!












































































































Figure B.11: Additional Serum Chemistry 21 Days after Gd3+:HP PR Administration. !!!
!
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Figure B.13: Gd3+:HP PR Mediated Human Red Blood Cell Hemolysis.  !!!
Table B.1: Full Protein Corona For Gd3+:HP-β-CD F127 PR  !
Protein ID Percent PR Corona 
Apolipoprotein A-I 23.68948669 
Complement C3 8.263679457 
Serum albumin 8.220708843 
Apolipoprotein A-II 7.051049504 
Apolipoprotein C-III 5.251471188 
Apolipoprotein C-I 5.213928823 
Apolipoprotein C-II 4.642077285 
Ig kappa chain C region 4.499298055 
Apolipoprotein E 4.059720575 
Ig gamma-1 chain C region 2.983669078 
Apolipoprotein A-IV 2.4906027 
Alpha-2-HS-glycoprotein 1.849838394 
Complement component C9 1.76530601 
Clusterin 1.343077522 
Transthyretin 1.188196742 
Complement component C8 gamma chain 1.177818036 
Ig lambda-1 chain C regions 1.129279556 
Ig gamma-2 chain C region 0.842647227 
Gd3+:HP F127 PR  
Gd3+:HP L35 PR  Gd3+:HP L64 PR  
Gd3+:HP L81 PR  
Triton X-100 PBS 1 µg/mL 5 µg/mL 20 µg/mL Triton X-100 PBS 1 µg/mL 5 µg/mL 20 µg/mL 
Triton X-100 PBS 1 µg/mL 5 µg/mL 20 µg/mL Triton X-100 PBS 1 µg/mL 5 µg/mL 20 µg/mL 
!!
218 
Apolipoprotein D 0.812863719 
Alpha-1-antitrypsin 0.77790649 
Complement C5 0.727512772 
Complement component C6 0.682837914 
Platelet factor 4 0.579958284 
Serum amyloid A-4 protein 0.568312149 
Ig mu chain C region 0.537593438 
Ig lambda-2 chain C regions 0.52351147 




Complement component C8 alpha chain 0.394673404 
Alpha-1-acid glycoprotein 1 0.388432005 
Ig alpha-1 chain C region 0.360224829 
Complement component C7 0.350408181 
Complement C4-B 0.348490537 
Properdin 0.34043785 
Apolipoprotein B-100 0.315072774 
Serum amyloid A-1 protein 0.306051745 
Prothrombin 0.281454303 
Ig kappa chain V-III region 0.275511648 
Haptoglobin 0.262253153 
Ig heavy chain V-III region  0.259189982 
Complement component C8 beta chain 0.258203987 
Alpha-2-macroglobulin 0.213920632 
Ig kappa chain V-I region  0.211241187 
Ig kappa chain V-IV region  0.183280206 
Antithrombin-III 0.158366291 
Coagulation factor X 0.152111554 
Serum amyloid P-component 0.107284277 
Apolipoprotein M 0.103351409 
Secreted phosphoprotein 24 0.097129455 
Serum paraoxonase/arylesterase 1 0.093964233 
Vitamin K-dependent protein C 0.086723995 
Inter-alpha-trypsin inhibitor heavy chain H2 0.083963117 
Histidine-rich glycoprotein 0.077874255 
Hemopexin 0.065339865 
Ig kappa chain V-I region 0.064885988 
Hemoglobin subunit beta 0.064873797 
Plasma protease C1 inhibitor 0.061897832 
Inter-alpha-trypsin inhibitor heavy chain H4 0.056681786 
Ig gamma-4 chain C region 0.055677006 
Integrin alpha-M 0.054038598 
Alpha-1-microglobulin 0.051589591 
Alpha-S1-casein 0.049818026 
Hemoglobin subunit alpha 0.048519382 
Alpha-1-acid glycoprotein 2 0.048075723 




Complement factor B 0.045937114 
Alpha-1-antichymotrypsin 0.043530752 
Complement factor H 0.043322168 
Apolipoprotein(a) 0.04317659 
Haptoglobin-related protein 0.040441025 
Hemoglobin subunit alpha 0.037714761 
C4b-binding protein alpha chain 0.033862303 
Fibronectin 0.033549542 
Phospholipid transfer protein 0.032842187 
Virion-packaging protein  0.032486179 
Coagulation factor IX 0.03179155 
Alpha-1B-glycoprotein 0.030934665 
Vitamin D-binding protein 0.028933039 
Lipopolysaccharide-binding protein 0.028903828 
Myosin light chain 4 0.027195711 
Coagulation factor VII 0.025920957 
Ig gamma-3 chain C region 0.024733054 
Dystrophin 0.024004662 
Apolipoprotein F 0.023305555 
Inter-alpha-trypsin inhibitor heavy chain H1 0.022148596 
Apolipoprotein L1 0.021885655 
Gelsolin 0.019207083 
Protein S100-A7 0.018603779 
Heparin cofactor 2 0.017337087 
Ig lambda chain V-III region LOI 0.016265495 
Ig mu heavy chain disease protein 0.01389369 
Coagulation factor V 0.013161321 
Bovine serum albumin precursor 0.012433301 
Vitamin K-dependent protein S 0.012332399 
Complement factor H-related protein 1 0.012249404 
Retinol-binding protein 4 0.01212186 
Glyceraldehyde-3-phosphate dehydrogenase 0.010818937 
Alpha-2-antiplasmin 0.010512345 
Zinc-alpha-2-glycoprotein 0.010305449 
Complement C4-A 0.008968295 
Plasminogen 0.008951262 
Angiotensinogen 0.008415168 
Vitamin K-dependent protein Z 0.007606276 
Melanoma-associated antigen B3 0.007489954 
Ig alpha-2 chain C region 0.007414991 
Beta-2-glycoprotein 1 0.006513962 
Alstrom syndrome protein 1 0.004523926 
Junction plakoglobin 0.003855662 
Thyroid receptor-interacting protein 11 0.003446788 
Fibrinogen alpha chain 0.002542826 
Filaggrin-2 0.002270906 
Inter-alpha-trypsin inhibitor heavy chain H3 0.001997603 
Hyaluronan-binding protein 2 0.00129618 
!!
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Table B.2: Full Protein Corona For Gd3+:HP-β-CD F68 PR !
Protein ID Percent PR Corona 
Apolipoprotein A-I 31.99542965 
Apolipoprotein A-II 9.218839973 
Apolipoprotein C-III 6.672272054 
Apolipoprotein C-II 6.659471591 
Apolipoprotein C-I 6.290285153 
Complement C3 6.13462544 
Alpha-2-HS-glycoprotein 4.46555885 
Serum albumin 3.993341851 
Apolipoprotein E 2.655028306 
Apolipoprotein A-IV 2.448874185 
Ig kappa chain C region 2.033188027 
Complement component C9 1.538969444 
Clusterin 1.485710311 
Ig gamma-1 chain C region 1.202353223 
Complement component C8 gamma chain 1.134662774 
Apolipoprotein D 1.127944085 
Prothrombin 0.813765188 
Serum amyloid A-4 protein 0.797553547 
Transthyretin 0.788184866 
Ig lambda-1 chain C regions 0.644944697 
Complement component C6 0.584552077 
Complement C5 0.511521581 
Vitronectin 0.424684704 
Alpha-1-antitrypsin 0.371398632 
Ig gamma-2 chain C region 0.365379064 
Complement component C8 alpha chain 0.351054313 
Ig mu chain C region 0.336750745 
Coagulation factor X 0.328234473 
Complement component C7 0.305902386 
Vitamin K-dependent protein C 0.270904472 
Apolipoprotein C-IV 0.265705108 
Properdin 0.258461451 
Apolipoprotein B-100 0.211974335 
Ig lambda-2 chain C regions 0.191403458 
Complement component C8 beta chain 0.183038036 
Serum amyloid A-1 protein 0.161193182 
Complement C4-B 0.151806751 
Ig alpha-1 chain C region 0.138911016 




Ig heavy chain V-III region 0.132940282 
Serotransferrin 0.131142529 
Secreted phosphoprotein 24 0.116843661 
Kininogen-1;Kininogen-1 heavy chain 0.114281305 
Ig kappa chain V-I region  0.108644652 
Alpha-1-acid glycoprotein 1 0.106762106 
Platelet factor 4 0.087991827 
Ig kappa chain V-IV region 0.087919773 
Antithrombin-III 0.081305193 
Alpha-2-macroglobulin 0.079591525 
Coagulation factor VII 0.067886684 
Coagulation factor IX 0.058775535 
Integrin alpha-M 0.055784832 
Serum paraoxonase/arylesterase 1 0.053473618 
Apolipoprotein M 0.050678852 
Myosin light chain 4 0.049670782 
Inter-alpha-trypsin inhibitor heavy chain H2 0.042035827 
Apolipoprotein(a) 0.041214205 
Vitamin K-dependent protein S 0.037175123 
Complement factor B 0.034587627 
Vitamin K-dependent protein Z 0.033661102 
Ig kappa chain V-I region CAR 0.033567277 
Virion-packaging protein 0.029101171 
C4b-binding protein alpha chain 0.028870479 
Hemoglobin subunit beta 0.0283774 
Lipopolysaccharide-binding protein 0.025215943 
Hemopexin 0.025212402 
Ig gamma-4 chain C region 0.025077765 
Zinc finger FYVE domain-containing protein 1 0.02419474 
Serum amyloid P-component 0.023928273 
Histidine-rich glycoprotein 0.023246885 
Plasma protease C1 inhibitor 0.022726697 
Inter-alpha-trypsin inhibitor heavy chain H4 0.020428572 
Alpha-1-microglobulin 0.020253214 
Apolipoprotein F 0.019206169 
Fibronectin 0.018752376 
Complement factor H 0.017938007 
Haptoglobin-related protein 0.017677155 
Apolipoprotein L1 0.01756036 
Hemoglobin subunit alpha 0.017467754 
Vitamin D-binding protein 0.017167583 
Alpha-1-acid glycoprotein 2 0.014494482 
Ceruloplasmin 0.014024362 
Zinc-alpha-2-glycoprotein 0.01331371 






Phospholipid transfer protein 0.010301834 
Melanoma-associated antigen B3 0.009708493 
Ig lambda chain V-III region  0.008128606 
Dystrophin 0.006729086 
Glyceraldehyde-3-phosphate dehydrogenase 0.006254356 
Heparin cofactor 2 0.006079758 
Coagulation factor V 0.005818274 
Inter-alpha-trypsin inhibitor heavy chain H1 0.005259805 
Thyroid receptor-interacting protein 11 0.005250333 
Ig alpha-2 chain C region 0.004713103 
Ig mu heavy chain disease protein 0.004651338 
Plasminogen 0.004113757 
Complement C4-A 0.003394206 
Beta-2-glycoprotein 1 0.003332363 
Fibrinogen alpha chain 0.003322615 
Retinol-binding protein 4 0.003282424 
Junction plakoglobin 0.00198218 
Alpha-2-antiplasmin 0.001665667 
Angiotensinogen 0.00158319 
Serum albumin precursor 0.001457638 
Inter-alpha-trypsin inhibitor heavy chain H3 0.000896388 
Filaggrin-2 0.000809962 





Table B.3: Full Protein Corona For Gd3+:HP-β-CD L35 PR  !
Protein ID Percent PR Corona 
Vitronectin 12.83014065 
Apolipoprotein C-III 7.994388561 
Serum albumin 6.900445584 
Apolipoprotein C-II 6.722644919 
Apolipoprotein A-II 6.460543675 
Ig kappa chain C region 5.106817942 
Hyaluronan-binding protein 2 4.756287373 
Complement C3 4.653739172 
Apolipoprotein A-I 4.456003931 
Clusterin 3.557088095 
Ig gamma-1 chain C region 3.123661581 
Apolipoprotein E 2.78340154 
Apolipoprotein C-I 2.694849924 
Ig lambda-1 chain C regions 1.925077969 
Prothrombin 1.913831307 
Ig mu chain C region 1.371190996 
Inter-alpha-trypsin inhibitor heavy chain H2 1.220287554 
Platelet factor 4 1.155834789 
!!
223 
Apolipoprotein D 1.14725169 
Transthyretin 1.040334076 
Complement C4-B 1.0396153 
Apolipoprotein A-IV 0.984705935 
Alpha-2-HS-glycoprotein 0.837271274 
Ig lambda-2 chain C regions 0.763197687 
Alpha-2-antiplasmin 0.761857589 
Alpha-1-antitrypsin 0.74847711 
Ig gamma-2 chain C region 0.71790249 
Complement component C9 0.684143621 
Ig heavy chain V-III region BRO 0.57254594 
Serum paraoxonase/arylesterase 1 0.543715789 
Inter-alpha-trypsin inhibitor heavy chain H1 0.510336179 
Apolipoprotein B-100 0.471271247 
Apolipoprotein M 0.469243498 
Ig alpha-1 chain C region 0.460902948 
Serum amyloid A-4 protein 0.450129272 
Apolipoprotein C-IV 0.384815461 
Antithrombin-III 0.378568664 
Phospholipid transfer protein 0.362558495 
Serum amyloid A-1 protein 0.362468608 
Apolipoprotein F 0.356046797 
Vitamin K-dependent protein C 0.342648542 
Alpha-1-microglobulin 0.33603681 
Haptoglobin  0.312616949 
Coagulation factor X 0.310989243 
Serotransferrin 0.278797984 
Ig kappa chain V-III region  0.275119207 
Ig kappa chain V-IV region 0.271003853 
Alpha-1-acid glycoprotein 1 0.255279118 
Galectin-3-binding protein 0.242933872 
Coagulation factor IX 0.214829598 
Secreted phosphoprotein 24 0.202161722 
Ig kappa chain V-I region WAT 0.196739734 
ATM interactor 0.196053693 
Inter-alpha-trypsin inhibitor heavy chain H3 0.193857071 
Vitamin K-dependent protein Z 0.181873137 
Complement component C8 gamma chain 0.162488848 
Haptoglobin-related protein 0.159558871 
Serum albumin precursor 0.152009542 
Complement C5 0.135913718 
Alpha-2-macroglobulin 0.118851938 
Complement component C6 0.116367636 
Kininogen-1 0.115004353 
Inter-alpha-trypsin inhibitor heavy chain  0.082429201 
Apolipoprotein(a) 0.081398177 
Plasma protease C1 inhibitor 0.080776568 
Ig kappa chain V-I region  0.075748873 
Complement component C8 alpha chain 0.061999252 
!!
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Complement factor H 0.059623033 
Properdin 0.057301549 
Melanoma-associated antigen B3 0.057204784 
Complement component C7 0.051996426 
Hemopexin 0.051530336 
Alpha-1-acid glycoprotein 2 0.044049449 
Complement component C8 beta chain 0.041599954 
C4b-binding protein alpha chain 0.039647186 
Trypsin-3 0.039063791 
Apolipoprotein L1 0.038808678 
Alpha-1-antichymotrypsin 0.035346266 
Fibronectin 0.034286961 
Ig mu heavy chain disease protein 0.033488025 
Histidine-rich glycoprotein 0.03332859 
Coagulation factor VII 0.029976776 
Lipopolysaccharide-binding protein 0.028507289 
Ig gamma-4 chain C region 0.028422687 
Ig gamma-3 chain C region 0.027383973 
Ceruloplasmin 0.027217812 
Zinc finger FYVE domain-containing protein 1 0.026894805 
Alpha-1B-glycoprotein 0.026457563 
Serum amyloid P-component 0.025255192 
Complement factor H-related protein 3 0.024630404 
Angiotensinogen 0.022646486 
Virion-packaging protein  0.022320933 
Complement factor B 0.020601153 
Gelsolin 0.019936472 
Vitamin K-dependent protein S 0.019160592 
Ig lambda chain V-III region 0.017913911 
Complement C4-A 0.017281794 
Vitamin D-binding protein 0.016991855 
Heparin cofactor 2 0.014825762 
Hemoglobin subunit alpha 0.012862119 
Ig lambda-3 chain C regions 0.011874866 
Hemoglobin subunit alpha 0.0116793 
Plasminogen 0.010348966 
Hemoglobin subunit beta 0.010266856 
Lumican 0.008654928 
Ig alpha-2 chain C region 0.00833412 
Zinc-alpha-2-glycoprotein 0.007584108 
Retinol-binding protein 4 0.007340766 
Beta-2-glycoprotein 1 0.007284382 
Junction plakoglobin 0.006746253 
Coagulation factor V 0.006657744 
Dystrophin 0.006337971 
Glyceraldehyde-3-phosphate dehydrogenase 0.00481623 
Thyroid receptor-interacting protein 11 0.004010944 
BPI fold-containing family B member 1 0.003884575 
Complement factor H-related protein 1 0.003142598 
!!
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Protein Z-dependent protease inhibitor 0.002767364 
Alstrom syndrome protein 1 0.002165109 
Filaggrin-2 0.001187266 
Fibrinogen alpha chain 0.00110959 






Table B.4: Full Protein Corona For Gd3+:HP-β-CD L64 PR 
 
Protein ID Percent PR Corona 
Transthyretin 36.92882834 
Apolipoprotein C-III 5.640337171 
Apolipoprotein A-I 5.343226422 
Prothrombin 4.491836376 
Serum albumin 4.453993079 
Apolipoprotein C-II 3.932134511 
Apolipoprotein A-IV 3.646873692 
Hyaluronan-binding protein 2 3.404816171 
Vitronectin 3.20820959 
Inter-alpha-trypsin inhibitor heavy chain H2 2.468669522 
Clusterin 2.390341589 
Apolipoprotein A-II 2.116701292 
Ig kappa chain C region 2.007984058 
Complement C3 1.904499153 
Inter-alpha-trypsin inhibitor heavy chain H1 1.447922545 
Alpha-2-HS-glycoprotein 1.424555287 
Alpha-1-microglobulin 1.42007729 
Inter-alpha-trypsin inhibitor heavy chain H3 1.206435029 
Ig gamma-1 chain C region 1.005444601 
Apolipoprotein E 1.004896536 
Complement C4-B 0.926836926 
Apolipoprotein C-I 0.909890523 
Retinol-binding protein 4 0.804254485 
Alpha-1-antitrypsin 0.767491151 
Ig lambda-1 chain C regions 0.606262844 
Antithrombin-III 0.538761909 
Kininogen-1 0.477711863 
Platelet factor 4 0.473345395 
Plasma protease C1 inhibitor 0.469965752 
Complement component C9 0.403608715 
Apolipoprotein D 0.351008701 
Serum amyloid A-1 protein 0.272371526 





Ig gamma-2 chain C region 0.192116812 
Apolipoprotein F 0.143355345 
Ceruloplasmin 0.137814099 
Ig lambda-2 chain C regions 0.135135608 
Ig alpha-1 chain C region 0.134466404 
Integrin alpha-M 0.129901011 
Apolipoprotein C-IV 0.11797449 
Vitamin K-dependent protein C 0.111432101 
Alpha-2-antiplasmin 0.109772303 
Coagulation factor X 0.108681552 
Alpha-1-acid glycoprotein 1 0.089894765 
Haptoglobin 0.085065625 
Serum paraoxonase/arylesterase 1 0.080363152 
Ig kappa chain V-III region  0.074537397 
Coagulation factor IX 0.073994393 
ATM interactor 0.071650532 
Serotransferrin 0.06452884 
Heparin cofactor 2 0.062297109 
Apolipoprotein B-100 0.059946943 
Complement component C8 gamma chain 0.059632176 
Ig kappa chain V-IV region Len 0.054765379 
Ig mu chain C region 0.049350375 
Apolipoprotein M 0.04492418 
Complement C1s subcomponent 0.038062794 
Vitamin K-dependent protein S 0.03651887 
Serum amyloid A-4 protein 0.035002193 
Complement C5 0.033944174 
Alpha-2-macroglobulin 0.033293991 
Coagulation factor V 0.032879545 
Secreted phosphoprotein 24 0.028040823 
Vitamin K-dependent protein Z 0.025804357 
Inter-alpha-trypsin inhibitor heavy chain  0.025693961 
Complement component C6 0.025578459 
Fibronectin 0.024755654 
Properdin 0.022761783 
Ig heavy chain V-III region  0.018972975 
Alpha-1-acid glycoprotein 2 0.018430936 
Complement C4-A 0.017760539 
Complement component C8 beta chain 0.017112765 
Complement component C8 alpha chain 0.015196272 
Alpha-1B-glycoprotein 0.013571499 
Hemopexin 0.01255781 
Virion-packaging protein 0.012410339 
Angiotensinogen 0.011667359 
Zinc finger FYVE domain-containing protein 1 0.011378758 
Coagulation factor VII 0.010987358 
Ig lambda chain V-III region LOI 0.01007801 
Lipopolysaccharide-binding protein 0.009771991 
Protein Z-dependent protease inhibitor 0.009585967 
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Histidine-rich glycoprotein 0.009491318 
C4b-binding protein alpha chain 0.009006857 
Carboxypeptidase N subunit 2 0.008879723 
Ig gamma-4 chain C region 0.008588134 
Haptoglobin-related protein 0.008343286 
Complement component C7 0.007963676 
Apolipoprotein(a) 0.00794482 
Gelsolin 0.00728464 
Complement factor B 0.007281434 
Hemoglobin subunit beta 0.006780236 
Vitamin D-binding protein 0.006760971 
Apolipoprotein L1 0.005780626 
Peptidase inhibitor 16 0.004961467 
Biotinidase 0.00489594 
Galectin-3-binding protein 0.004892097 
Zinc-alpha-2-glycoprotein 0.003960639 
Fibulin-1 0.003926677 
Complement factor H 0.003322653 
Insulin-like growth factor-binding protein complex acid labile subunit 0.003030425 
Ig gamma-3 chain C region 0.002981662 
Ig alpha-2 chain C region 0.002334308 
Melanoma-associated antigen B3 0.002300667 
Phospholipid transfer protein 0.002270665 
Hemoglobin subunit alpha 0.002193323 
Golgi-specific brefeldin A-resistance guanine nucleotide exchange 
factor 1 
0.001694413 
Glyceraldehyde-3-phosphate dehydrogenase 0.001387415 
Dystrophin 0.001274781 
Bovine serum albumin precursor 0.001250752 
Alstrom syndrome protein 1 0.001086554 
Beta-2-glycoprotein 1 0.000922916 
Thyroid receptor-interacting protein 11 0.000645284 
Complement factor H-related protein 1 0.000311923 





Table B.5: Full Protein Corona For Gd3+:HP-β-CD L81 PR 
 
Protein ID Percent PR Corona 
Serum albumin 17.11418567 
Apolipoprotein C-III 10.94908584 
Apolipoprotein A-I 7.466318677 
Ig kappa chain C region 7.203133214 
Apolipoprotein C-I 7.167013517 
Complement C3 6.622339883 
Apolipoprotein C-II 6.557470377 
!!
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Ig gamma-1 chain C region 4.653725509 
Clusterin 4.096785956 
Apolipoprotein E 2.366180581 
Apolipoprotein A-II 2.053647321 
Ig lambda-1 chain C regions 1.777470732 
Transthyretin 1.66188389 
Complement C4-B 1.646949368 
Alpha-1-antitrypsin 1.440540318 
Ig gamma-2 chain C region 1.208887267 
Complement component C9 1.084131271 
Apolipoprotein A-IV 0.985567942 
Ig mu chain C region 0.851889708 
Alpha-2-HS-glycoprotein 0.820199699 
Serotransferrin 0.763060085 
Ig lambda-2 chain C regions 0.709683265 
Vitronectin 0.691084103 
Apolipoprotein B-100 0.605295156 
Ig alpha-1 chain C region 0.54865245 
Haptoglobin 0.513437652 
Apolipoprotein C-IV 0.49431673 
Apolipoprotein D 0.491007078 
Ig heavy chain V-III region  0.474002846 
Ig kappa chain V-III region 0.412235808 
Alpha-1-acid glycoprotein 1 0.325917387 
Alpha-2-macroglobulin 0.270595297 
Ig kappa chain V-IV region 0.26032636 




Complement component C8 gamma chain 0.208190854 
Complement factor H 0.208154523 
Complement C5 0.207399227 
Integrin alpha-M 0.19222514 
ATM interactor 0.189552396 
Secreted phosphoprotein 24 0.18123971 
Ig kappa chain V-I region 0.169103338 
Serum amyloid A-4 protein 0.165667627 
Apolipoprotein M 0.160574074 
Serum paraoxonase/arylesterase 1 0.149060121 
Complement component C6 0.132584484 
Inter-alpha-trypsin inhibitor heavy chain H2 0.12542807 
C4b-binding protein alpha chain 0.116129399 
Lipopolysaccharide-binding protein 0.098632283 
Haptoglobin-related protein 0.097369727 
Plasma protease C1 inhibitor 0.09432651 
Inter-alpha-trypsin inhibitor heavy chain H4 0.094258288 




Ig gamma-4 chain C region 0.08122044 
Ceruloplasmin 0.080970148 
Hemopexin 0.078256929 
Serum amyloid A-1 protein 0.069949226 
Apolipoprotein(a) 0.068815812 
Complement component C7 0.065100318 
Apolipoprotein F 0.063089415 
Coagulation factor IX 0.059848337 
Zinc finger FYVE domain-containing protein 1 0.059628285 
Alpha-1-antichymotrypsin 0.058212412 
Alpha-1B-glycoprotein 0.056996919 
Vitamin K-dependent protein C 0.055856779 
Complement factor B 0.05464146 
Serum amyloid P-component 0.053646413 
Apolipoprotein L1 0.053048689 
Fibronectin 0.052225051 
Ig gamma-3 chain C region 0.051516351 
Coagulation factor X 0.048804145 
Trypsin-3 0.048100147 
Heparin cofactor 2 0.047674481 
Histidine-rich glycoprotein 0.046309415 
Alpha-1-microglobulin 0.04590583 
Gelsolin 0.043439513 
Complement component C8 beta chain 0.041366985 
Inter-alpha-trypsin inhibitor heavy chain H1 0.041269102 
Hemoglobin subunit alpha 0.038360329 
Coagulation factor VI 0.038250484 
Vitamin D-binding protein 0.036154865 
Alpha-2-antiplasmin 0.030340658 
Platelet factor 4 0.028203418 
Melanoma-associated antigen B3 0.02780215 
Hemoglobin subunit beta 0.027551364 
Plasminogen 0.026457209 
Virion-packaging protein UL25 0.026188993 
Protein S100-A7 0.025486454 
Beta-2-glycoprotein 1 0.022188076 
Vitamin K-dependent protein Z 0.019566054 
Complement C4-A 0.017411295 
Ig lambda chain V-III region LOI 0.016635952 
Ig alpha-2 chain C region 0.014571562 
Vitamin K-dependent protein S 0.012993529 
Angiotensinogen 0.012544486 
Complement factor H-related protein 1 0.012294497 
Dystrophin 0.011698827 
Sorting nexin-25 0.011139946 
Glyceraldehyde-3-phosphate dehydrogenase 0.009815528 
Ig mu heavy chain disease protein 0.009751499 
Hemoglobin subunit alpha 0.009114132 
Inter-alpha-trypsin inhibitor heavy chain H3 0.007733188 
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Hyaluronan-binding protein 2 0.007700139 
Zinc-alpha-2-glycoprotein 0.005453507 
Myosin light chain 4 0.005418754 
Complement C1s subcomponent 0.005384176 
Thyroid receptor-interacting protein 11 0.005323248 
BPI fold-containing family B member 1 0.004398327 
Alstrom syndrome protein 1 0.004326538 
Lumican 0.004006985 
Junction plakoglobin 0.003557358 
Coagulation factor V 0.003300065 
Filaggrin-2 0.003163411 
Bovine serum albumin precursor 0.002865957 










Figure C.1: Representative Human Red Blood Cell Hemolysis of Various Threaded PRs. !!!!
!
Figure C.2: Venn Diagram of Protein Coronas for PRs Threaded with Various CDs !!!!!!























Table C.1: Full Protein Corona For 100% Me-β-CD PR !
Protein ID Percent PR Corona 
Complement C3 17.35131077 
Apolipoprotein E 16.92263363 
Serum albumin 10.91695191 
Apolipoprotein B-100 6.069452089 
Ig gamma-1 chain C region 5.337392476 
Ig kappa chain C region 5.311549879 
Apolipoprotein A-II 5.010290265 
Apolipoprotein D 3.573277261 
Complement component C9 3.421953775 
Apolipoprotein A-I 2.773780863 
Complement C4-B 2.147698529 
Serum paraoxonase/arylesterase 1 1.574657144 
Apolipoprotein C-II 1.53214378 
Apolipoprotein C-III 1.49304561 




Serum amyloid A-4 protein 0.928412544 
Ig lambda-1 chain C regions 0.864075528 
Ig gamma-2 chain C region 0.723246176 
Complement component C8 gamma chain 0.67356527 
Alpha-1-antitrypsin 0.599975658 
Ig alpha-1 chain C region 0.575594754 
Complement C5 0.533477927 
Ig lambda-2 chain C regions 0.530984734 
Apolipoprotein A-IV 0.471891492 
Vitronectin 0.441088529 
Haptoglobin 0.426356289 
Complement component C6 0.425590389 
StAR-related lipid transfer protein 13 0.384695112 
Complement component C8 alpha chain 0.360745597 
Apolipoprotein M 0.359177197 
Ig mu chain C region 0.355445431 
Trypsin-3 0.316173635 
Complement C3 precursor 0.314145462 
Serotransferrin 0.291926866 
Ig kappa chain V-III region  0.219937471 
Alpha-2-macroglobulin 0.180829896 
Ig kappa chain V-II Region 0.159345924 
Ig kappa chain V-IV region 0.151155363 
Complement component C7 0.138784673 
Complement component C8 beta chain 0.125416043 
Alpha-2-HS-glycoprotein 0.122913118 
Alpha-1-acid glycoprotein 1 0.116044253 
Bovine serum albumin precursor 0.11226316 
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Virion-packaging protein  0.104959681 
Ig heavy chain V-III region  0.091750199 
Prothrombin 0.091467918 
Complement factor B 0.088788385 
Kininogen-1 0.084874068 
Apolipoprotein C-IV 0.066036277 
Complement factor H 0.064479154 
C4b-binding protein alpha chain 0.059855223 
Ig gamma-3 chain C region 0.053852204 
Inter-alpha-trypsin inhibitor heavy chain H2 0.052548384 
Antithrombin-III 0.051148376 
Alpha-1-acid glycoprotein 2 0.04660158 
Integrin alpha-M 0.044774863 
Ig gamma-4 chain C region 0.040199133 
Fibronectin 0.039148087 
Properdin 0.034597398 
Ig lambda-3 chain C regions 0.031109361 
Kinesin-like protein KIF14 0.027876126 
Plasminogen 0.026237346 
Hemopexin 0.022435728 
Vitamin D-binding protein 0.022092966 
Complement C4-A 0.019611471 
Thyroid receptor-interacting protein 11 0.01757897 
Haptoglobin-related protein 0.015992161 
Ceruloplasmin 0.014079815 
Lipopolysaccharide-binding protein 0.010576861 
Apolipoprotein L1 0.008129117 




Table C.2: Full Protein Corona For 100% β-CD PR 
 
Protein ID Percent PR Corona 
Serum albumin 16.53602536 
Ig kappa chain C region 15.00432799 
Complement C3 11.74536491 
Ig gamma-1 chain C region 7.757086463 
Apolipoprotein E 5.161341666 
Apolipoprotein A-II 4.808387011 
Apolipoprotein D 4.074641027 
Apolipoprotein A-I 3.408645335 
Ig lambda-1 chain C regions 3.358983503 
Apolipoprotein B-100 2.938530875 
Complement component C9 2.077125525 





Apolipoprotein C-I 1.370046556 
Clusterin 1.286344099 
Ig lambda-2 chain C regions 1.184513069 
Haptoglobin 1.173103474 
Serotransferrin 1.119652755 
Complement C4-B 1.090155363 
Ig alpha-1 chain C region 0.910046172 
Apolipoprotein C-III 0.785609786 
Ig kappa chain V-III region 0.711515336 
Apolipoprotein(a) 0.611002255 
Alpha-2-HS-glycoprotein 0.599766338 
Serum amyloid A-4 protein 0.526835897 
Ig kappa chain V-IV region 0.41330472 
Vitronectin 0.399344949 
Apolipoprotein C-II 0.396346063 
Alpha-1-acid glycoprotein 1 0.368698926 
Complement component C8 gamma chain 0.352681316 
Apolipoprotein A-IV 0.33923101 
Prothrombin 0.338574104 
Ig mu chain C region 0.330838953 
Ig kappa chain V-II region  0.315459061 
Complement C5 0.309866416 
Alpha-2-macroglobulin 0.25471217 
Complement component C6 0.223347339 
Serum paraoxonase/arylesterase 1 0.201263818 
Trypsin-3 0.17630581 
Ig heavy chain V-III region 0.13827517 
Ig lambda-3 chain C regions 0.132262268 
Alpha-1B-glycoprotein 0.125124813 
Apolipoprotein M 0.120461273 
StAR-related lipid transfer protein 13 0.115661118 
Kininogen-1 0.106938194 
Complement factor H-related protein 3 0.102301557 
Ig gamma-4 chain C region 0.098285175 
Complement component C8 alpha chain 0.09588706 
Complement factor H 0.093727719 
Complement component C8 beta chain 0.083179893 
Vitamin K-dependent protein S 0.081113763 
Hemopexin 0.071740997 
Ceruloplasmin 0.070374189 
Serum amyloid P-component 0.06797167 
Integrin alpha-M 0.067079838 
Alpha-1-acid glycoprotein 2 0.065530194 
Inter-alpha-trypsin inhibitor heavy chain H2 0.064962681 
Complement component C7 0.060031227 
Ig kappa chain V-I region 0.057912853 
Antithrombin-III 0.056426389 
Ig gamma-3 chain C region 0.051334256 
C4b-binding protein alpha chain 0.051141564 
!!
235 
Hemoglobin subunit alpha 0.05083386 
Vitamin D-binding protein 0.0465446 
Immunoglobulin J chain 0.046265831 
Complement factor B 0.044157128 
Plasma protease C1 inhibitor 0.043953647 
Fibronectin 0.039297599 
Haptoglobin-related protein 0.032577358 
Virion-packaging protein UL25  0.027102111 
Plasminogen 0.026321724 
Ig alpha-2 chain C region 0.023512734 
Alpha-1-microglobulin 0.019298157 
Inter-alpha-trypsin inhibitor heavy chain H1 0.017941292 
Properdin 0.017598707 
Beta-2-glycoprotein 1 0.016747021 
Kinesin-like protein KIF14 0.014765174 
Inter-alpha-trypsin inhibitor heavy chain H4 0.013872733 
Thyroid receptor-interacting protein 11 0.012113308 
Hemoglobin subunit alpha 0.011058311 
Histidine-rich glycoprotein 0.009965854 
Retinol-binding protein 4 0.008762275 
Complement C4-A 0.00807529 
Ig lambda chain V-III region LOI 0.007280351 
Inter-alpha-trypsin inhibitor heavy chain H3 0.006762819 
Heparin cofactor 2 0.004492358 !!!
Table C.3: Full Protein Corona For Mixed 50:50 HP-β-CD: SBE-β-CD PR !
Protein ID Percent PR Corona 
Complement C3 19.76495094 
Apolipoprotein E 12.28036258 
Serum albumin 9.427281564 
Apolipoprotein A-II 6.865297508 
Apolipoprotein C-II 6.692607783 
Ig gamma-1 chain C region 5.92949059 
Ig kappa chain C region 4.87297314 
Apolipoprotein B-100 4.636129789 
Complement component C9 3.846580792 
Apolipoprotein D 3.114959404 
Apolipoprotein A-I 2.537299079 
Complement C4-B 2.083473432 
Trypsin-3 2.050791718 
Apolipoprotein C-III 1.876260875 
StAR-related lipid transfer protein 13 1.437949237 






Ig lambda-1 chain C regions 0.797377646 
Transthyretin 0.508421658 
Ig kappa chain V-III region 0.472864812 
Complement C5 0.409102322 
Ig lambda-2 chain C regions 0.408439993 
Vitronectin 0.386887198 
Virion-packaging protein UL25  0.373320683 
Alpha-2-HS-glycoprotein 0.370567282 
Ig alpha-1 chain C region 0.351367489 
Complement component C6 0.35043853 
Complement component C8 alpha chain 0.338142243 
Serotransferrin 0.322695802 
Prothrombin 0.312206117 
Apolipoprotein A-IV 0.288919612 
Apolipoprotein M 0.282081709 
Ig kappa chain V-II region TEW 0.277292021 
Complement component C8 gamma chain 0.251238506 
Alpha-1-antitrypsin 0.236792051 
Serum amyloid A-4 protein 0.168315796 
Zinc finger FYVE domain-containing protein 1 0.163808249 
Ig mu chain C region 0.163277059 
Kinesin-like protein KIF14 0.159029894 
Kininogen-1 0.155152083 
Complement component C8 beta chain 0.136685208 
Alpha-2-macroglobulin 0.125795225 
Complement factor H 0.124140998 
Alpha-1-acid glycoprotein 1 0.112376881 
Complement component C7 0.086259676 
 Hemoglobin subunit alpha 0.074191017 
Integrin alpha-M 0.065432259 
C4b-binding protein alpha chain 0.06140164 
Serum paraoxonase/arylesterase 1 0.04911196 
Alpha-1B-glycoprotein 0.047913856 
Inter-alpha-trypsin inhibitor heavy chain H2 0.047756275 
Properdin 0.041372879 
Ig gamma-3 chain C region 0.040607109 
Ig gamma-4 chain C region 0.039725469 
Fibronectin 0.039566759 
Antithrombin-III 0.023736557 
Complement C4-A 0.015649696 
Plasminogen 0.013425822 
Inter-alpha-trypsin inhibitor heavy chain H4 0.011348498 !!!!
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Table C.4: Full Protein Corona For 100% HP-β-CD PR  !
Protein ID Percent PR Corona 
Serum albumin 21.76828436 
Ig kappa chain C region 19.04835025 
Apolipoprotein A-II 10.81040494 
Apolipoprotein A-I  7.919583224 
Apolipoprotein E 7.066407588 
Apolipoprotein C-II 4.992757233 
Apolipoprotein C-III 3.944752799 
Ig gamma-1 chain C region 3.311732771 
Transthyretin 1.985551149 




Ig alpha-1 chain C region 1.482215949 
Clusterin 1.035208084 
Ig lambda-1 chain C regions 0.931474445 
Ig kappa chain V-III region 0.773907913 
Apolipoprotein D 0.753715631 
Ig gamma-2 chain C region 0.647140603 
Ig lambda-2 chain C region 0.604695051 
Apolipoprotein C-I 0.577602372 
Ig kappa chain V-IV region 0.566482484 
Complement factor B 0.491751743 
Complement component C9 0.44836062 
Apolipoprotein A-IV 0.432932847 
Serum amyloid A-4 protein 0.295004027 
Alpha-1-acid glycoprotein 1 0.274771898 
Ig kappa chain V-II region  0.24360112 
Ig lambda-3 chain C regions 0.238716143 
Hemopexin 0.212616684 
Alpha-1-acid glycoprotein 2 0.193231301 
Apolipoprotein B-100 0.189701937 
Ig mu chain C region 0.184108676 
Alpha-2-HS-glycoprotein 0.183975192 
StAR-related lipid transfer protein 13 0.151046784 
Prothrombin 0.144881134 
Complement C4-B 0.121920477 
Apolipoprotein M 0.120745176 
Ig lambda chain V-IV region Hil 0.111804397 
Ig heavy chain V-III region  0.109882251 
Vitronectin 0.09080639 








Complement component C8 gamma chain 0.056231927 
Transmembrane protein 108 0.050667755 
Trypsin-3 0.050159271 
Virion-packaging protein UL25 0.037443861 
Ig gamma-4 chain C region 0.034376382 
Immunoglobulin J chain 0.027815042 
Inter-alpha-trypsin inhibitor heavy chain H2 0.023979446 
Properdin 0.019515406 
Inter-alpha-trypsin inhibitor heavy chain H1 0.018916383 
Plasma protease C1 inhibitor 0.017867315 
Complement factor H 0.014151158 
C4b-binding protein alpha chain 0.014079214 
Complement component C6 0.013544596 
Kinesin-like protein KIF14 0.010562691 
Kininogen-1 0.007878089 !!!!
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100% Me-β-CD PR 
100% β-CD PR 
50:50 HP-β-CD:SBE-β-CD PR 
 100% HP-β-CD PR 
Gd3+:DOTA F127 PR 
Gd3+:DOTA F68 PR 
Gd3+:DOTA L35 PR 
Gd3+:DOTA L64 PR 
Gd3+:DOTA L81 PR 




















Christopher J. Collins was born in Woodbridge, Virginia on October 7th, 1987. He earned a 
bachelors degree in Chemistry from the College of William and Mary in Williamsburg, VA with 
a minor in Mathematics. While at William and Mary, Christopher had the opportunity to do 
undergraduate research in two distinct laboratories. First, he worked on synthesizing polymer 
precursors for radiation shielding materials under Dr. Robert Orwoll. Later, Christopher worked 
on synthesizing and determining the thermochemical properties of pentapeptides containing 
unnatural proline derivatives in the laboratory of John C. Poutsma. In 2010, Christopher began 
his doctoral work at Purdue University under the guidance of Dr. David Thompson. His work 
focused on the synthesis and screening of polyrotaxanes as novel Niemann-Pick Type C 
therapeutics and the in vivo characterization of polyrotaxanes for biomedical applications. 
Christopher earned several awards during his time at Purdue University, including best poster 
awards at the 2013 H. C. Brown Symposium and the 2014 University of Michigan Vaughan 
Symposium, the Fall 2014 Student Seminar Award, and the 2014 H.C. Brown Graduate Student 






Synthesis, Characterization, and Evaluation of Pluronic-Based
β‑Cyclodextrin Polyrotaxanes for Mobilization of Accumulated
Cholesterol from Niemann-Pick Type C Fibroblasts
Christopher J. Collins,§,# Leslie A. McCauliff,†,# Seok-Hee Hyun,§ Zhaorui Zhang,§ Lake N. Paul,‡
Aditya Kulkarni,§ Klaus Zick,⊥ Mary Wirth,§ Judith Storch,† and David H. Thompson*,§
§Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47904, United States
†Department of Nutritional Sciences and Rutgers Center for Lipid Research, Rutgers University, New Brunswick, New Jersey 08901,
United States
‡Bindley Biosciences Center, Discovery Park, Purdue University, West Lafayette, Indiana 47904, United States
⊥Bruker BioSpin GmbH, Silberstreifen, 76287 Rheinstetten, Germany
*S Supporting Information
ABSTRACT: Several lines of evidence suggest that β-
cyclodextrin (β-CD) derivatives initiate the efflux of
accumulated, unesterified cholesterol from the late endo-
somal/lysosomal compartment in Niemann Pick C (NPC)
disease models. Unfortunately, repeated injections or con-
tinuous infusions of current β-CD therapies are required to
sustain suppression of symptoms and prolong life. In an effort
to make CD treatment a more viable option by boosting
efficacy and improving pharmacokinetics, a library of Pluronic
surfactant-based β-CD polyrotaxanes has been developed
using biocompatible poly(ethylene glycol) (PEG)−polypro-
pylene glycol (PPG)−PEG triblock copolymers. These
compounds carry multiple copies of β-CD as shown by 1H NMR, 2D nuclear Overhouser effect spectroscopy, gel permeation
chromatography/multiangle light scattering, analytical ultracentrifugation analysis, matrix assisted laser desorption/ionization
mass spectrometry, and diffusion-ordered spectroscopy. Analyses of free β-cyclodextrin contamination in the compounds were
made by reverse phase high pressure liquid chromatography and hydrophilic interaction liquid chromatography. Dethreading
kinetics were studied by reverse phase high pressure liquid chromatography, UV/vis, and 1H NMR analysis. Filipin staining
studies using npc2−/− fibroblasts show significant reversal of cholesterol accumulation after treatment with polyrotaxane
compounds. The rate and efficacy of reversal is similar to that achieved by equivalent amounts of monomeric β-CD alone.
1. INTRODUCTION
Niemann-Pick Type C (NPC) disease is one of a large set of
lysosomal storage disorders that arise as a consequence of
abnormal function within the late endosome/lysosome (LE/
LY) compartment. In this rare disease, the accumulation of
cholesterol and other lipids within the LE/LY compartment
gives rise to various disease states in the patient.1−3 Often, the
defect manifests itself in the form of neurological, hepatic, and/
or pulmonary symptoms that increase in intensity over time.4
These can involve enlargement of organs, dysarthria, dysphagia,
ataxia, and other neurological symptoms including epilepsy and
dementia.2 NPC typically manifests in children and is ultimately
fatal, even with current treatment regimens.5
The underlying causes of NPC are genetic mutations that
disrupt the function or localization of either the NPC1 (95% of
cases) or NPC2 (5% of cases) proteins. These proteins are
ubiquitously expressed and are localized to the LE/LY
compartment.1,2 In a normally functioning cell, NPC1 and
NPC2 are responsible for the efflux of unesterified cholesterol
(UC) from the LE/LY compartment into the cytosol and are
generally thought to function in a common UC efflux pathway.6
The dysfunction of either NPC protein causes aberrant
sequestration of UC in the LE/LY compartment.5 The
accumulation of UC, in turn, causes lysosomal swelling,
upregulation of the genes controlling cholesterol synthesis
and LDL uptake, elevation in intrinsic total cholesterol
synthesis and lipoprotein uptake, and neurological effects
including demyelination of brain cell axons and the death of
Purkinje cells.3,7,8 Additionally, the onset of macrophage
activity in affected tissues results in the release of pro-
inflammatory cytokines in most organs.7,9−11 The cumulative
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impact of these factors is cell death and presentation of the
NPC disease state.
Since its demonstration by Camargo et al., an increasing
body of evidence shows that derivatives of β-cyclodextrin (β-
CD), a macrocycle consisting of 7 glucose subunits, are able to
initiate the efflux of accumulated UC from the LE/LY
compartment of npc1 and npc2 deficient cells.3,4,7−13 Dietschy
and co-workers have recently reported several studies that
demonstrate the ability of β-CD derivatives (e.g., HP-β-CD) to
mobilize UC in the murine model of NPC1 disease.3−5,8,9,14
Upon treatment with HP-β-CD, a normalization of intracellular
UC levels, suppression of intrinsic cholesterol synthesis,
activation of the target genes for the LXR nuclear receptors,
and suppression of target genes for SREBP were observed in
several organs. All of these factors contribute to rapid egress of
sequestered UC from sites of abnormal storage.8,10,11 When
injected directly into the CNS, similar effects were seen in the
brains of npc1−/− mice,4,7 and continuous infusion with β-CD
derivatives was shown to prevent expected neurodegeneration.7
β-CD has also been shown to have similar positive effects in
npc2−/− mice.13 At the cellular level, addition of β-CD to either
npc1−/− or npc2−/− patient fibroblasts has been shown to rescue
the cholesterol accumulation phenotype of these cells.12,13
While reversal of UC storage in mice was seen after
administration of β-CD, evidence indicated that the animals
began reaccumulating cholesterol shortly after dosing was
terminated.8,9,11 β-CD derivatives, therefore, overcome choles-
terol transport defects in NPC1 disease, but the alleviation is
temporary such that repeated or continuous infusions are
needed for prolonged effects.7,9 Increasing the efficiency of β-
CD delivery, by improving the pharmacokinetics and
biodistribution of the dose, would make β-CD much more
viable as a possible NPC therapeutic. One potential method for
achieving these goals would be to deliver β-CD via a high
molecular weight, long circulating vehicle. A β-CD formulation
offering improved circulation time and lower clearance rates
could potentially deliver a more efficacious dose and be
beneficial in NPC treatment.
Polyrotaxanes (PRTx) are supramolecular assemblies that
have been of considerable interest in biomaterials applications
such as drug and gene delivery and hydrogel formation.15−19
These complexes are typically prepared by threading macro-
cycles noncovalently onto a polymer core to produce a
pseudopolyrotaxane with subsequent addition of bulky end-
caps onto the central polymer termini to yield a polyrotaxane.
The end-caps prevent macrocycle dethreading and can be
tuned to be bioresponsive toward changes in pH20 or toward
enzyme activity,21,22 allowing for control over when and how
the PRTx degrades to release its macrocyclic cargo. Cyclo-
dextrin-based PRTx derivatives have been synthesized using
Scheme 1. Synthesis of β-CD/Pluronic PRTxa
aFor Pluronic base F127, m = 100 and n = 32.
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many polymer cores including polyesters,23 polyamides,24
poly(ethylene glycol) (PEG),25−27 polypropylene glycol
(PPG),28 and many di- and triblock copolymers.29
In this study, a library of PRTx derivatives has been
synthesized using Pluronic block copolymers and β-cyclo-
dextrin as building blocks. Pluronic polymers have a PEG−
PPG−PEG triblock copolymer architecture that differs in the
relative lengths of the PEG and PPG blocks. Molecular weights
of the Pluronics used in this study range from 1900 to 12 600
g·mol−1. These polymers were chosen because of their previous
uses in pharmaceutical applications and their known bio-
compatibility.30 Our aim was to increase the efficiency of β-CD
delivery into NPC cells using biocompatible Pluronic-derived
β-CD PRTx.
The PRTx library was subsequently characterized by
solubility tests, nuclear magnetic resonance (NMR), 2D nuclear
overhouser effect spectroscopy (NOESY), gel permeation
chromatography (GPC), analytical ultracentrifugation (AUC),
atomic force microscopy (AFM), matrix assisted laser
desorption/ionization mass spectrometry (MALDI), and
diffusion-ordered spectroscopy (DOSY). Analyses of free β-
CD contamination levels in the compounds were made by
reverse phase high-pressure liquid chromatography (RPLC)
and hydrophilic interaction liquid chromatography (HILIC).
Dethreading kinetics were studied by RPLC, 1H NMR, and
UV/vis analysis. Finally, the capacity of these compounds to
mobilize UC in npc2−/− fibroblasts was evaluated by filipin
staining, while PRTx localization to LE/LY compartments was
studied by fluorescent PRTx colocalization with Lysotracker
Blue.
2. MATERIALS AND METHODS
2.1. Materials. (1,1)-Carbonyldiimidazole (CDI) and 2,4,6-
trinitrobenzenesulfonic acid (TNBS) were purchased from
Research Organics. Tris(2-aminoethyl)amine (TREN), β-
cyclodextrin, Pluronic polymers, and 2,2′-(ethylenedioxy)bis-
(ethylamine) were purchased from Sigma-Aldrich. The four
Pluronics used in this study were F127, F68, L64, and L35. All
solvents were dried and distilled from an appropriate desiccant
prior to use unless otherwise noted. Human fibroblasts cells
from an apparently healthy donor (GM03652) and from an
NPC2 patient (GM18455) were from Coriell Institute of
Medical Research (Camden, NJ). Filipin and fluorescein were
purchased from Sigma and Lysotracker Blue from Molecular
Probes.
2.2. Synthesis of TREN-Terminated Pluronics. The
synthesis of F127 Pluronic-based β-CD polyrotaxane will be
described in detail below. All other β-CD:Pluronic PRTx were
synthesized and purified in the same manner, except where
noted.
The Pluronic precursor was added to a dry round-bottom
flask under a dry N2 atmosphere and then dissolved in benzene
before solvent evaporation. This azeotropic drying procedure
was repeated three times before finally drying the polymer
under a vacuum at 80 °C overnight.
Pluronic F127 (4.0 g) was dissolved in 20 mL of
dichloromethane (DCM) and added to CDI (9.5 mmol, 30
equiv, dissolved in 20 mL of DCM) by syringe over the course
of 6 h. The solution was stirred for 18 h at 20 °C before
concentration by evaporation and addition to TREN (6.4
mmol, 20 equiv, dissolved in 20 mL of DCM) over 3 h. After
being stirred at 20 °C for 24 h, the solution was concentrated
by rotary evaporation, and the residue was precipitated in ether
(3 × 350 mL), before collection by centrifugation and drying
overnight under a vacuum. The TREN derivatives of L35 and
L64 were isolated as viscous yellow liquids, whereas the F127
and F68 derivatives were isolated as white solids. TREN-
polymers proved difficult to purify completely and as such were
used without further purification. Extensive washing and
dialysis of the final PXR compounds would serve to remove
any impurity retained after the earlier steps.
2.3. Threading, End-Capping, and Purification of
TREN-Terminated β-CD:Pluronic Polyrotaxanes. TREN-
F127 (2.5 g) was added to a saturated aqueous solution of β-
CD (5.9 mmol β-CD in 361 mL H2O). After dissolution of the
polymer, the solution was bath sonicated for 10 min at 65 °C to
ensure complete mixing. Finally, the solution was probe
sonicated using a 1/2 in. tipped transducer for 3 min, followed
by agitation on a rocker plate for 14 days to promote threading.
For the liquid polymers L35 and L64, a white precipitate
formed in the flask almost immediately and increased over time.
The threading progressed much more slowly for the solid
polymers (F127 and F68), with precipitate appearing usually
after 24 h and increasing thereafter.
After completion of the threading reaction, TNBS (4 equiv,
1.5 mmol, 5.1 mL in a 10% solution) was added to the reaction
mixture and left on the rocker plate overnight to effect the end-
capping reaction.
The L35-, L64-, and F68-based PRTx were first collected by
centrifugation from the reaction mixture for 3 min at 7000 rpm.
They were then diluted with 30 mL of H2O, vortexed, and
recentrifuged under identical conditions. Water washes were
continued in this manner until the washes ran nearly clear;
usually 3−5 repetitions. The F127-based PRTx was not
collected by centrifugation due to the formation of viscous
suspensions; therefore, this product was purified by extensive
dialysis as described below.
The products were again suspended in 30 mL of H2O and
dialyzed against H2O using dialysis tubing correlating to the
estimated MW of the final product. L35- and L64-based PRTx
were dialyzed with MWCO 3500 and 6−8000 kDa tubing,
respectively. F68 and F127-based PRTx were dialyzed against
water in MWCO 12−15 kDa tubing. The products were
dialyzed for 3 days with an average of six water changes, or until
water remained clear for two consecutive water changes.
Upon completion of dialysis, the purified products were
frozen and lyophilized to yield yellow-orange powders. β-
CD:F127 PRTx was obtained in 32.9% yield (1.883 g). β-
CD:F68 PRTx, β-CD:L64 PRTx, and β-CD:L35 PRTx gave
13.29% (0.502 g), 29.1% (4.773 g), and 19.1% (1.12 g) of solid,
respectively. F127 1H NMR: (400 MHz, DMSO-d6, 22 °C) δ
8.94−8.76 (br s., 8H, TNB), 5.73−5.65 (m, 266H, O2H, O3H
of CD), 4.8 (s, 133H, H1 of CD), 4.45 (t, 133H, O6H of CD),
3.67−3.59 (m, 532H, H3, H6, H5, H4 of CD), 3.51−3.48 (m,
995H, PPO and PPG −CH2−), 1.04−1.01 (d, 195H, PPG
−CH3).
After the initial purification processes, the PRTx were
analyzed by both RPLC and HILIC, with the two methods
consistently agreeing within 8%. Initial free CD measurements
for β-CD:F127 PRTx were 19.9% by HILIC and 26.9% by
RPLC. Samples containing >5% free β-CD by RPLC were
suspended in 15 mL of H2O, vortexed for 2 min, and gathered
by centrifugation as previously described. After three
repetitions, the samples were lyophilized and reanalyzed for
free β-CD content. This process was repeated until the HILIC
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and/or RPLC analyses indicated that the free β-CD content
was ≤5% free β-CD.
The inability to wash and collect β-CD:F127 PRTx by
centrifugation made them more difficult to purify of free and/or
entrained β-CD contamination. Samples containing >5% free β-
CD contamination after initial purification were resuspended in
H2O, vortexed for 3 min, and again left to dialyze against water
in either MWCO 12−14 kDa dialysis tubing or a 20 kDa
dialysis cassette for 2 days, lyophilized, and retested. This
process was repeated until the HILIC and/or RPLC analyses
indicated that the free β-CD content was ≤5% free β-CD.
Fluorescein modified β-CD:F127 PRTx was synthesized by
dissolution of 400 mg β-CD:F127 PRTx in dry DMSO before
activation with CDI (6.1 mmol) and coupling to ethylene
diamine (7.4 mmol). A second activation with CDI (6.1
mmol), followed by fluorescein coupling (6.1 mmol), and
precipitation twice in MeOH yielded the fluorescent PRTx
derivative. Fluorescent PRTxs were used without further
purification.
2.4. Determination of Threading Efficiency by 1H
NMR. 1H NMR spectra were acquired on a 400 MHz Bruker
ARX400 spectrometer, using the solvent peak as the reference
standard and the chemical shift given in parts per million.
NOESY spectra were taken on a 500 MHz Bruker DRX500
spectrometer with a 5 mm TBI probe. DMSO-d6 was used as
NMR solvent unless otherwise noted. Determinations of PRTx
threading efficiencies were initially performed by 1H NMR
spectral integration. The characteristic β-CD H1 proton at ∼4.8
ppm was directly compared to the PPG methyl protons of the
polymer at 1.0 ppm. The PPG resonance was normalized to the
average number of hydrogens expected for that specific
Pluronic’s methyl group. Given that each β-CD monomer has
seven acetal protons, the corresponding integration for the
number of β-CD H1 protons present in the sample was divided
by seven. This yielded an average number of β-CDs per PRTx.
This estimate of threading efficiency was then recalculated once
the amount of free, unthreaded β-CD in the sample was
determined by chromatographic analysis.
2.5. Determination of Free β-CD in β-CD/Pluronic
PRTx. Determinations of free β-CD in PRTx samples were
done in two ways. First, PRTx solutions of ∼1 mg/mL were
prepared in H2O for analysis on a custom-made HILIC silica
packed column with 700 nm nonporous silica nanoparticles
that were surface-modified with amide groups.31 Before
analysis, PRTx were subjected to two rounds of vortexing for
2 min and bath sonication at 50 °C for 10 min. The
temperature of the column oven was maintained at 25 °C. All
runs were performed under the gradient conditions of 90−70%
acetonitrile (ACN) with 0.1% formic acid. Determinations were
made on a Thermo Accela UPLC system (Thermo Fischer
Scientific, MA, USA) and LTQ Velos LC-MS. Mobile phases A
and B were ACN with 0.5% (v/v) formic acid and water with
0.5% (v/v) formic acid. Chromatographic separation started at
an initial mobile phase of 95% A, held for 1 min, then followed
by a linear gradient from 80 to 60% mobile phase A in 15 min.
The solvent composition then changed to 50% A over 0.1 min
and was maintained for 5 min before being re-equilibrated to
95% A. The flow rate was 150 μL/min.
Mass spectrometric data were acquired in the positive ion
mode. The ESI conditions were as follows: ESI spray voltage, 4
kV; temperature setting, 300 °C; sheath gas flow, 30 U
(arbitrary units); auxiliary gas flow, 8 U.
Additionally, PRTx solutions in H2O (∼1 mg/mL) were
analyzed by RPLC using an H2O:ACN gradient elution as
described by Agueros, Campanero and Irache.32 Analyses were
performed using an Agilent Technologies 1200 Series HPLC
equipped with an ESA Corona Detector and an Agilent Zorbax
Eclipse XDB-Phenyl column (2.1 × 1250 mm, 5 μm particles).
Known concentrations of β-CD were used for both HILIC and
RPLC measurements to construct standard curves for fitting
the PRTx sample data.
2.6. Gel Permeation Chromatography. Corroboration of
NMR molecular weight measurements and threading efficien-
cies were made by gel permeation chromatography (GPC)
analysis. PRTx samples (∼30 mg/mL in DMSO) were
prepared and analyzed as described by Beirne, Truchan, and
Rao.33 GPC measurements were made using an Agilent
Technologies GPC system equipped with an OHpak SB-
803HQ column (8 mm × 300 mm), Dawn Helios II multiangle
light scattering detector (Wyatt Technology Corporation), and
Optirex RI detector (Wyatt Technology Corporation) using
DMSO as the mobile phase. The detectors were normalized
using 25 kDa pullulan and calibrated using 11.6 kDa and 48.6
kDa dextran standards. The flow rate was 0.16 mg/mL and a
100 μL injection volume was used.33
2.7. Analytical Ultracentrifugation. Analytical ultra-
centrifugation was done in the Purdue Bindley Bioscience
Center on a Beckman Coulter XLI (Beckman-Coulter, CA)
ultracentrifuge using absorbance optics at 346 and 422 nm and
interference optics at 675 nm. PRTx were characterized in PBS
buffer at pH 7.4 at concentrations of 0.1, 0.2, and 0.4 OD.
Sedimentation equilibrium (SE) experiments were done at
speeds of 25 000, 35 000 and 40 000 rpm for a total of 67.8 h
and analyzed by the species analysis model in SEDPHAT (v.
9.4).34 The system was standardized by running unmodified
F127 Pluronic (found to be 12 500 g/mol as expected).
Sedimentation velocity experiments were conducted at 50 000
rpm using a 2 channel charcoal centerpiece for 15 h and
analyzed using SEDFIT (v. 12.43). 35 All experiments were
carried out at 20 °C using an Anton 60 Ti rotor. Buffer density
and viscosity were calculated using SEDNTERP.36 The partial
specific volume of polyrotaxane without a PEG derivative was
calculated to be 0.62 mL/g.37 The partial specific volume of the
polyrotaxanes with PEG derivatives was 0.85 mL/g, which
agrees well with published values.38
2.8. Atomic Force Microscopy. AFM images were
acquired by depositing and drying 1 μL of probe sonicated
PRTx-DMSO solution onto a mica plate. All samples were fixed
∼5 min after probe sonication. Images were obtained using a
Dimension 3100 AFM from Veeco Instruments (USA).
Tapping mode images were collected using an NSC15/AIBS
325 kHz cantilever with a 46 N/m force constant and an
amplitude set point of 1 V.
2.9. Mass Spectrometry Analysis. An ionic liquid matrix
(ILM) was made for analyzing the PRTx by MALDI. The ILM
was made as follows: 2′,4′,6′-trihydroxyacetophenone mono-
hydrate (THAP) and 1,1,3,3-tetramethylguanidine (TMG)
were mixed at a molar ratio of 1:2 in methanol. The solution
was then sonicated for 15 min at 40 °C. After removal of
methanol by centrifugal evaporation in a SpeedVac for 3 h at 20
°C, ILMs were left under a vacuum overnight. Final solutions
were then prepared at a concentration of 90 mg/mL in DMF
for use as a matrix. The polyrotaxane samples were prepared at
3 mg/mL in DMF. The samples for MALDI-MS analysis were
prepared by mixing the PRTx sample and ILM in a 1:80 ratio.
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Then, 0.6 μL of the mixture was deposited on a mirror polished
stainless steel MALDI target and allowed to dry at 20 °C and
atmospheric pressure overnight. The spectra were acquired at a
laser power of 6500 using 600 laser shots in linear mode on an
AB4800 MALDI TOF/TOF analyzer.
ESI mass spectrometry of the TNB terminated 2,2′-
(ethylenedioxy)bis(ethylamine) was done on a Waters ZQ
electrospray mass spectrometer in negative ion mode.
2.10. Dethreading Analysis. Bulk dethreading experi-
ments of β-CD:Pluronic PRTx were done by suspending each
PRTx in H2O, adjusted to pH 7.4 or 5.5, at concentrations of 1
mg/mL. Samples were placed in a constant temperature bath at
37 °C and sampled at 1, 2, 4, 8, 16, and 24 h. Aliquots were
analyzed by RPLC as described above to monitor the increase
in free β-CD in each sample. 1H NMR analysis of similarly
incubated PRTx was also conducted to reveal any changes in
TNB peaks characteristic of successful end-capping.
A short, unthreaded TNB end-capped PEG-bis-amine (MW
570.4 g/mol) was synthesized to better visualize any possible
changes in the encap 1H NMR spectrum in the presence of
glutathione (structure, synthesis, and NMR given in SI). This
compound was subjected to a D2O solution of 10 mM
glutathione at pH 7.4, incubated at 37 °C, and monitored at
intervals for 48 h. The PEG-TNB concentration was 1 mg/mL.
UV/vis analyses of TNB end-caps were made using an
Agilent HP 8453 UV/vis spectrophotometer (Agilent Tech-
nologies, Inc., Santa Clara, CA, USA). PBS solutions of an
unthreaded F68-TNB polymer were dissolved at 1 mg/mL with
10 mM glutathione at either pH 7.4 or 5.5. Emission spectra
were taken at 1, 2, 4, 8, 16, 24, and 48 h, with monitoring at 346
and 420 nm wavelengths.
2.11. Diffusion-Ordered Spectroscopy. Experiments
were performed on a Bruker AVIII300WB spectrometer using
a diff50 diffusion probe with a maximum gradient strength of
30 T/m. The pulse sequence used was a stimulated echo
diffusion sequence (PGSTE)39 with an additional spoiler
gradient in the diffusion period. Signal attenuation was achieved
by varying the gradient strength while all the timings in the
pulse sequence were kept constant. The main experimental
parameters were as follows. The effective gradient pulse
duration (δ) was 1 ms using a sinusoidal gradient shape, the
diffusion time (Δ) was 20 ms, and the repetition time 2 s. The
gradient amplitude was varied in 64 steps linearly between 9
and 572 G/cm (90−5720 mT/m). For each gradient step, 64
scans were performed. The samples were dissolved in DMSO at
1 mg/mL and the temperature was kept constant at 25 °C.
Data was processed using the Bruker Dynamics Center
program.
2.12. Cell Studies. Human fibroblasts from npc2−/− or
unaffected patients were seeded on eight-well tissue culture
slides at a density of 6 × 103 cells, in Eagle’s minimum essential
medium with Earle’s salts and nonessential amino acids +15%
FBS at 37 °C with 5% CO2. Sterile β-CD:Pluronic PRTx
samples were solubilized in DMSO and diluted in culture media
to a concentration that would yield 25 μM β-CD. The final
DMSO concentration in all preparations was ≤0.001% (v/v).
Treatments were administered to cells 36−48 h after plating.
Following varying incubation periods, as indicated, cells were
Figure 1. 1H NMR spectra of free β-CD and PRTx-F127 product in DMSO-d6. Peak broadening shows inclusions of polymer inside β-CD core.
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rinsed with PBS and fixed in situ with 10% buffered formalin.
Cell density and viability, determined by trypan blue exclusion,
were determined using cells collected immediately prior to
fixation. No changes in cell numbers or viability (>95%) were
found, indicating an absence of toxicity under the range of
conditions used in the present studies. Fixed cells were washed
with PBS and stained with 50 μg/mL filipin in PBS for 1 h.
Images were acquired using a DAPI filter set on a Nikon
Eclipse E800 epifluorescence microscope (Nikon Inc.),
equipped with NIS-Elements BR 3.2 software (Nikon Inc.).
Antifade mounting agents and microscope light settings
ensured the absence of photobleaching. Filipin accumulation
in cells was determined using NIS-Elements selection tools and
calculated as a ratio of filipin area to cell area. The results in β-
CD:Pluronic PRTx and β-CD treated cells were normalized to
filipin accumulation in untreated npc2−/− fibroblasts and are
expressed as mean ± SE.
Fluorescein labeled β-CD:F127 PRTx was prepared as
described above and administered to npc2−/− fibroblasts
approximately 24 h after plating. Cells were rinsed with PBS
0.5 or 1 h after addition of the compound and incubated with
50 nM Lysotracker Blue (Life Technologies) in PBS for 10
min. Cells were rinsed again and fixed in situ with buffered
formalin. Images were obtained using DAPI and B-2A filter sets
for the fluorescent PRTx and Lysotracker, respectively.
3. RESULTS AND DISCUSSION
3.1. β-CD/Pluronic PRTx Characterization. Multiple
techniques were used to characterize the β-CD:Pluronic
PRTx products, including verification of successful end-capping
reactions, characterization of β-CD threading efficiencies,
determination of PRTx product molecular weights, and analysis
of their purity with respect to free β-CD content.
The β-CD:Pluronic PRTx products were poorly soluble in all
solvents tested, except DMSO. Poor solubility is a well-known
property of PEG-based PRTx compounds.40 Poor solvent
access to the threaded polymer core, combined with their high
molecular weights, produce limited solubility of these
derivatives.19 Pluronic-based β-CD PRTx were expected to
have similar properties.
This characteristic was exploited to purify the PRTx from the
β-CD and Pluronic precursors that are both quite water-soluble.
Free Pluronic polymers, TREN-terminated Pluronic intermedi-
ates, and free β-CD were removed by repeated aqueous
washing of the relatively water-insoluble PRTx products.
Unsuccessfully and partially end-capped PRTx are also
expected to dethread upon repeated suspension in water
since there is nothing obstructing diffusion of β-CD off the end
of the unreacted polymer core, eventually rendering these
byproducts water-soluble and removable by the washing and
dialysis processes.
Multiple lines of 1H NMR evidence suggest that PRTx
formation was successful. End-cap peaks were observed
indicating successful reaction of TNBS with the terminal
amines of the TREN-pseudorotaxane intermediate. These
peaks were present in NMR spectra of each β-CD:Pluronic
PRTx species. There was also evidence of broadening in the β-
CD O2H, O3H, H1, and O6H protons as well as in the signal
corresponding to the Pluronic PPG methyl group. These
characteristic changes, previously reported for β-CD PRTx, are
a result of restricted β-CD mobility upon threading onto the
Pluronic core.40
2D NOESY NMR was also performed as an additional
confirmation of PRTx formation. Signals corresponding to the
inward facing protons (H-3 and H-5) of the β-CD cavity
(Figure 2) and the proton resonances of the Pluronic PPG
methyl groups are found to be cross-correlated. The close
proximity of these substituents indicates that the cyclodextrin
molecules are threaded onto the Pluronic core.41
Initial characterization of the threading efficiency was done
using 1H NMR integration with subsequent correction for the
free β-CD contamination levels present in the sample as
determined by chromatographic analysis. Since β-CD has seven
identical H1 protons at the acetal position of each glucose
Figure 2. Partial 2D-NOESY spectra of PRTx-F27. The characteristic cross-peak between β-CD hydrogens H3/H5 and the PPG methyl group is
shown.
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subunit that appear at ∼4.8 ppm, the intensity of this signal can
be directly related to the signal intensity of the Pluronic PPG
block methyl group. This method indicated that the PRTx
threading efficiencies typically ranged between 62 and 100%.
Initial attempts to produce highly threaded Pluronic PRTx
were less than satisfactory, with threading efficiencies often in
the range of 20−30%. We attributed these failed attempts to
aggregation of the Pluronic precursors. Since the critical
aggregation concentration for the Pluronic precursors used is
quite low (0.004−1 wt %), we attempted to disperse the
micelles into Pluronic unimers in the threading mixture.31
Decreasing the Pluronic feed concentration and addition of a
probe sonication step into the threading procedure increased
the threading efficiencies for each of the Pluronic PRTx cores
(Table 1). It is hypothesized that probe sonication of solutions
at the initiation of the threading reaction disrupts micelle
formation, thus allowing for the initial threading of β-CD
molecules onto the Pluronic unimer which, in turn, prevents
the immediate reformation of micelles and allows for further
threading (Figure 3).
Quantification of the free β-CD content in a given PRTx
sample is an important parameter to measure so that the
performance of these compounds can be properly evaluated
during in vitro and in vivo testing of cholesterol mobilization in
NPC models. By having PRTx compounds essentially free of
unthreaded β-CD, it can be safely assumed that any observed
increases in cholesterol efflux or decreases in cholesterol
synthesis are a product of β-CD initially entering the cell as a
PRTx complex where it is then dethreaded into the active
monomeric form. A goal of ≤5% free CD was selected as an
acceptable target of purity. PRTx that did not meet this
criterion were further purified as described. One round of
further purification was usually enough to bring the PRTx
samples below the 5% free β-CD threshold as determined by
RPLC and/or HILIC.
GPC analysis of PRTx compounds produced molecular
weight estimates that were in agreement with the masses
determined by NMR (after correction for free β-CD). The β-
CD:F127 PRTx molecular weight was 30 800 g/mol. GPC
analysis indicated a mass of 33 300 g/mol, with evidence of low
levels of free β-CD noted in all samples analyzed. A mass of 30
000 g/mol was determined by both sedimentation velocity and
sedimentation equilibrium experiments (Figure 4). Taken
together, these data suggest that the average molecular weight
of β-CD:F127 PRTx is ∼31 kDa. Molecular weights for each
member of the β-CD:Pluronic PRTx library corresponded well
with respect to GPC, AUC, and NMR analysis (Table 2).
MALDI-MS analysis gave additional confirmation of the β-
CD:F127 PRTx molecular weights as well as information about
the heterogeneity of the material. The spectrum contains a
mass peak at ∼30 kDa, representing a PRTx with a threading of
15 β-CDs as found by other measures. Other peaks in the
spectrum correspond to members of the β-CD:F127 PRTx
population with greater and lesser degrees of threading.
Specifically, additional m/z peaks corresponding to 18, 8, 7,
6, and 1 threaded CD also appear (Figure 5). As expected,
there is some heterogeneity in the amount of threading on any
given PRTx. Additionally, MALDI spectra of lower molecular
weight PRTx showed evidence of dimer formation. This fits
well with the aggregation behavior noted in AFM analysis (see
below). Full MALDI spectra for each PRTx are available in
Supporting Information.
AFM analysis of the β-CD:F127 PRTx material produced
evidence of PRTx aggregation after DMSO evaporation. To try
and image nonaggregated particles, PRTx samples were probe
sonicated before fixation onto mica plates. Sonication did not
prevent aggregation, but did decrease the diameter and height
Table 1. Average Number of CDs per PRTx, Threading













F127 12,500 200:65 15 71.4 32.9 4.4
F68 8,350 151:29 14 100 13.3 3.6
L64 2,900 26:30 12 92 29.1 2.4
L35 1,900 22:16 5 63 19.1 1.2
Figure 3. Hypothesized mechanism of increased β-CD threading upon
probe sonication.
Figure 4. Sedimentation equilibrium (SE) profile of β-CD:F127
PRTx. The data were fitted using SEDPHAT using a species analysis
model. The molecular weight obtained from the SE experiment agrees
well with the apparent molecular weights calculated from the
sedimentation velocity.
Table 2. Molecular Weight Measurements by NMR, GPC,
and AUC
CD:Pluronic PRTx NMR (g/mol) GPC (g/mol) AUC (g/mol)
F127 30,800 33,300 30,000
F68 25,500 28,500 27,000
L35 11,000 13,200 12,000
L64 17,700 17,100 21,000
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of imaged particles. It is hypothesized that β-CD:Pluronic
PRTx are forming hollow micelles in solution as previously
reported in a related β-CD:Pluronic PRTx system.41 Consistent
with this expectation, we found that higher PRTx concen-
trations produced larger aggregates. Samples at a concentration
of 10−5 mg/mL produced an average diameter of 45 nm after
probe sonication. Samples at 10−7 mg/mL averaged 41 nm in
diameter, while concentrations of 10−9 mg/mL gave particles
with an average diameter of 32 nm (Figure 6A−C). Thus,
higher β-CD:F127 PRTx concentrations promote aggregation
and micellization into particles whose diameter depends on the
PRTx concentration in solution.
DOSY measurements were also able to confirm rotaxanation
and provide further insight into how the β-CD:Pluronic PRTx
constructs behave in solution. The diffusion constants (D) for
β-CD:L35, β-CD:L64, and β-CD:F68 PRTx were 5.84 × 10−11
m2/s, 5.30 × 10−11 m2/s, and 3.38 × 10−11 m2/s, respectively.
These diffusion constants scale with molecular weight and are
in reasonably good agreement with the diffusion behavior of
similar systems.42,43 Additionally, the least-squares fit of a
log(D) vs log(MW) plot gave a scaling constant of −0.63
(plots, spectra, and diffusion constants available in Supporting
Information S.10). Scaling constants < −0.6 are indicative of
semiflexible wormlike systems,44 showing that the PRTx system
has more rigidity in DMSO solution than would a well-solvated
unbranched random coil polymer.45
3.2. Dethreading Behavior. Experiments were performed
to characterize the dethreading behavior of the β-CD:Pluronic
PRTx under acidic and reducing conditions in an attempt to
mimic the LE/LY environment (Figure 7). Experiments in
which β-CD:Pluronic PRTx were suspended in solutions at
either pH 7.4 or 5.5 and then sampled at various time intervals
showed no increase in free β-CD levels by RPLC analysis up to
24 h after dissolution. This was in agreement with the design of
the PRTx, which were intended to be stable under acidic
conditions.
Additionally, 1H NMR and UV/vis studies were conducted
to monitor changes in end-cap status upon exposure to acidic
pH and 10 mM glutathione. 1H NMR analysis of a short bis-
amine PEG-NH-TNB (SI Section S.8) analogue showed no
changes in the characteristic TNB peaks even after 48 h
incubation with glutathione at 37 °C, indicating that the TNB
nitro groups had not been reduced. Similarly, the UV/vis
spectra of the F68-TNB end-caps remained unchanged even
after 48 h of incubation in glutathione at both acidic and neutral
pH. We infer from these findings that dethreading of β-
CD:Pluronic PRTx is not triggered by acid-mediated end-cap
cleavage or glutathione reduction of the TNB end-cap.
Figure 5. MALDI-MS spectrum of β-CD:F127 PRTx at laser power 6,500. Peak assignments were made by addition of modified polymer MW and
1135n where n is the potential number of bound CDs. Lesser peaks flanking assigned masses can be attributed to variations in MW inherent in the
base polymer.
Figure 6. AFM images of β-CD:F127 PRTx at 10−5 mg/mL (A), 10−7 mg/mL (B) and 10−9 mg/mL (C) with probe sonication. Scale bar represents
500 nm. Size distributions are shown below images.
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Finally, the possibility that β-CD:Pluronic PRTx were
dethreaded upon solubilization in DMSO and addition to the
cell culture media was investigated. 1H NMR analysis of PRTx
samples showed that neither incubation with DMSO/MEM
nor DMSO/PBS buffer resulted in any changes in the threaded
extent of the samples when compared to PRTx controls
(Supporting Information, Figure S.9). β-CD:Pluronic PRTx
should, therefore, be stable in culture before cellular encounter
and internalization.
3.3. Cell Studies. Npc2−/− fibroblasts were incubated with
each β-CD:Pluronic PRTx derivative, and reductions in cellular
cholesterol accumulation were monitored over time to evaluate
their impact on a cellular model of NPC disease. Initially, it was
hypothesized that this library of PRTx constructs, which was
not designed to be either acid sensitive or reductively labile,
would stimulate little or no reduction in npc2−/− cholesterol
accumulation. Figure 8A and B, however, shows that a single
dose of any β-CD:Pluronic PRTx species, yielding 25 μM β-
CD, results in a reduction of approximately 60−75% in
accumulated cholesterol levels by 6 h, relative to untreated
controls. Results were similar to monomeric β-CD, which
decreased cholesterol levels to ∼30% of the level of untreated
cells over the same time period.
It is worth noting that the levels of β-CD monomers used in
the present studies are within the range of effective
concentrations shown by Peake and Vance to clear cholesterol
from murine npc1−/− neurons and glial cells,46 as well as by
Storch and co-workers, to clear cholesterol from human
npc2−/− fibroblasts.12 Levels that were demonstrated to cause
neuronal cell toxicity, e.g., 10 mM, were not used in the present
studies.46 In addition, although the fibroblasts were exposed to
potentially cytotoxic TNB upon end-cap release, no alterations
in cell density or viability were observed in any of the cell
samples (Figure 8C).
While each of the compounds induces rapid efflux of
cholesterol in a manner similar to monomeric β-CD,
differences in the efficacy of the PRTx species are apparent.
For example, L35, carrying 5 β-CDs, stimulates the lowest
degree of cholesterol efflux from npc2−/− cells while L64, with
12 β-CD monomers, is the most effective (p < 0.05). These
differences in relative cholesterol clearance by the PRTx species
suggest that end-cap cleavage and dethreading of CD is
occurring within the LE/LY, following bulk phase endocytosis
of the intact compounds (Figure 8B). Furthermore, if
dethreading were occurring in the media prior to cellular
uptake, approximately equal degrees of cholesterol clearance
would instead be expected for all the β-CD:Pluronic PRTx
Figure 7. Hypothesized and experimentally tested mechanisms for PRTx dethreading. (A) Glutathione incubation with PRTx at acidic and neutral
pH and (B) acid catalyzed dethreading at 37 °C showed no signs of dethreading. Hypothesized dethreading (C) by enzymatic cleavage of carbamate
linkages yields free β-CD in vitro.
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compounds, since each treatment would yield 25 μM
monomeric β-CD.
In order to determine whether the β-CD:Pluronic PRTx
compounds were in fact entering the LE/LY compartment, a
fluorescein labeled β-CD:F127 PRTx was synthesized. Thirty
minutes after addition of the compound to npc2−/− fibroblasts,
fluorescein was observed to overlap entirely with Lysotracker
Blue staining, indicating localization of the compound to the
LE/LY (Figure 9). Therefore, it is likely that the carbamate
linkages used to attach the PRTx end-caps are being cleaved by
enzymatic activation within the LE/LY. Hydrolysis of
carbamate linkages has been previously reported and, indeed,
has been used as a method for designing prodrugs.47−49 Thus,
carbamate cleavage would allow for dethreading of β-CD
monomers at high concentration within the LE/LY and
subsequent efflux of cholesterol from this compartment.
4. CONCLUSIONS
We have synthesized a family of β-CD:Pluronic PRTx
compounds as potential therapeutics for treating Niemann-
Pick Type C disease. The threading efficiency, molecular
weight, and free β-CD contamination in these analogues have
been characterized. Each of the compounds has shown the
capacity to trigger the efflux of cholesterol from npc2−/−
fibroblasts in vitro via filipin staining studies. The rate and
efficacy of β-CD:Pluronic PRTx mediated cholesterol removal
has been shown to be comparable to monomeric β-CD
treatment alone. On the basis of these findings, β-CD:Pluronic
polyrotaxanes warrant further investigation with regard to their
safety, pharmacokinetics, biodistribution, and durability of
response toward cholesterol efflux and/or synthesis suppression
in an in vivo model of Niemann-Pick C disease.
Figure 8. Filipin accumulation in NPC2-deficient fibroblasts treated with β-CD:Pluronic PRTx. Human NPC2 deficient fibroblasts were incubated
with 25 μM monomeric β-CD or PRTx yielding 25 μM β-CD and were fixed and stained with 0.05 mg/mL filipin at varying time points. (A)
Representative images reveal stimulation of cholesterol efflux from npc2−/− fibroblasts by β-CD and two PRTx compounds over time. (B) Filipin
accumulation was determined as the ratio of filipin stain area to total cell area. Results are expressed relative to control untreated cells, and are
represented as mean ± SE (n = 3). (C) Viability of npc2−/− fibroblasts was determined by Trypan Blue staining 6 h after administration of each β-
CD:Pluronic PRTx. Results are expressed relative to control untreated cells.
Figure 9. Fluorescein-labeled β-CD/F127 PRTx localizes to the LE/
LY in npc2−/− fibroblasts. (A) Representative image of fluorescein
localization in NPC2 deficient fibroblasts following a 1 h incubation
period with labeled β-CD:F127 PRTx. (B) Lysotracker Blue staining
identifies LE/LY compartments. (C) Fluorescein fluorescence overlays
with Lysotracker Blue, indicating presence of labeled β-CD:F127
PRTx in the LE/LY compartment. (D) Intensity plot for each stain
throughout an image section as indicated by the white arrow in panel
C. Overlap in the localization of peak intensities is shown.
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1H NMR spectra, 2D NOESY spectra, GPC chromatograms,
AFM images, MALDI mass spectrometry data, DOSY data, and
filipin staining images are reported for each compound. The
complete syntheses and 1H NMR spectra for the unthreaded
F68-TNB polymer and short PEG-TNB compound are also
provided. Additionally, procedures and spectra for DMSO and
media stability tests are given. This material is available free of
charge via the Internet at http://pubs.acs.org.
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Microfluidic assembly of cationic-β-cyclodextrin:
hyaluronic acid-adamantane host:guest pDNA
nanoparticles†
Aditya Kulkarni,‡ Ross VerHeul, Kyle DeFrees, Christopher J. Collins, Ryan A. Schuldt,
Alexander Vlahu and David H. Thompson*
Transfection complexes are typically formed by bulk mixing, pro-
ducing particles with high polydispersity and limited control over
vector size. Herein, we demonstrate the use of a commercial
microreactor to assemble pDNA:cationic cyclodextrin:pendant
polymer nanoparticles using a layer-by-layer approach. Our
studies reveal that the particles formulated via microfluidic assem-
bly have much smaller sizes, lower polydispersity, lower ζ-poten-
tials, and comparable cell viability and transfection profiles in
HeLa cells than bulk mixed particles. The complexes also show a
flow rate-dependent stability, with particles formed at slower
flow rates giving rise to more stable complexes as determined by
heparin challenge experiments. Our findings suggest that micro-
fluidic reactors offer an attractive method for assembling reprodu-
cible, size-controlled complexes from multi-component transfec-
tion complex assemblies.
Gene therapy is a promising alternative to conventional
chemotherapy due to its high specificity and modest off-target
effects.1 While various viral vectors exist for the delivery of
nucleic acids, they suffer from issues such as safety, scalability
and immunogenicity. Non-viral carriers that can condense the
nucleic acids into ≤200 nm positively charged nanocomplexes
are gaining prominence because of their modest immunogeni-
city and ease of production.2,3 Many different carrier designs
based on cationic polypeptides,4 cationic lipids,5 polymers6–8
and cyclodextrin9 nanoparticles have been developed. While
most of these materials are able to effectively condense and
deliver pDNA, they still exert relatively little control over the
vector assembly process and final dimensions. This introduces
large polydispersities and little control over initial physical
characteristics such as diameter or ζ-potential of the transfection
complexes.10 Vortex mixing and/or bulk mixing is the most
common process used by researchers to assemble such nano-
particle complexes, but these complexation methods have high
inherent variability due to gradients in concentration and temp-
erature that are formed during the mixing process. Such batch-
to-batch inconsistency can lead to poor reproducibility and false
negative results in biological experiments.11
Microfluidics-based techniques such as flash nanoprecipi-
tation (FNP)12–14 and hydrodynamic flow focusing (HFF)15–17
have been demonstrated as robust techniques for the formu-
lation of drug-loaded polymeric nanoparticles, but similar
control has yet to be shown for the formulation of nucleic acid
cargo. Microfluidic formulation of nucleic acid-loaded nano-
particles has been previously performed for the rapid gen-
eration of libraries of siRNA-containing lipid nanoparticles18
and pDNA-containing cyclodextrin-based supramolecular
nanoparticles.19 While these techniques are excellent tools for
high throughput screening of nucleic acid nanoparticles,
control over the physical properties of the nanoparticle com-
plexes, in most cases, has not been demonstrated. Recently,
Cullis et al., have demonstrated the formulation of limit-sized
lipid nanoparticles and lipid-siRNA nanoparticles using rapid
microfluidic mixing of lipids dissolved in an ethanol
stream.20,21 The authors demonstrated that microfluidic
mixing was a powerful technique for formulation of both polar
and non-polar core structures. They also showed that they
could achieve particle sizes as small as 20–50 nm with encap-
sulated siRNA using this technique. Leong et al., have develo-
ped the technique of microfluidics-assisted confinement of
complexes in picoliter oil droplets. They demonstrated a
reduction of size, polydispersity index (PDI), ζ-potential and
cytotoxicity, as well as higher transfection efficiency than the
bulk mixed counterparts.22 The ability to tune the physical
characteristics based on flow rate alone, in a manner similar
to FNP or HFF, has still not been demonstrated. Herein, we
demonstrate the flow rate-dependent control over particle
characteristics such as diameter, PDI, ζ-potential, and decom-
plexation rate. To control these properties, we formulated the
transfection complexes in a commercially available glass
Chemtrix microreactor (Fig. 1). Our results suggest that the
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microreactor provides improved control over the physical
characteristics of the nanoparticles generated under a wide
range of feed conditions and flow rates. We also show that the
flow mixing technique is a reproducible, operator-indepen-
dent, and potentially scalable technique that can improve the
uniformity and performance of nucleic acid nanoparticle com-
plexes for transfection.
As an extension of our previously reported poly(vinyl
alcohol)-based pendant polymer designs,23,24 we developed a
new hyaluronic acid (HA)-based pendant polymer system
capable of forming complexes with cationic cyclodextrins and
pDNA. HA (350 kDa) was chosen for its high water solubility,
CD44-targeting capabilities, and biocompatibility.25,26 Ada-
mantane-conjugated HA (HA-Ad) was synthesized via EDC
mediated coupling between HA and adamantane methylamine
(ESI†). Poly(ethyleneimine) (PEI) of molecular weight 2.5 kDa
was used to introduce a single modification on the β-cyclodex-
trin 1° hydroxyl rim. Briefly, β-cyclodextrin was converted to
the monotosylated form27 and was further converted to CD-PEI
after isolation of the pure 6-monotosyl-β-cyclodextrin28 by
treatment with an excess of PEI2.5k. The CD-PEI product was
purified by precipitation in ether and exhaustive dialysis
against DMSO and water. The HA-Ad and CD-PEI components
(Fig. 2) were then used for assembly of the pDNA nanoparticle
complexes via bulk or flow mixing techniques. For bulk mixed
complexes, the CD-PEI and pDNA were mixed first and incu-
bated for 1 h before the HA-Ad was added with vortex mixing
and further incubation for 1 h. At the same time, the pDNA,
CD-PEI and HA-Ad component solutions were assembled
under different flow mixing conditions using the Chemtrix
microreactor as described below (Fig. 1).
The flow reactor (Fig. S1†) chosen provided sufficient length
and volume to enable efficient mixing of the feed solutions.
This reactor is equipped with 2 input channels, 1 quench
channel, and 1 output channel with a total reactor volume of
10 μL and reactor length of 60 μm. CD-PEI and pDNA
(pAcGFP1, Clontech) were introduced in separate input chan-
nels while HA-Ad was added via the quench channel. This
setup replicates the stepwise assembly process used in bulk
mixing by allowing the pDNA and CD-PEI to first yield pDNA:
CD-PEI polyplexes before adding HA-Ad to consolidate the
initially formed condensed pDNA core to generate the final
transfection complexes. All the individual components were
diluted in sterile, filtered, nanopure water instead of buffer to
ensure that buffer counterions did not interfere with complex
formation. Transfection complexes were assembled at N/P
ratios of 10, 20 and 30, since these were the ratios shown to
have optimal activity for the bulk mixed complexes in initial
screening experiments. Flow mixing was carried out at pDNA
flow rates of 5, 10, and 20 μL min−1. CD-PEI and HA-Ad flow
rates were adjusted accordingly to afford the required N/P
ratios.
Our studies revealed that higher flow rates resulted in
smaller complexes and lower PDIs than bulk mixed particles at
the same N/P ratios (Fig. 3A). Flow mixing also produced par-
ticles with lower ζ-potentials than the bulk mixed particles of
the same N/P ratio (Fig. 3B). AFM analysis of the complexes
showed that flow mixed complexes were smaller and more
monodisperse than the corresponding bulk mixed particles
(Fig. 3C–3F), with average diameters of 50 ± 10 nm for flow
mixed transfection complexes and 120 ± 20 nm for bulk mixed
complexes of the same composition (Fig. S3†).
The relative complexation ability and colloidal stability of
the transfection complexes were studied by gel retardation
(Fig. S4†) and PicoGreen competitive binding assays (Fig. 4),
respectively. PicoGreen is a highly sensitive dye that fluoresces
upon intercalation into dsDNA, but remains non-fluorescent
when the DNA is tightly condensed and inaccessible for dye
binding. The bulk mixed and flow mixed complexes were incu-
bated for 30 min with increasing amounts of the negatively
charged polysaccharide heparin to promote polyion exchange
of CD-PEI:HA-Ad from the pDNA core. This was followed by
addition of the dye and fluorescence analysis. Interestingly,
while the gel shift assay indicated very similar complexation
profiles for the bulk mixed and flow mixed complexes, the
PicoGreen assay showed that the decomplexation character-
istics of the various complexes were very different.
The PicoGreen studies indicated that complexes formulated
by flow mixing, in general, were more susceptible to disassem-
bly in the presence of polyanions than those prepared by bulk
mixing. Competitive binding assays also showed that the trans-
fection complexes prepared by flow mixing at higher flow rates
were prone to disassemble more readily than those produced
at lower flow rates. These data indicate that the complexation
ability of all the pDNA:CD-PEI:HA-Ad ratios and flow rates are
nearly the same, however, disassembly is more facile in the
presence of a negatively charged polymer challenge when the
transfection complexes have been prepared by flow mixing.
This can be attributed to the shorter interaction time between
Fig. 1 Conceptual diagram of HA-Ad:CD-PEI:pDNA transfection complex
preparation by microfluidic assembly. CD-PEI (far left) is first mixed with pDNA
(mid-left); intermediate polyplexes (center) are mixed with HA-Ad (mid-right),
resulting in the final nanoparticles (far right) of controlled diameter, compo-
sition, and low polydispersity.
Fig. 2 Chemical structures of (left) HA-Ad and (right) CD-PEI.
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the individual components when they are flow mixed than
occurs for bulk mixed complexes. The longer interaction times
in the bulk mixed case enables multiple encounters with other
particles, leading to larger and more highly entangled ionomer
complexes with higher polydispersity. These findings suggest
that the flow mixing strategy demonstrated here gives us
control over properties such as diameter, PDI and ζ-potential,
as well as a less described characteristic, the disassembly pro-
pensity of the complexes.
The MTS cell viability assay was performed to compare the
HA-Ad and CD-PEI materials using bPEI as control. These
studies indicated that CD-PEI and the CD-PEI:HA-Ad com-
plexes had negligible effects on cell viability, even at concen-
trations as high as 1 mM, whereas bPEI had an LD50 of
∼0.15 mM (Fig. S5†). The relative transfection efficiencies and
cell viabilities of the bulk and flow mixed complexes were then
studied. Upon incubation with HeLa cells, flow mixed com-
plexes demonstrated improved cell viability, but lower transfec-
tion efficiency, than the bulk mixed complexes (Fig. 5). We
infer from these data that the flow mixed complexes undergo
reduced cellular uptake due to their lower ζ-potential and
reduced stability in the presence of polyanions present in the
culture media. Cell viability was also evaluated using the 7AAD
viability stain during the transfection experiment. We found
that cells treated with flow mixed complexes had higher cell
viabilities (85–90%) than bulk mixed complexes (70–80%;
Fig. 5).
Fig. 3 (A) Diameter and polydispersity indices (PDI); (B) ζ-potentials; and AFM
images of transfection complexes produced at N/P = 20 by (C) bulk mixing and
flow mixing at pDNA flow rates of (D) 5, (E) 10 and (F) 20 μL min−1. Scale bar =
500 nm.
Fig. 4 PicoGreen competitive binding assay showing colloidal stability of bulk
and flow mixed pDNA:CD-PEI:HA-Ad complexes assembled at different N/P
ratios and flow rates in the presence of increasing amounts of heparin (0, 2, 10,
20, 40, and 80 times the mass of pDNA used for complex formation).
Fig. 5 Quantification of relative transfection efficiency and cytotoxicity of bulk
and flow mixed pDNA:CD-PEI:HA-Ad complexes in HeLa cells with bPEI as a
control. Incubation for 4 h in 10% serum-supplemented medium was followed
by flow cytometry analysis at 24 h.
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The presence of uncomplexed polycations in bulk mixed
complexes has been shown to be the reason for their higher
in vitro cellular uptake and transfection efficiency.29 These free
polycations are also responsible for increased in vitro cyto-
toxicity.30 Since no free CD-PEI was detected in our transfec-
tion complexes, the lower transfection efficiency and improved
cell viability of the flow mixed complexes may arise from the
absence of similarly uncomplexed polycations.
While a significant amount of research has been carried
out in the development of therapeutic genes and non-viral car-
riers, the absence of a robust operator-independent technique
for the production of nucleic acid complexes is still needed.
Unpackaging and escape of nucleic acids from transfection
complexes that have been internalized is regarded as a crucial
barrier to realizing more efficient gene delivery. Traditionally,
transfection complex disassembly has relied on chemical
approaches, such as pH-31 or enzyme-32 responsive linkages, or
physical approaches such as temperature cycling.33 Herein, we
have demonstrated control over decomplexation properties
based solely on the formulation parameter of mixing rate
without making any changes to the carrier materials
themselves.
Conclusions
While control over diameter and PDI has been demonstrated
by use of microfluidics-assisted confinement, to our knowl-
edge there exists no technique that has shown flow rate-depen-
dent control over formulation of nucleic acid transfection
complexes. The high reproducibility of this technique allows
for more rigorous analysis of the dependence of transfection
efficiency on particle diameter, PDI, ζ-potential and disassem-
bly rate.
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